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ABSTRACT 
Fetal undernutrition is a major factor in the pathophysiology of fetal growth 
restriction (FGR) in many species, including humans. Our hypothesis is that mild 
maternal nutrient restriction (MNR) in a mouse provides a clinically relevant model to 
study FGR mechanisms and long-term effects similar to humans and the developmental 
origins of health and disease (DOHaD) predisposition. A MNR mouse model of FGR was 
developed by feeding mothers 70% normal daily caloric intake during E6.5 to E18.5 
gestation. Significant reduction in fetal weight and fetal liver and lung weights with less 
impact on brain weight resulted, similar to asymmetric human FGR.  To determine 
autocrine/paracrine and endocrine factors and mechanisms underlying FGR, the insulin-
like growth factor (IGF) and glucocorticoid systems were investigated in the liver, 
placenta and lungs at E18.5 and postnatally. At E18.5, MNR fetal livers increased the 
expression of growth inhibiting IGF binding proteins (IGFBPs), with corresponding 
increases in circulating levels. MNR males developed glucose intolerance six months 
postnatally with pancreatic morphology indicating pathophysiology of underlying 
glucose intolerance. Glucocorticoids stimulate maturation in fetal organs, however when 
elevated levels are prolonged, they restrict growth. To determine if glucocorticoids cause 
aberrant fetal lung maturation with postnatal pulmonary function impairment, we studied 
circulating glucocorticoids and glucocorticoid metabolizing enzyme 11-β hydroxysteroid 
dehydrogenase. At E18.5, maternal and fetal plasma corticosterone concentrations were 
higher in FGR, lung weight disproportionately reduced compared to fetus, fewer type II 
alveolar cells and decreased SP-A and SP-C expression. At one and three months 
postnatally, MNR female offsprings demonstrated impaired lung compliance. We 
     
 iv 
investigated placental morphology and function in MNR. At E18.5, MNR caused reduced 
placental efficiency with placental weight reduced disproportionately compared to the 
fetus. Placental stereology indicated decreased surface area for nutrient exchange and 
increased interhemal membrane thickness. Passive and faciliated diffusion was decreased, 
although secondary active amino acid transport was unchanged. Despite the increased 
placental IGF-2 mRNA expression, increased IGFBP mRNA expression suggests local 
sequestation of IGF-2, thus impeding placental growth. These studies demonstrated that 
mild MNR in a mouse caused asymmetric growth restriction similar to human FGR with 
gender-specific long-term impact on glucose intolerance (males) and pulmonary 
dysfunction (females); IGF and glucocorticoid systems may play prominent roles in the 
pathophysiology. 
 
Keywords:  Fetal growth restriction, Insulin-like growth factor system, Glucocorticoid 
system, developmental programming, fetal pancreas, fetal liver, fetal lung, placental 
efficiency, stereology,  type 2 diabetes, surfactant proteins, pulmonary function 
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CHAPTER I 
LITERATURE REVIEW 
1.1 FETAL GROWTH RESTRICTION IN HUMANS 
1.1.1 Definitions, Types and Causes 
Fetal growth restriction (FGR) or intrauterine growth restriction (IUGR) is 
defined as a pregnancy in which the fetus fails to achieve his/her genetically determined 
growth potential or optimal growth. Optimal fetal growth is defined as birth weight that is 
achieved in the absence of fetal, maternal or placental factors that can exert a pathological 
effect on growth (1). Clinically, whether the fetus or newborn has achieved appropriate 
growth for gestation is inferred from gender-specific standardized growth charts. FGR is 
diagnosed if the weight is below the 10th percentile for a given gestational age. During 
pregnancy, the diagnosis is made if the estimated fetal weight (EFW) has either fallen 
below the 10th percentile or if it is on a downward trajectory on consecutive 
measurements indicating that FGR can be diagnosed even if the EFW is within the 
normal percentiles. Therefore, an accurate assessment of the gestational age of a 
pregnancy is critical for the diagnosis of FGR.  
After prematurity, FGR is the leading cause of perinatal morbidity and mortality 
(2). The incidence of FGR is estimated to be approximately 10 percent in the general 
obstetric population (3), but as the incidence of high-risk pregnancies such as multiple 
gestations rises, so does the number of FGR pregnancies (4). The incidence of FGR 
varies among various populations and its prevalence increases with decreasing gestational 
age (i.e. premature births are more likely to be FGR) (5). FGR is a serious health concern 
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worldwide (6); approximately 10% of term infants in developed countries, and almost a 
quarter of term infants in developing countries are diagnosed with FGR (5). There is a 
greater perinatal mortality rate in FGR fetuses at all gestations – at term, fetuses of less 
than 2,500 g have a perinatal mortality rate that is 5 to 30 times greater than those at the 
50th percentile, and it increases to 70 to 100 times higher in fetuses less than 1,500 g (2).  
FGR results in the birth of an infant who is small for its gestational age (SGA). A 
widely used definition for SGA is a fetus whose estimated weight is below the 10th 
percentile for its gestational age (7, 8). Thus, FGR and SGA are not synonymous. FGR 
indicates a pregnancy associated with pathology, whereas, SGA refers to a newborn 
whose birth weight is below expected for the gestational age. The designation of a 
newborn as SGA does not distinguish him/her as pathologically growth restricted or 
constitutionally small. Constitutionally small infants have reached their appropriate 
growth potential. They are well proportioned and developmentally normal (2). In 
contrast, FGR results from pathological pregnancies and includes infants whose estimated 
weight is above or below the 10th percentile but growth restricted relative to their growth 
potential. These fetuses are malnourished and dysmorphic (2). Approximately 70 percent 
of fetuses with a birth weight below the 10th percentile for gestational age are 
constitutionally small, whereas the remaining 30 percent, the FGR is pathological (2).  
FGR infants may be symmetrically or asymmetrically growth restricted. 
Symmetric FGR occurs when the ponderal index (PI = birth weight [g] x 100/length 
[cm]) remains normal and all growth measurements of the body are proportional to body 
size (2). Reduction in growth in symmetric FGR begins early in gestation and may be 
caused by congenital infections, chromosomal abnormalities, skeletal abnormalities, fetal 
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alcohol syndrome, constitutional short stature and low socio-economic status (9). The 
decreased nutrient supply early in development can restrict growth in all organs (5). Since 
symmetric FGR fetuses appear similar to constitutionally small fetuses, it can be 
concluded that a fetus is constitutionally small only after a pathological process has been 
excluded. Generally, these infants are at low risk for neonatal complications following 
birth (10). 
Asymmetric FGR results in a low ponderal index - birth length and head growth is 
normal, but birth weight is reduced (2). Asymmetic FGR is a late-onset growth failure 
usually beginning in the late second or third trimesters (9). This abnormal fetal growth is 
due to a reduction in the supply of nutrients to the fetus that limit glycogen and fat 
storage yet allow continued brain growth, due to preferential blood flow to the brain and 
away from organs such as the gut, liver, muscle and skin (11-16). Generally, these infants 
are at a higher risk for neonatal complications and death (10). Reductions to fetal nutrient 
supply are commonly caused by placental insufficiency, pre-eclampsia (and other 
maternal hypertensive syndromes), maternal renal disease, long-standing diabetes 
mellitus, smoking, and living at high altitude (9).  
FGR may therefore be caused by maternal, placental or fetal factors, with 
approximately one-third attributed to genetics and the remainder attributed to a poor 
intrauterine environment (17). However, no underlying etiology can be identified in at 
least 40 percent of FGR infants (5). Other than mitigating known risk factors, such as 
treating maternal conditions and attempting to prevent high-risk pregnancies through 
education, there is currently no effective treatment for FGR (4). 
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1.1.2 Short-Term Consequences 
The consequences of FGR during gestation are evident in the perinatal as well as 
adult life with elevated risk of chronic diseases. Fetal, neonatal and perinatal mortality is 
increased in FGR infants, rising abruptly when birth weight is below the 5th percentile 
(5). In utero, fetal undernutrition in FGR fetuses results in reduced glycogen content in 
skeletal muscle and liver due to lower fetal plasma glucose and insulin concentrations (5, 
18). Concentrations of most essential amino acids are lower in umbilical cord blood of 
FGR fetuses compared to normal fetuses, due to decreased placental transfer and/or 
increased protein catabolism by fetus and placenta (19, 20). FGR fetuses with these 
metabolic derangements develop with less total body fat, lean mass and bone mineral 
content (21). At the time of birth, induction of labour and operative delivery occurs with 
greater frequency in FGR pregnancies. Following birth, FGR infants may suffer from 
impaired immune function, hypothermia due to increased heat loss and reduced heat 
production due to reduced subcutaneous fat, hypoglycemia from low intrauterine insulin 
concentrations resulting in lower glycogen stores, and viscous blood from intrauterine 
hypoxia inducing erythropoietin production (5). Many FGR infants are also born 
prematurely, and as a result, may have additional complications such as greater rates of 
neonatal death, necrotizing enterocolitis and respiratory distress syndrome (22). 
 
1.1.3 Long-Term Consequences  
FGR infants who survive the perinatal period are at increased risk for later 
morbidity and mortality, such as cardiovascular disease, obstructive pulmonary disease, 
type 2 diabetes mellitus, renal insufficiency and impaired reproductive function (7, 23) 
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(TABLE 1.1). Many of these associations of low birth weight to disease in adulthood 
have been demonstrated worldwide, in different cultures and countries of varying 
affluence (24). This suggests the importance of optimal development during early life to 
minimize future disease susceptibility. 
It is generally thought that the fetus adapts to an inadequate maternal environment 
in utero with changes to its body structure, physiology and metabolism resulting in 
reduced fetal growth (48). Although these adaptations may be suitable to survive the 
intrauterine environment, the persistence of these prenatal adaptations postnatally may 
lead to dysfunction or disease (23). The presence of additional risk factors in adulthood 
(i.e. smoking, obesity and inactivity) can further increase the risk of disease (24).  
Ninety percent of FGR infants experience catch-up growth, which generally 
occurs during the first two years of life and is most rapid in the first six months (7). It is 
thought that the fetus adapts its growth rate to survive the poor environment in utero, 
however when nutrition improves after birth, compensatory growth occurs. Catch up 
growth in humans has been associated with the development of obesity, chronic diseases 
and shortened lifespan (49). FGR neonates are born with less adipose tissue (21) and 
catch up growth likely promotes increased adiposity (50) as fat mass is accumulated 
much faster than muscle mass (7). A study of 8-year-old Indian children found that 
insulin resistance, lipid concentrations and blood pressure were inversely correlated with  
birth weight, and positively correlated with current ponderal index, such that the highest 
measurements for each of these parameters were seen in children with the lowest birth 
weights and highest current ponderal index (51). Similar findings have been 
demonstrated in studies from other countries (52-54). Usually, FGR infants show 
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TABLE 1.1 Long-term consequences in organ systems following fetal growth 
restriction.  
ORGAN DISEASE STATE REF 
   
Brain and Nervous System Schizophrenia (25) 
 Impaired Learning and Cognition (26) 
 Neurological Disorders, Dementia (27) 
   
Lung Bronchopulmonary Dysplasia (28) 
 Compromised Pulmonary Function (29) 
 Chronic Obstructive Airways Disease (30) 
 Asthma (31) 
   
Heart Coronary Heart Disease (32) 
   
Blood vessels Atherosclerosis (33) 
 Hypertension (34) 
   
Liver Dyslipidemia (35) 
 Coagulation Disorders (36) 
 Insulin Resistance (37) 
   
Kidney Renal Disease  (38) 
 Renin Angiotensin System (38) 
   
Pancreas Type 2 Diabetes Mellitus (39) 
   
Bone Osteoporosis (40) 
   
Muscle Insulin Resistance (37) 
   
Fat Obesity (41) 
 Insulin Resistance (37) 
   
Endocrine System Hypothalamic-Pituitary-Adrenal Axis (42) 
 Growth Hormone-IGF Axis (43) 
   
Reproductive system Early Menarche/Adrenarche (44) 
 Polycystic Ovarian Syndrome (45) 
   
Immune System Thyroid Autoantibodies (46) 
 IgE Concentrations (47) 
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moderate insulin resistance during the catch-up growth period in the first 2 years of life 
(54, 55) and tend to remain insulin resistant as infants and children if catch up growth 
was achieved (53, 54).  
Compensatory growth represents a dilemma, as ample nutrition has a positive 
effect on brain and neural development, and poor postnatal growth increases the risk of 
compromised neurodevelopment. The most important predictor of subnormal 
performance on standard psychological and intelligence tests in 18 year old Swedish 
males born SGA is the absence of catch-up growth (56). However, promoting rapid 
weight gain and fat deposition of FGR infants increases the risk of developing metabolic 
and cardiovascular diseases later in life. Breast-feeding results in a slower rate of weight 
gain during infancy (57) due to lower calorie and protein intakes and different patterns of 
insulin response to feeding; this may be protective against developing obesity (7). 
Relative undernutrition in early life is associated with diminished insulin resistance in 
adolescence; FGR infants fed ordinary formula or breast milk had fewer incidences of 
insulin resistance in adolescence than those fed with nutrient-enriched formula (58). 
These studies suggest that postnatal insulin resistance following FGR may be prevented 
by prohibiting calorie-dense formulas being fed to these infants. 
 
1.2 MEDIATORS OF FETAL GROWTH AND LONG-TERM DISEASE 
 Factors mediating fetal growth have an important role also in determining adult 
health and susceptibility to disease. Manipulation of fetal hormone levels by exogenous 
administration, drug treatment, gene deletion or surgical ablation of endocrine glands 
have identified hormones essential for normal fetal growth and development (59). Of 
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these, insulin, insulin-like growth factors (IGFs) and glucocorticoids are particularly 
sensitive to changes in the intrauterine environment and respond to a wide range of 
metabolic, endocrine and neural stimuli (59). In utero, these hormones trigger key 
developmental events and control cellular availability of nutrients for fetal growth; they 
regulate rates of cell proliferation, apoptosis and differentiation in many fetal tissues (59). 
The ability of these hormones to respond to changes in the intrauterine environment may 
signal the availability of oxygen and nutrients to the developing fetal tissues to match the 
rate of fetal growth to the fetal nutrient supply (59). They may also regulate fetal growth 
by mediating changes in the placenta, and thereby controlling maternal resources 
allocated for fetal growth (60). Changes to the expression of insulin/IGF axis and 
glucocorticoid systems may persist after birth and are associated with the development of 
chronic adult diseases associated with low birth weight (42, 43). Abnormalities in the 
insulin/IGF axis have been observed in cardiovascular disease, diabetes and osteoporosis 
with low serum IGF levels (43). These observations have generated interest in the 
insulin/IGF axis as a putative mechanism to explain the associations between low birth 
weight and adult disease as the insulin/IGF axis may influence postnatal growth, insulin 
resistance, and consequently the risk of disease. Studies in humans and animals have 
correlated low birth weight and prenatal stress to altered hypothalamic-pituitary-adreanal 
(HPA) axis activity later in life (61). Glucocorticoids are released into circulation during 
maternal stress, with approximately 10% of maternal cortisol crossing the placenta to 
enter the fetal compartment (62). Therefore, increased maternal cortisol concentrations 
could contribute to a significant change to fetal glucocorticoid exposure during 
development, which could be compounded by reduced metabolism in the placenta before 
     
 
9
entering the fetal circulation (61, 62). Human studies have found that maternal stress 
during mid-gestation reduces birth weight and head circumference (63) and 
glucocorticoid treatment during preterm labor is associated with alterations in insulin 
resistance (64).  
 
1.2.1 Insulin and Insulin-like Growth Factors 
Insulin and IGFs are structurally related peptides essential for optimal embryonic 
and fetal development. Fetal insulin deficiency caused by transient neonatal diabetes or 
pancreatic agenesis in humans causes uniform growth restriction with the majority of 
fetal tissues equally affected (59, 65). Fetal hyperinsulinaemia increases fetal fat 
deposition and weight gain (59, 65). Insulin may act to promote fetal growth by several 
mechanisms including supporting uptake and utilization of nutrients by insulin sensitive 
fetal tissues to cause cellular hypertrophy, direct mitogenic actions on cells or release of 
other growth factors (such as IGFs and their binding proteins) (65).  
IGF-I and -II are polypeptides homologous to pro-insulin, both approximately 7.6 
kDa (66). IGF-I and -II are essential to appropriate fetal growth and development, as 
deletion of Igf1 or Igf2 in mice results in a 40% decrease in birth weight compared to 
wild-type littermates. If both Igf1 and Igf2 genes are deleted, there is an additive growth 
retardation of 80% decrease in birth weight (TABLE 1.2). The importance of the IGF 
system during gestation has been confirmed in humans as case reports of IGF1 gene 
mutations describe severe FGR, mental retardation and sensorineural deafness (4).  Liver 
is the major site of IGF-I and IGF-II production in fetal and postnatal life, although 
almost all tissues express these peptides (59, 67), suggesting that local expression of IGF- 
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TABLE 1.2. Placental and embryonic/fetal phenotypes resulting from altered 
function of the IGF system in knockout and transgenic mice1. 
GENOTYPE BW (% 
of WT) 
FETAL PHENOTYPE PLACENTAL 
PHENOTYPE 
REF 
 
KNOCKOUT MICE 
 
Igf1 -/- 60 Small, poor postnatal 
growth 
Normal size (71, 72) 
     
Igf2 -/- 60 Small, normal postnatal 
growth 
Size smaller; fewer cells; 
fewer glycogen cells. 
(73) 
     
Igf1r -/- 45 Small, die after birth with 
respiratory distress 
Normal size. (71, 72) 
     
Igf2r m-/p+ 140 Large, late gestation 
demise, cardiomegaly, 
kinky tail 
Larger; grows until term 
(WT complete at E17) 
(74) 
     
Igfbp2 -/- 100 No fetal phenotype Normal size (74) 
     
Igfbp4 -/- 85-90 Not described Not described [Pintar] 
     
Ins1 -/-& Ins2-/- 78 Increased pancreatic islet 
size 
Not described (75) 
     
Insr -/- 90 Normal at birth, die 
within week 
Not described (75) 
     
Igf2 paternal 
disomy 
150 Large, organomegaly Larger (75) 
 
TRANSGENIC MICE 
 
mIgf2 136 Heart, liver, kidney 
overgrowth. Increased 
pancreatic islet size 
Increased size (25% of 
WT) 
 
(75) 
     
hIgfbp1 (MT)1 100 No fetal phenotype Not described (76, 77) 
     
hIgfbp-1 (AFP) 83-92 18% reduction in fetal 
size 
15% larger (77) 
     
hIgfbp-1 (hIGFBP-
1) 
100 No fetal phenotype Larger labyrinth; fewer 
glycogen cells; smaller 
decidual component 
(76) 
     
hIgfbp-1 (AFP) 80 Liver, brain and kidneys 
disproportionately small 
Size smaller (70% of 
WT) 
(77) 
     
mIgfbp2 (CMV) 100 No fetal phenotype Not described (75) 
     
hIgfbp3 (MT) 100 Not described Not described (75) 
     
hIgfbp3 (PGK) 90 Not described Not described (78) 
     
hIgfbp3 (CMV) 90 Not described Not described (78) 
     
hIgfbp-5 (β-actin) 80 Fewer pancreatic β cells Not described 
 
(78) 
     
BW = birth weight; WT = wild type; 1promoter in parentheses. 
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 I and IGF-II regulate fetal growth via autocrine or paracrine mechanisms (65). IGFs act 
at several stages of the cell cycle and affect cell proliferation, differentiation, 
maintenance, regeneration and apoptosis (66). They stimulate cell differentiation in fetal 
muscle, bone, brain and adrenal cells during late gestation in preparation for extrauterine 
life (60). They also have anabolic effects on fetal metabolism, stimulating glucose 
utilization and protein synthesis (60). IGFs may also influence growth and development 
as they have a major influence on the production of insulin (68). IGFs control pancreatic 
β cell mass and the capacity for insulin secretion in the fetus (68). Insulin up-regulates 
tissue expression and circulating concentrations of IGF-I, while IGF-I reduces circulating 
insulin levels in the fetus (60). IGFs begin expression in pre-implantation embryos, with 
IGF-II expression greater in fetal tissues than IGF-I during gestation in rodents and 
humans (4). IGF-II is imprinted and expressed only from the paternal allele in the 
placenta and fetal tissues excluding the brain, where it is expressed from both alleles (69). 
Following birth in humans, IGF-II expression becomes biallelic, (but this does not occur 
in rodents) and plasma levels of IGF-I increase rapidly as growth hormone (GH) 
stimulates its production (69). GH is the major regulator of growth postnatally, 
stimulating tissue production of IGFs and elevating circulating levels (69). However, in 
the fetus, pituitary GH has little or no role regulating growth, except in late third trimester 
growth when mild growth restriction occurs if GH is deficient (70).  
Manipulation of the Igf2 gene demonstrates the importance of promoter and tissue 
specific expression of this imprinted gene to placental and fetal growth and development. 
In Igf2 null mice, the placenta is smaller (79), in contrast to Igf1 null mice where 
placental size is not altered (72). However, IGF-I may alter placental nutrient transfer by 
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regulating the expression of placental glucose and amino acid transporters (80). 
Selectively mutating the placental promoter of a placental specific Igf2 isoform (Igf2P0) 
results in a small placenta and FGR at term, however, all components of the murine 
placenta experience growth restriction earlier in gestation than the fetus (79, 81). This 
Igf2 isoform contributes only 10% of all placental IGF-II mRNA (81), yet, it is vital for 
fetal and placental growth as no further reductions in placental growth are observed when 
all forms of Igf2 are absent (82). IGF-II promotes many aspects of placental development 
- stimulating the migration and invasion of placental trophoblast cells during early 
placental development (83, 84), increasing surface area and reducing barrier thickness for 
solute exchange (82). IGF-II has been shown to affect expression of many nutrient 
transporters in human and murine placenta (85). In the Igf2P0 null mouse, fetal tissues 
continue to express IGF-II, but not in the complete Igf2 null (82). The continued 
expression of IGF-II from the fetal tissues appears to act as a fetal signal to the placenta 
to supply more substrates despite compromised placental growth as the Igf2P0 placenta 
transfers more glucose and amino acids per gram than the wild-type placenta and up-
regulates expression of glucose and amino acid transporters (59, 79, 82). This 
demonstrates that IGFs affect growth of fetal tissues not only directly but indirectly 
through changes in placental capacity to deliver nutrients to the fetus (59, 79, 82). In 
contrast, IGF-II overexpression either through relaxation of imprinting (74) or deletion of 
the Igf2r (86), leads to fetal and placental overgrowth. Overexpression of IGF-II in 
human infants also causes overgrowth as demonstrated in Beckwith-Weidemann 
syndrome (87). 
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Numerous studies, conducted within a range of birth weights, have found a 
positive relationship between fetal cord blood IGF-I and birth weight in normal term 
pregnancies as well as other parameters of size, namely birth length, ponderal index, 
placental weight, and head circumference (61). In pregnancies complicated by FGR, 
umbilical cord blood IGF-I is reduced (61). It is generally thought that IGF-II is not 
correlated to birth weight (61) but there may be a positive correlation between cord blood 
IGF-II and placental weight (88). Since plasma IGF-I concentrations are more responsive 
to glucose and oxygen levels than IGF-II levels in the fetus, IGF-I may act as a nutrient 
sensor that ensures fetal growth is coupled to nutrient supply, while IGF-II provides 
continuous drive to fetal growth (59).  
 
1.2.2 IGF Receptors 
IGF-I and -II promote growth primarily by binding to the insulin-like growth 
factor type 1 receptor (IGF1R), which is a transmembrane heterotetrameric (α2β2) 
glycoprotein with extracellular ligand-binding and intracellular tyrosine kinase domains 
(89). The extracellular α-subunit of IGF1R binds IGF-I and IGF-II, though it has an 
affinity for IGF-I that is 15-20 times greater than for IGF-II (65, 90). Following IGF 
binding, IGF1R activates insulin receptor substrate 1 (IRS1) and the AKT and MAP-
kinase pathways to induce cellular proliferation and survival, resulting in general growth 
(4). Deletion of the Igf1R, which is responsible for the actions of both IGF-I and -II, 
causes a greater degree of growth retardation than deletion of either Igf gene. Igf1r-/- 
mice, at birth are only 45% of normal weight and die within minutes after birth, due to 
respiratory failure resulting from widespread muscle hypoplasia, which includes the 
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respiratory muscles (TABLE 1.2). Case reports of defects in IGF1R affect growth as 
patients present with pre- and post-natal growth retardation, mental retardation and 
behavioural abnormalities (4). The insulin-like growth factor type 2 receptor 
(IGF2R)/(mannose-6-phosphate receptor) is a single chain polypeptide with a high 
affinity for IGF-II, but an inability to bind IGF-I or insulin (71). IGF2R inhibits IGF-II 
action, eliminating excess IGF-II from the cellular environment (4) and has intracellular 
signaling functions (91). Although IGF-II functions primarily via IGF1R, it can also act 
through the insulin receptor (INSR) early in development prior to IGF1R expression (4). 
Insulin receptors are found in all fetal tissues and their binding affinity for insulin 
increases with progressing gestation (92), making the actions of fetal insulin most 
apparent late in the third trimester (65). INSR transcript undergoes alternative splicing 
producing splice variants of INSR (isoforms A and B); the INSR-A isoform displays high 
affinity for IGF-II (93). Hybrid receptors may form from dimerization of IGF1R and 
INSR hemireceptors, creating receptors with differential affinities for IGF-I, IGF-II and 
insulin (93). An IGF1R/INSR-A hybrid receptor binds IGF-I, IGF-II and insulin, while 
an IGF1R/INSR-B hybrid receptor binds IGF-I with high affinity, IGF-II with low 
affinity, but does not bind insulin (93). 
 
1.2.3 IGF Binding Proteins (IGFBPs) 
The expression of IGFs and IGF1R during gestation is ubiquitous, but expression 
of IGFBPs is precisely regulated by the gestational age and within each organ (65). This 
implies that the major level of control of the IGF axis in development is regulation of IGF 
bioavailability and actions by IGFBPs (65, 69, 94). IGFs are bound to one or more of the 
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six high affinity IGF binding proteins, IGFBP-1 through IGFBP-6, which serve as carrier 
proteins to extend the biological half-life and control IGF action by either interacting or 
competing with IGF1Rs (69, 94). IGFBP-1 and -2 contain an integrin-binding motif that 
allows binding to integrins on the cell surface and may potentiate IGF actions by 
facilitating the presentation of IGFs to the IGF1R (65, 66, 94). All IGFBPs except 
IGFBP-1 contain heparin-binding domains, which allow binding to sulfated 
glycosaminoglycans in the extracellular matrix (ECM) and cell membrane (65, 94). 
Insulin and IGF-I regulate the production of IGFBPs, which can both enhance and 
impede delivery of IGFs and insulin to IGF1R (60). 
Of the IGF binding proteins, IGFBP-1 has been implicated to have a major role in 
inhibiting fetal growth by sequestering IGF-I and IGF-II, as its affinity for IGFs is greater 
than either of the IGF receptors (95). IGFBP-1 thus prevents the growth promoting 
actions of IGFs. IGFBP-1 exists in several phosphorylated forms, but it is the heavily 
phosphorylated isoforms that have the greatest affinity for IGF-I (96). Fetal serum 
contains large amounts of nonphosphorylated IGFBP-1 (97); plasma from pregnant 
mothers contains nonphosphorylated and less phosphorylated isoforms (98), while 
plasma from non-pregnant females contains highly phosphorylated forms (98). 
Dephosphorylation of IGFBP-1 during pregnancy may increase the bioavailability of 
IGF-I (96). Fetal serum IGFBP-1 concentrations are inversely correlated with birth 
weight (61). In FGR fetuses, the concentration of IGFBP-1 in fetal cord serum is 
significantly higher (61) with an increased proportion of phosphorylated IGFBP-1 (99), 
suggesting greater inhibition of IGF actions by IGFBP-1. IGFBP-1 may inhibit 
embryonic growth and development by binding to and impairing the activities of IGFs 
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causing FGR. IGFBP-1 is dynamically regulated in human plasma with levels varying 
more than 10-fold in response to changes in insulin and hypoxia, which regulate IGFBP-1 
expression (95). IGFBP-3 circulates with IGF-I or IGF-II and the acid labile subunit 
(ALS) (4). It is the primary binding protein that extends the half-life of IGFs; acting as a 
reservoir for IGFs in the circulation (4). There is a positive correlation between IGFBP-3 
and birth weight in preterm and term infants (61). IGFBP-3 levels fall in fetal cord serum 
of FGR infants (100).  
Deletion of genes encoding the IGFs and their receptors causes obvious disruption 
to fetal growth and disruption of genes encoding IGFBPs or the acid labile subunit has 
little effect on fetal growth, due to compensation of the deleted IGFBP by the other 
IGFBPs or redundancy among IGFBPs (7) (TABLE 1.2). IGFBP-2,-4,-5, and -6 are 
present in low concentrations in fetal plasma (61). However, modest postnatal growth 
restriction had been documented in transgenic models of mice overexpressing IGFBP-1, 
IGFBP-2, or IGFBP-3 (101, 102) (TABLE 1.2). 
 
1.2.4 Glucocorticoids 
Glucocorticoids are essential for the development and maturation of fetal organs 
before birth, as elevated levels stimulate differentiation of a wide range of fetal tissues 
including liver, lungs, gut skeletal muscle and adipose tissue (103). They induce 
biochemical, morphological and functional changes in fetal tissues, which may have little 
or no function in fetal life but are essential for long-term adaptations to extrauterine life 
and survival (59). The ability of glucocorticoids to stimulate maturation of fetal organs, 
particularly the lung has been exploited clinically as a treatment for women at risk of 
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premature delivery to lower the risk of neonatal respiratory distress syndrome and its 
associated mortality (104, 105).  
Glucocorticoids are beneficial to induce tissue maturation, however, they may 
also inhibit fetal growth. The actions of glucocorticoids are predominantly catabolic in 
utero (59). They restrict fetal tissue accretion in the fetus by activating endogenous 
glucose production and enhance proteolysis (103), reduce placental weight, with weight 
reduction in the placenta greater than that in the fetus (59) and interfere with expression 
of the IGF axis. Glucocorticoids affect expression of IGF-I and -II in the placenta and 
other fetal tissues (liver, skeletal muscle, and adrenal) in a tissue specific manner (59, 60) 
and suppress ß cell development and insulin content of pancreas (103). The rise in 
cortisol prior to term may be responsible for the transition to GH dependent production of 
endocrine IGF-I characteristic of adults (103, 106) and the transition from IGF-II to IGF-I 
as predominant growth regulatory IGF (106).  
Due to the growth inhibitory actions of glucocorticoids in humans and many 
animal species, the surge of cortisol prior to term corresponds to the period when fetal 
weight remains constant (107). Fetal glucocorticoid levels rise with adverse intrauterine 
conditions, such as undernutrition and hypoxia, which may contribute to FGR (108, 109). 
Administration of glucocorticoids to the mother during late gestation leads to FGR in 
several species including humans, with the most significant reductions in fetal growth 
occurring in fetuses receiving multiple doses of antenatal glucocorticoids compared to a 
single dose before birth (105, 110-113). Total body weight and weight of most individual 
fetal tissues are proportionately reduced by these treatments (103), with animal models 
demonstrating decreased brain weight, neurological damage and placental lesions (61). 
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The degree of FGR depends on the dose and type of glucocorticoid used, frequency and 
route of administration, and sex and gestational age of fetus (59).  
Glucocorticoids appear to act as a switch from fetal tissue accretion to tissue 
differentiation in preparation for delivery (59). If this switch occurs prematurely, due to 
glucocorticoid overexposure, the normal pattern of fetal growth may be altered with 
inappropriate tissue development for the gestational stage with long-term consequences 
for tissue function later in life (59). 
 
1.2.5 11ß-Hydroxysteroid Dehydrogenase Enzymes (11ß-HSD) 
In humans, two isoforms of 11ß-hydroxysteroid dehydrogenase (11ß-HSD1 and 
11ß-HSD2) interconvert glucocorticoids with their inactive 11-keto metabolites (114). 
11ß-HSD type 1 catalyzes the bi-directional interconversion of cortisol and cortisone, but 
acts primarily to convert cortisone to cortisol due to its higher affinity for cortisone (114). 
11ß-HSD1 is found in the liver, adipose tissue, lung and testis, where it functions to 
increase the availability of glucocorticoids to the glucocorticoid receptor (GR) (114). The 
expression and activity of 11ß-HSD1 increases with advancing gestation, possibly to 
allow for the rise in cortisol concentration at term to regulate fetal maturation and activate 
pathways associated with labor (115). 11ß-HSD type 2 is a high affinity unidirectional 
enzyme, catalyzing only the dehydrogenase reaction, which converts active cortisol to 
inactive cortisone (114). In the placenta, 11ß-HSD2 primarily controls the passage of 
cortisol from mother to fetus (114). Maternal cortisol concentrations are 5-10 times 
higher than fetal cortisol concentrations, and 11ß-HSD2 protects the fetus from this high 
concentration of maternal glucocorticoids (62). Synthetic glucocorticoids, (such as 
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dexamethasone and betamethasone) are poorly metabolized by 11ß-HSD2 and therefore 
pass unaltered through the placenta and into the fetal circulation (42). There are 
conflicting results regarding whether the expression and/or activity of 11ß-HSD2 
increases or decreases with advancing gestation (116); at term, approximately 75% of 
cortisol found in the fetus is of fetal origin, while all the cortisone in the fetus is of 
maternal origin, suggesting that placental 11ß-HSD2 is an effective glucocorticoid barrier 
as fetal cortisol is predominately derived from the fetal adrenal and not from the mother 
(116, 117).  Birth weight is positively correlated to placental 11ß-HSD2 activity (61). 
Pregnancies complicated by FGR demonstrate a reduction in placental 11ß-HSD2 
expression and activity (61) with reduced concentrations of umbilical cord vein cortisone, 
demonstrating less placental conversion of cortisol to cortisone (118). Furthermore, 
animal studies have implicated decreased 11ß-HSD2 activity and elevated levels of fetal 
glucocorticoids in developmental programming (42, 119, 120), demonstrating the 
importance of placental glucocorticoid metabolism in the regulation of fetal growth and 
long-term development of disease.  
 
1.3 ANIMAL MODELS 
1.3.1 Importance of Animal Models 
Appropriate animal models that mimic FGR in humans are essential to 
understanding how the fetus adapts to the poor intrauterine environment and the 
development of complex multisystem diseases postnatally. Epidemiological research in 
humans only allows associations to be established between FGR and less invasive 
measurements such as growth factors in plasma, or non-invasive measurements such as 
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morphometric body measurements (121). Once similar associations are confirmed in an 
animal model, experiments may be conducted in animals that cannot be performed in 
humans to establish the pathophysiological mechanisms of FGR during gestation. It is 
possible to design protocols aimed at dissecting the relative contributions of nutrients, 
oxygenation, growth factors and genetics to the onset of FGR in a well-controlled 
research environment (121). In an animal model, it is feasible to utilize invasive 
techniques to sample tissue or blood during different stages of development (122). 
Additionally, it is possible to modify both prenatal and postnatal environmental 
conditions including nutrition, to determine mechanisms of disease and ultimately to 
design potential therapeutic interventions (122). Environmental manipulation is 
extremely important for studies elucidating the epigenetic mechanism of long-term 
programming, as postnatally, many factors in the environment can also affect disease 
risk, particularly during the period of compensatory growth. As previously described, 
other than mitigating known risk factors, such as treating maternal conditions and 
attempting to prevent high-risk pregnancies through education, there are no medical 
treatments for FGR (4). Animal models allow scientist to test which treatments may be 
effective or harmful to advances in the care of FGR infants.  
 
1.3.2 Forms of Manipulation to induce Fetal Growth Restriction (FGR)  
Experimental animal models that mimic the human clinical condition use 
manipulations in each the maternal, placental and fetal compartments (TABLE 1.3). 
Interventions to the mother to cause FGR include dietary regimes, where there is a 
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TABLE 1.3 Manipulations of species utilized to produce fetal growth restriction with 
postnatal consequences. 
MANIPULATION SPECIES LONG-TERM DISEASE REF 
 
   
Maternal Undernutrition    
    
    Calorie Deprivation Rat Hypertension, 
hypercholesterolemia, obesity, 
glucose intolerance 
(125-127) 
    
 Guinea Pig Hypertension, insulin resistance, 
obesity 
(128, 129) 
    
 Sheep Hypertension, altered HPA axis (130, 131) 
    
    Protein Deprivation Rat Hypertension, glucose intolerance, 
insulin resistance 
(132-134) 
    
    Iron Deficiency Rat Hypertension (135) 
 
   
Placental Insufficiency    
    
    Increased litter size Guinea Pig Glucose intolerance, insulin 
deficiency 
(128) 
    
    Restricted Blood Flow Rat Glucose intolerance, insulin 
deficiency and resistance 
(136) 
    
 Guinea Pig Hypertension (137) 
    
    Decreased Placental Size Sheep Hypertension, glucose intolerance (138) 
 
   
Glucocorticoid Exposure    
    
    Maternal Dexamethasone Rat Hypertension, glucose intolerance, 
insulin resistance, obesity 
(139-141) 
    
 Guinea Pig Altered HPA axis (142) 
    
 Sheep Hypertension, insulin resistance, 
altered HPA axis 
(143-145) 
    
    Placental 11B HSD2   
Inhibition 
Rat Hypertension, glucose intolerance, 
insulin resistance 
(146, 147) 
    
    Maternal Stress Rat Altered HPA axis (148) 
 
   
Gene Deletion    
   IGF-I-/- Mouse Infertile, Postnatal Growth Deficit (149) 
    IGFR1-/- Mouse Postnatal Growth Deficit (150) 
    Plag1-/- Mouse Reduced Fertility (151) 
    IRS-1-/- Mouse Insulin Resistance (152) 
    Gcgr-/- Mouse Altered Islet Development (153) 
    TR4-/- Mouse Reproduction & Maternal 
Behaviour Defects 
(154) 
Referenced from Vuguin (123) and Fowden et al. (123). 
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reduction in global caloric intake, macronutrients (e.g. low protein diets), or 
micronutrients (e.g. iron deficiency) or over-nutrition at various points during gestation.   
Alternatively, FGR can be induced via the mother by pharmacological means, 
such as administering glucocorticoids, or manipulating the environment to induce 
maternal hyperthermia.  Interfering with placental function by ligating the uterine blood 
vessels to restrict blood flow to the placenta and umbilical embolization or surgical 
removal of placental components is possible primarily in large animals such as sheep, to 
induce FGR (123, 124).  The fetus itself may be manipulated for the development of FGR 
through infection (123), although with the advent of genetic manipulation, many gene-
targeting experiments specifically in the fetus or placenta have produced FGR phenotypes 
during gestation and contributed significantly to knowledge of the genes and mechanisms 
necessary to sustain adequate fetal growth (121, 123). 
 
1.3.3 Species Utilized for Fetal Growth Restriction (FGR) Research  
There are many different experimental animal models of human FGR involving 
studies in rats, mice, guinea-pigs, sheep and non-human primates (124) (TABLE 1.3), 
with each species having benefits and disadvantages as models of human FGR (TABLE 
1.4). Two species, sheep and rat, have been extensively studied for determination of fetal 
adaptations to an adverse intrauterine environment and long-term implications on adult 
health.  
The pregnant sheep is a long-standing model for the study of placental-fetal 
interactions. Similar to humans, sheep have a long gestation period with organogenesis 
occurring early in gestation with the fetal endocrine, nervous, renal and cardiovascular  
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TABLE 1.4 Benefits and disadvantages of common species utilized to model 
human fetal growth restriction. 
SPECIES ADVANTAGES DISADVANTAGES 
   
Non-Human Primates Similarity to Humans Expensive Housing 
 Large Species Long Lifespan 
 Similar Placenta Ethical Considerations 
 Non-litter bearing  
   
Sheep Large Species Expensive Housing 
 Prenatal Nervous & Endocrine 
Maturation Long Lifespan 
 Non-litter bearing Different Placenta Structure 
   
Guinea Pig Prenatal Nervous & Endocrine 
Maturation Few studies performed 
 Similar placenta to humans Litter bearing 
   
Rat Short Life-Span Litter bearing 
 Similar Placenta Postnatal Nervous & Endocrine Maturation 
 Extensively Studied Model  
   
Mouse Short Life-Span Litter-Bearing 
 Genetic Manipulation Postnatal Nervous & Endocrine Maturation 
   
Referenced from Vuguin (123) and Armitage et al. (155) 
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systems relatively mature by late gestation and responsive to intrauterine insults (156-
158). The long period of gestation allows fetal adaptations to be studied in acute and 
chronic intrauterine insults (124). Several experimental approaches have been used in 
sheep to mimic human FGR caused by a range of factors, including maternal nutrient 
restriction, administration of glucocorticoids (GC), maternal overnutrition in the pregnant 
adolescent ewe and experimental induction of maternal hyperthermia (106, 123, 124, 
155) (TABLE 1.3). The benefit of the sheep model is the large size of the organism, 
which allows surgical manipulation of the placenta including the removal of most of the 
endometrial caruncles from the non-pregnant uterus prior to conception, ligation of the 
umbilical artery or embolization of the placenta (124)  (TABLE 1.4). These surgical 
models target undernutrition of the fetus and placenta as well as hypoxia, which models 
placental insufficiency in humans (124)  (TABLE 1.4). The large size of the sheep fetus 
allows catheters and other instrumentation to measure changes in blood gases, hormones 
and cardiovascular parameters in response to placental dysfunction (122) (TABLE 1.4). 
Disadvantages of the sheep models are the different structure of the placenta and the long 
periods of gestation and lifespan (155) (TABLE 1.4). The long lifespan makes it difficult 
and expensive to monitor long-term developmental programming effects (155). All sheep 
models are capable of inducing FGR, but the degree of growth restriction is variable 
depending on the breed, maternal nutrition and intervention used (123). 
Most studies are performed in rodents as they have a short gestation period and 
are excellent for follow-up studies to determine adult health outcomes after FGR because 
of their short life-span (159). Furthermore, molecular mechanisms can be dissected 
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relatively easily given the genetic information available for the mouse and rat (123) 
(TABLE 1.4).  
Many models of nutrient manipulation, including high fat diets (160, 161), total 
caloric restriction, and iron deficiency (TABLE 1.4) have been performed in rats and 
demonstrate long-term sequelae. A low protein diet in pregnant rats is the most 
extensively studied model of early growth restriction (106, 123, 124, 155, 159) (TABLE 
1.4). Rat dams are fed a control diet of standard 20% protein or an isocaloric low (5-8%) 
protein (LP) diet during pregnancy and lactation (159). At mid-pregnancy, glucose and 
insulin levels are significantly lower in LP mothers compared to controls (162). Litter 
size does not differ between groups, but pups born to LP mothers have reduced birth 
weight of approximately 15 percent (159). The LP rat model of FGR is an important 
model for studying developmental programming as many organ systems have 
demonstrated to be affected in adulthood in a similar manner as characterized in humans 
(TABLE 1.1 and TABLE 1.5). 
The caveats of the LP diet model are the variations of diet used to establish FGR, 
as the composition of the diet elicits different programming effects (155). The 
Southampton and the Hope farm diets are low protein diets most commonly used in 
animal models of fetal programming. The Southampton diet programs adult hypertension 
(176) and the Hope farm diet programs insulin resistance (177). Methionine is a major 
component of the Southampton diet, and is in excess compared to other amino acids 
within the diet (123, 155). Methionine may cause elevated circulating homocystine 
levels, a known risk factor for cardiovascular disease, whereas the Hope farm diet 
contains cardioprotective polysaturated fatty acids (123, 155). The clinical relevance of 
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this model system may be limited to those who lack adequate protein intake either for 
economical or cultural reasons (123). Global undernutrition may provide a more relevant 
model, as placental insufficiency or maternal undernutrition, results in fetal 
undernutrition of all nutrients. 
 
     
 
27
 
TABLE 1.5 Long-term consequences in organ systems following maternal low 
protein in rat dams.  
ORGAN DISEASE STATE REF 
   
Brain and Nervous System Physical & Behavioural Deficits (163) 
 Lower Intelligence (164) 
   
Lung Altered Pulmonary Mechanics (165) 
   
Heart Cardiac Dysfunction (166) 
   
Blood Vessels Endothelial Dysfunction (155) 
 Hypertension (167) 
   
Liver Dyslipidemia (155) 
 Insulin Resistance (159) 
   
Kidney Fewer Kidney Nephrons (168) 
 Renin-Angiotensin System (169) 
   
Pancreas Type 2 Diabetes Mellitus (159) 
   
Bone Reduced Adult Bone Mass (170) 
   
Muscle Insulin Resistance (159) 
   
Fat Obesity N/A 
 Insulin Resistance (159) 
   
Endocrine System Hypothalamic-Pituitary-Adrenal Axis (171) 
 Growth Hormone-IGF Axis (172) 
   
Reproductive System Females: Delayed Sexual Maturation & 
Premature Aging of Reproductive 
Function 
(173) 
 Males: Delayed Sexual Maturation & Low 
Sperm Counts 
(174) 
   
Immune System Impaired Acute Phase Immune Response (175) 
 Impaired Cytokine Production (175) 
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CHAPTER 2 
THESIS INTRODUCTION AND RATIONALE 
2.1 MOUSE AS THE ANIMAL MODEL OF CHOICE 
Clinicians taking care of pregnant women, fetuses and newborns have benefited 
from translational knowledge obtained from FGR studies in several experimental animal 
species (rodents, guinea pigs, sheep, non-human primates), each making unique 
contributions to our understanding of the physiology of normal growth and 
pathophysiology of abnormal growth. The majority of FGR studies (approximately 75%) 
are performed on rodents. As mammals, the mouse and rat are similar to humans, sharing 
a similar genome, biochemical pathways, tissue systems and organs, and physiology. 
However, only a small portion (~ 10%) of rodent studies use the mouse as a model 
system, mainly because of the genetic variations of the mouse, challenges in animal care 
and maintenance when pregnancy is perturbed, and inconsistencies in pregnancy and fetal 
outcomes compared to the rat. The mouse and rat share many common characteristics 
which make them ideal models for studying fetal growth restriction and its long-term 
outcomes. Both share a placental structure (hemochorial) similar to humans with many 
cell types of identical structure and function. The short life-span of the rat and mouse 
allows changes to tissue structure and physiology resulting from in utero insults to be 
monitored over the short course of life-span and is ideal for studying pathophysiological 
mechanisms at tissue, cellular and molecular levels of short and long term impacts on the 
phenotype and disease processes in multiple organs and systems (developmental 
programming or developmental origins of adult health and disease - DOHaD). Mice and 
rats are litter-bearing animals allowing studies of variations among fetuses (such as 
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gender studies) in a similar in utero environment in the same mother. However, the most 
important advantage of creating a mouse model of fetal growth restriction is the 
availability of genetically manipulated mouse models to conduct subsequent studies to 
further delineate potential relevance of a single gene or use genetic manipulation of 
overexpression or deletion of a single gene identified in FGR studies. Gene targeting and 
transgenic experiments have lead to considerable advances in the knowledge of genes 
responsible for placental and fetal growth, however, maternal and fetal responses to in 
utero insults have been lacking due to unavailability of information on the impacts in 
normal wild type animals. Advances in understanding epigenetics, alterations to the 
epigenome by one of the most important components of the developing embryo/fetal 
environment, the nutritional environment, and the potential epigenetic mechanisms that 
may be responsible for long-term impact on the expression of crucial genes in critical 
cells of the manipulated animals may delineate the mechanisms of DOHaD. 
 
2.2 POTENTIAL BENEFITS OF THE MODEL 
Our laboratory has developed a mouse model that consistently and reproducibly 
induces FGR by a mild maternal nutrient reduction (MNR) of 70% of normal daily total 
caloric and nutrient intake during 6.5 to 18.5 days of gestation. We believe that this type 
of nutrient restriction is most relevant clinically. It creates fetal undernutrition, which is a 
common pathophysiology underlying the majority of FGR in humans, in both developed 
and developing countries. In developed countries, fetal undernutrition is caused by 
placental insufficiency, whereas in developing countries, it is caused by maternal under- 
or mal-nutrition. Therefore, it represents the fetal and placental adaptation to maternal 
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undernutrition during pregnancy, relevant particularly to developing countries, and fetal 
adaptation to placental insufficiency, relevant to developed countries. Importantly, 
identification of specific genes or pathways in fetal adaptation will allow future genetic 
manipulation studies to delineate tissue/cellular mechanisms in fetal growth restriction or 
long-term adverse outcomes.  
 
2.3 OVERALL HYPOTHESIS 
The overall hypothesis of this thesis is that mild maternal total caloric and 
nutrient restriction in a mouse leads to adaptation of placenta and fetal tissues and organs 
to maintain fetal survival resulting in fetal growth restriction similar to human FGR, and 
changes in the genome that ultimately results in endocrine/metabolic and 
cardiorespiratory disorders in childhood and adulthood (DOHaD). This model will 
provide an ideal model for mechanistic studies of fetal growth and developmental 
programming (DOHaD), particularly epigenetic mechanisms for further studies. 
 
2.4 RATIONALE FOR ORGANS STUDIED  
The first thesis chapter addresses the hypothesis that global maternal caloric 
restriction is a clinically relevant model to study alterations in fetal growth and long-
term developmental programming, and is similar to human FGR and predisposition to 
DOHaD. To support this hypothesis, we determined changes to placental, fetal and fetal 
organ weights to investigate how fetal growth is affected by total caloric and nutrient 
restriction and whether it represents a symmetric or asymmetric form of FGR. Changes to 
the IGF system in fetal circulation as well as changes in placental and fetal tissues were 
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assessed as major autocrine/paracrine and endocrine regulators of fetal growth. 
Alterations to fetal liver structure and function were assessed as the liver is the major 
organ that is impacted in FGR and may be responsible for some of the 
metabolic/endocrine outcomes of DOHaD, and is the main organ that produces 
circulating IGFs and IGFBPs. Finally, this chapter will describe whether this mouse 
model, which does not subject postnatal animals to overnutrition unlike other models, 
develops glucose intolerance one of the outcomes of DOHaD. 
The second thesis chapter addresses the hypothesis that global maternal caloric 
restriction disrupts normal fetal lung development and compromises postnatal 
pulmonary function. Asymmetric FGR is associated with higher incidences of neonatal 
morbidity and mortality; some may be the result of respiratory complications. Organs 
commonly affected by FGR are the liver and lung, and these organs typically weigh less 
in proportion to the weight of the fetus. Developmental programming of the pulmonary 
system in FGR has been reported in humans but little research has been done due to a 
lack of appropriate animal models. Our mouse model may be suitable to study lung 
development during FGR and the mechanisms which compromise long-term lung 
function. To investigate our hypothesis, fetal lung structure, including lung weights, 
architecture and surfactant proteins were analyzed as well as alterations to circulating 
glucocorticoid levels and tissue glucocorticoid metabolism. Postnatal pulmonary function 
were measured prior to and following puberty to determine if fetal undernutrition 
permanently affects postnatal lung function. 
The third chapter of the thesis focuses on the placenta and hypothesizes that 
global maternal caloric restriction leads to adaptation of the placenta to provide 
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nutrient and substrates to the fetus and its failure contributes to FGR. The placenta 
forms the interface between the maternal and fetal environments. During maternal 
nutrient restriction, placental structure was analyzed in terms of weight, volume, 
variations to cell types, and dimensions of the vasculature. Changes to function were 
analyzed by determining the placental transport of EDTA, glucose and 
methylaminoisobutyric (MeAIB). Finally, alteration to the expression of the IGF system 
was assessed, to determine the paracrine system that could be responsible for changes in 
structure and function. 
This thesis aims to demonstrate the impact and adaptation of maternal nutrient 
restriction in a murine model to gain insights into the pathophysiological mechanisms of 
fetal growth restriction in humans. 
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CHAPTER 3 
 
MATERNAL NUTRIENT RESTRICTION ALTERS FETAL 
INSULIN AND INSULIN-LIKE GROWTH FACTOR 
SYSTEMS AND IMPAIRS LONG-TERM METABOLIC 
FUNCTION 
 
Manuscript submitted to Endocrinology 
 
3.1 INTRODUCTION 
Fetal growth restriction (FGR) in pregnancy occurs when the fetus fails to achieve 
his/her genetically determined growth potential or optimal growth due to fetal, placental 
or maternal factors. A small for gestational age (SGA) newborn is the outcome (1). FGR 
affects 3-10% of human pregnancies and is associated with high perinatal mortality and 
morbidity (2, 3). In developed countries, placental insufficiency is the major etiology, 
causing fetal undernutrition by impaired transfer of nutrients from mother to fetus despite 
normal maternal nutrition. In developing countries, inadequate maternal nutrition is the 
major etiology impairing availability of nutrients to the fetus.  Fetal growth restriction 
can be reproduced in experimental animals by maternal undernutrition, and is utilized to 
study the impact of fetal undernutrition in the fetus and placenta (4). The mouse is 
important to study the pathophysiology of FGR, since it is a mammalian species with 
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similar genetic makeup, biochemical pathways, cell types and physiology to humans (4). 
The mouse is also amenable to genetic manipulation, and knockout or transgenic models 
of genes of interest can be generated for mechanistic studies.  
Fetal and placental growth is regulated by many growth factors; the insulin-like 
growth factor (IGF) system is the principal growth factor.  It regulates cell proliferation, 
differentiation, migration, and aggregation during development by endocrine and 
autocrine/paracrine mechanisms (5). The IGF system includes two growth factors, IGF-I 
and IGF-II, two cell surface receptors, IGF-IR and IGF-IIR, and six IGF-binding 
proteins. Biologic effects of IGF-I and II are mediated by binding to IGF-IR and IGF-II 
binding to the insulin receptor A (INSRA) isoform (6). The INSRA isoform expression is 
elevated during gestation and mediates cell mitogenesis (6, 7), as opposed to the insulin 
receptor B isoform which is highly expressed postnatally and mediates the metabolic 
effects of insulin with little affinity for IGF-II (6, 7). Six high-affinity IGF binding 
proteins (IGFBP-1 to -6) regulate the availability of IGF peptides to developing fetal 
tissues, protecting them from degradation in circulation and modulating binding of IGF 
peptides to their receptors (8). The IGF peptides are synthesized by a wide variety of cells 
in the fetus and placenta with the paracrine IGFBPs determining the cells targeted for 
IGF actions (5). Expression of the IGF system is coupled to the supply of nutrients to 
ensure fetal growth is adequate for the amount of nutrients available (5). Alterations in 
fetal nutrient supply can change the expression of this system in a tissue specific manner 
to regulate overall fetal growth and development of individual fetal organs. 
Developmental alterations in organ structure may affect organ function 
immediately after birth, and ongoing effects on function leading to increased 
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predisposition to disease later in life. Adults who were fetal growth restricted in utero are 
at greater risk for development of diseases such as hypertension, coronary heart disease, 
stroke and type-2 diabetes as adults (9). This association has led to the concept of the 
“fetal origins of adult disease”, which hypothesizes that suboptimal growth during fetal 
life in response to undernutrition or other stresses causes fetal organ systems to adapt and 
develop in a way that predisposes them to the development of adulthood diseases (10).  
Several models of FGR use knockout and transgenic mice in which components 
of IGF system genes have been manipulated (11-15). The role of the IGF system in FGR 
has not been previously characterized in the mouse. To determine if the impact of fetal 
undernutrition on fetal growth in the mouse is similar to FGR in humans, we generated a 
maternal nutrient restricted (MNR) mouse model of FGR in which mothers were fed 
80%, 70% or 60% normal daily caloric intake during pregnancy. We studied growth of 
organ systems during fetal development by determining changes in fetal organ weights, 
and tissue-specific IGF-system expression. Specific structural changes in the liver, which 
is the major source of the endocrine IGF system, were analyzed. Since male FGR mice 
developed glucose intolerance as adults, changes to insulin and glucagon expression in 
the pancreas were investigated during fetal life and postnatally. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Animals and Dietary Restriction Protocol 
Protocols on Animal Care were approved by the University Council on Animal 
Care at the University of Western Ontario (appendix), and maintained in accordance with 
guidelines of the Canadian Council for Animal Care. Ten week old virgin CD-1 females 
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and stud males were obtained from Charles River Laboratories (Montreal, PQ, Canada). 
Mice were housed in the Lawson Health Research Institute Vivarium (London ON, 
Canada) with a 12:12 light:dark cycle and water provided ad libitum. Female mice were 
housed singly with stud males in late afternoon and checked the following morning for a 
vaginal plug, indicating embryonic day 0.5 (E0.5). Females were housed individually and 
fed grain-based dustless precision pellets (#F0173, Bio-Serv, Frenchtown NJ, USA) 
containing 20.7% protein, 4.0% fat, 6.7% ash, 59.6% carbohydrates, 4.0% fiber and 5.0% 
moisture ad libitum using feeding tubes with cage clips (Bio-Serv, Frenchtown NJ, USA) 
until E6.5. Feeds for control mice were pre-weighed each morning and remaining pellets 
weighed at the same time each day to establish average daily feed intake during 
pregnancy. MNR pregnant mice from E6.5 were fed daily either 80% (n = 8 litters), 70% 
(n = 9 litters) or 60% (n = 7 litters) by weight of average daily intake of control mice (n = 
24). Mice were euthanized at E18.5 by carbon dioxide inhalation. Fetal tissues and 
placentae, trimmed of membranes and yolk sac, were dissected, weighed, and pooled by 
litter before flash freezing in liquid nitrogen. Maternal and pooled fetal blood was 
obtained using heparinized capillary tubes (Fisher Scientific, Unionville ON, Canada).  
Weight data was analyzed for differences between MNR and control groups using 
one-way ANOVA followed by Tukey’s multiple comparisons test. Non-parametric data 
was analyzed using Kruskal-Wallis and Dunn’s post-hoc tests. 
 
3.2.2 Insulin and Insulin-Like Growth Factor (IGF) ELISAs 
Plasma insulin was measured in six month old adult males at 0, 60 and 120 
minute timepoints during a glucose tolerance test using Ultra Sensitive Mouse Insulin 
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ELISA Kit (Crystal Chem Inc., Downers Grove, IL) (Appendix 1.1.1). Plasma insulin of 
E18.5 mothers and their respective litter was quantified using the multiplexed bone 
metabolism mouse panel 1A biomarker immunoassay kit according to manufacturers’ 
instruction (Milliplex, Millipore Corp, MA). A Bio-PlexTM 200 readout system was used 
(Bio-Rad Laboratories, Hercules, CA), utilizing Luminex® xMAPTM fluorescent bead-
based technology (Luminex Corp., Austin, TX). Levels were calculated from standard 
curves using Bio-Plex Manager software (v.4.1.1, Bio-Rad). IGF system peptides were 
measured in maternal and fetal plasma using ELISA kits as per manufacturers’ 
instructions from AssayPro (St. Charles, MO) for IGF-I, Insight Genomics (Falls 
Church,VA) for IGFBP-1, ALPCO (Salem, NH) for IGFBP-2 and R&D Systems 
(Minneapolis, MN) for IGFBP-3.  
 
3.2.3 Glucose Tolerance Testing 
Blood glucose was measured with a Contour glucometer (Bayer Healthcare, 
Toronto ON). Thirteen control and nine 70% MNR males as well as ten control and ten 
70% MNR females were tested for glucose tolerance at 6 months of age. A bolus of 
glucose (2 mg/g weight) was given intraperitoneally following an overnight fast. Blood 
samples taken every 30 min for 2 hours during the test. Resulting blood glucose levels 
during the 30 min intervals were plotted and the area under the curve was calculated and 
compared between groups using a Mann-Whitney statistical test.  
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3.2.4 Quantitative real-time PCR (qRT-PCR) 
Total RNA from flash frozen control and 70% MNR fetal tissues were extracted 
using Trizol (Invitrogen, Burlington, ON) and purified with RNAeasy Mini Kit (Sigma, 
Maryland, USA), following manufacturer’s instructions.  
The relative abundance of IGF-I and -II and IGFBP-1, -2, and -3 mRNAs was 
determined using qRT-PCR with the Taqman MGB probe method (FAM dye-labeled) in 
an ABI PRISM 7900HT system (Applied Biosystems, Foster City, CA) with Sequence 
Detection System, Version 2.2.1 (Applied Biosystems). Loading controls were GAPDH 
mRNA for the lung and β-2-microglobulin (β2M) in remaining fetal tissues (TABLE 
3.1). PCR assays were run in triplicate using 100 ng RNA in 10 µl Taqman One-Step RT-
PCR Master Mix (#4309169, Applied Biosystems). One-step PCR cycling was carried 
out as follows: 48C, 30 min for 1 cycle; 95C, 10 min for 1 cycle; 95C, 15 sec; 
60C, 1 min for 40 cycles. Criteria for amplicon acceptance was an r2 > 95% and slope 
between -3.1 and -3.6 (with difference between target gene and endogenous control gene 
of no more than 0.2).  
 
3.2.5 Protein and DNA quantification 
Fetal livers were pooled for each litter, homogenized with protease inhibitors 
(Complete Mini, Roche Diagnostics, Mannheim, Germany) in phosphate buffer. For 
protein quantification, a sample aliquot was syringed three times and centrifuged at 
13,000 x g for 1 hr. Triplicate samples were quantified using bicinchoninic acid (BCA) 
assay (Pierce; Rockford, IL). DNA quantification was performed by fluorometric DNA 
assay. An aliquot was centrifuged at 4000 x g for 5 min. Supernatant was diluted with 2 
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TABLE 3.1 Catalog information for Primers and Probes from Applied 
Biosystems for real time RT-PCR 
Primer Name Catalog # 
IGF-I Mm00439561_m1 
IGFBP-1 Mm00515154_m1 
IGFBP-2 Mm00492632_m1 
IGFBP-3 Mm00515156_m1 
GAPDH Mm99999915_m1 
β2-Macroglobulin Mm0437764_m1 
IGF-II 5’-GTGGCATCGTGGAAGAGTGC-3’ 
5’-GTCCGGAAGTACGGCCTGAG-3’ 
Probe: 5’-GACCTGGCCCTCCTGGAGACATAC-3’ 
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mM EDTA and Hoechst 33342 dye (Molecular Probes; Eugene, OR) was added to 
samples. Duplicate measurements were obtained by fluorescence spectrophotometry 
(Fluoroskan Ascent FL, ThermoLabsystems; Milford, MA), and quantified against a 
standard curve generated with salmon testis DNA (Sigma-Aldrich; Oakville, ON).  
 
3.2.6 Liver Enzyme Activity Measurements 
Fetal and adult male liver tissues (approximately 50 mg) were homogenized 
(Ultra Turrax; IKA Works, Wilmington, NC) followed by sonication (Microson, NY) in 
50 mM Tris buffer with protease inhibitor (Roche, Mannheim, Germany) (16). 
Homogenates were prepared for enzyme measurement as previously described. The 
enzymes and assay conditions (found to give optimal activities) used have been described 
before for Glucokinase (EC 2.7.1.2) (17) and Phosphoenolpyruvate carboxykinase 
(PEPCK; EC 4.1.1.32) (16). 
 
3.2.7 Tissue Preparation 
Fetal mouse livers were harvested at E18.5 and fixed in 4% paraformaldehyde for 
48 hrs. Whole mouse embryos were harvested at E18.5, immersed in 4% 
paraformaldehyde for 24 hrs, bisected, and immersed in 4% paraformaldehyde for an 
additional 24 hrs. Adult mouse pancreases were harvested at 6 months of age, fixed in 4% 
paraformaldehyde for 24 hrs. Tissue specimens were washed 3 times in PBS over 3 days 
and preserved in 70% ethanol before embedded in paraffin. E18.5 fetal livers were 
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sectioned at 3 µm, with remaining tissues sectioned at 5 µm and mounted onto 
Superfrost® slides (Fisher Scientific, Fairlawn, NJ). 
 
3.2.8 In situ Hybridization (ISH) 
Fetal liver sections were utilized for analysis of IGF-I, IGF-II, IGFBP-1, -2 and -3 
mRNA expression by in situ hybridization using 35S-labeled antisense riboprobes as 
described previously (21). The 35S-labeled antisense and sense cRNA probes were 
generated from cDNA (TABLE 3.2) using the Promega Riboprobe Combination System 
SP6/T7 kit (Promega Corp., Madison, WI) and 35S-UTP (Perkin Elmer, Waltham, MA). 
In situ hybridization was performed as previously described (21) (Appendix 1.1.2). 
Slides were viewed under dark and bright fields, using a Carl Zeiss Axio Imager Z1 with 
photomicrographs obtained at 400× magnification using AxioCamHR3 and AxioVision 
Release 4.7.2 software. 
 
3.2.9 Immunofluorescence 
Sections were deparaffinized and rehydrated in a descending series of ethanol 
solutions. Tissue sections were blocked with Background Sniper Blocking Reagent 
(Biocare Medical, Concord, CA) for 10 min prior to application of primary antibodies; 
ter-119 and PCNA to liver sections at RT for 1 hour (TABLE 3.3). Tissue sections were 
washed, incubated for 30 min at RT with appropriate Alexa Fluor 568-conjugated IgG 
secondary antibodies (1:200; Molecular Probes Inc., Eugene OR), counterstained with 
pre-mixed DAPI (Molecular Probes Inc.) and coverslipped with ProLong® Gold 
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TABLE 3.2 cDNA Vectors for generating cRNA probes for in situ hybridization of 
IGF system mRNAs. 
Restriction Site AntiSense                           
Probe 
Target 
(gi #) 
Size 
(bp) AS S 
Vector Origin Ref 
        
mIgf-1 33612736 271 XhoI EcoRV pBluescript LION imaGenes                        -
        
mIgf-2 170172554 468 EcoR I Sst I 
pBluescript 
KS Dr. Graeme Bell (18) 
        
rIgfbp-1 6981079 1477 Kpln XhoI pGEM 7Zf Matt Rechler (19) 
        
rIgfbp-2 148747420 585 HindIII EcoR I pGEM 3z Matt Rechler (19) 
        
rIgfbp-3 6981083 905 EcoRI SmaI pGEM 3z Dr. Adrian H. Herington  (20) 
 
The nucleotide sequence homology between rat and mouse IGFBP-1 to -3 cDNAs is 90-94%. 
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TABLE 3.3 Primary Antibodies used for Immunohistochemistry and 
Immunofluoresence. 
Antibody Host Catalogue # Dilution Source 
     
IGF-I Rabbit #RB-9240-P 1:10 Labvision Corp., Fremont, CA 
     
IGF-II Rabbit PAAL1 1:15 GroPep, Adelaide SA, Australia 
     
IGFBP-1 Goat Sc-6072 1:400 Santa Cruz Biotech Inc., Santa Cruz, CA 
     
IGFBP-2 Rabbit #06-107 1:750 Upstate Biotech Inc., Lake Placid, NY 
     
IGFBP-3 Rabbit DSL-R00534 1:750 Diagnostic Systems Laboratories, Inc., Webster, TX 
     
Ter-119 Rat 116201 1:50 BioLegend, Inc., San Diego, CA 
     
PCNA Goat Sc-9857 1:500 Santa Cruz Biotech Inc., Santa Cruz, CA 
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AntiFade Reagent (Molecular Probes Inc.). Omission of primary antibody controlled for 
autofluorescence and nonspecific binding. Fluorescent images were captured and 
analyzed using a Carl Zeiss Axio Imager Z1 microscope equipped with AxioCamMR3 
camera and AxioVision Release 4.7.2 software. To determine the proportion of liver 
composed of hematopoietic cells in 8 control and 8 MNR fetuses, the number of cells 
expressing ter119 per total number of cells were counted in 12 random fields of view at 
400× magnification. The same technique was used to determine the proportion of 
proliferating cell nuclear antigen (PCNA) positive cells in the liver.  
At E18.5, eight control and seven 70% MNR mouse embryos and six month old 
adult mouse pancreas from thirteen control and seven 70% MNR animals were sectioned 
at 5 µm and every 10th section was collected for analysis of β-cell mass. Sections were 
deparaffinized as above then rinsed in PBS before applying Universal Sniper Blocking 
Agent (Biocare Medical, Concord, CA) for 10 min. Mouse anti-insulin (1:1000; Sigma-
Aldrich, St. Louis, MO) and Rabbit anti-glucagon (1:200; Dako, Capinteria, CA) was 
applied to sections for 1 h at RT. The slides were washed in PBS three times for 5 min 
and incubated for 30 min at room temperature with Alexa Fluor 488-conjugated goat anti-
mouse IgG diluted 1:200 (Invitrogen) for insulin and Alexa Fluor 568-conjugated Goat 
anti-rabbit at 1:200 for glucagon (Invitrogen). Pancreases were counterstained with DAPI 
as above. Fluorescent labeling was visualized and photographed using a Carl Zeiss Axio 
Imager Z1 microscope equipped with AxioCamMR3 camera and AxioVision Release 
4.7.2 software. In embryos, the percentage of pancreas area stained for insulin and 
glucagon was measured. In six month old adult pancreases, β-cell mass was calculated by 
measuring area of the pancreas stained with insulin and dividing by total area occupied 
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by pancreatic tissue. This ratio was multiplied by the total mass of the pancreas dissected 
from the mouse. Alpha-cell mass was calculated by measuring the area of the pancreas 
stained with glucagon and dividing by the total area occupied by pancreatic tissue and 
multiplying by the weight of the pancreas. 
 
3.2.10 Histochemistry 
Apoptotic cells were detected using an Apoptag Kit from Chemicon International 
(Millipore, Billerica, MA), as per the manufacturer’s instructions. To determine the 
percentage of apoptotic cells in the liver of eight control and eight MNR fetuses, the 
number of diaminobenzidine (DAB) positive cells were counted in 12 random fields of 
view per total number of nuclei at 400× magnification (Appendix 1.1.3).  
To determine the proportion of glycogen in eight control and eight MNR livers, 
Periodic acid-Schiff (PAS) staining was performed using PISSARRO-PAS Stain Kit 
(Biocare Medical, Walnut Creek, CA) according to manufacturer’s instructions. The area 
of PAS staining in 12 random fields of view was determined at 400× magnification 
(Appendix 1.1.4).  
 
3.2.11 Statistical Analysis 
All data was expressed as mean ± SEM. Parameters measured in control and 70% 
MNR animals were compared with Student’s non-paired two-tail t test. A Mann-Whitney 
test was performed to determine fold changes in 70% MNR litters for qRT-PCR. 
Significance was set at P < 0.05. 
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3.3 RESULTS 
3.3.1 Effects of MNR on the fetus and fetal organ weights 
To determine if our maternal undernutrition regimen induces a phenotype similar 
to human fetal growth restriction, fetal organ weights at E18.5 were determined for each 
treatment group.  Fetal weights were significantly less in each MNR regimen compared 
to controls (TABLE 3.4). The 70% MNR fetuses demonstrated the most consistent and 
significant organ weight reduction with exception of the heart, kidney and brain; this 
demonstrates an asymmetric phenotype of FGR (TABLE 3.4). In 80% MNR fetuses, the 
placenta and brain weights were spared with no significant reduction compared to 
controls, while remaining tissues were significantly reduced (TABLE 3.4). In the 60% 
MNR, the litter size was significantly reduced but fetal weight was maintained. In 60% 
MNR fetuses, organ weights were comparable to 80% MNR, with the exception of the 
liver (TABLE 3.4). Therefore, for the remainder of studies 70% MNR was used. 
 
3.3.2 Effects of FGR on the IGF system 
3.3.2.1 Endocrine IGF system 
 
Endocrine levels of the IGF system were determined in fetal and maternal blood 
to determine if similar changes in our mouse undernutrition model are similar to changes 
to endocrine levels of the IGF system documented in human pregnancies afflicited with 
fetal growth restriction. In maternal plasma of 70% MNR, IGF-I and IGFBP-3 
concentrations were significantly decreased (Fig. 3.1; IGF-I: control 56 ± 12 ng/mL vs. 
MNR 26 ± 4 ng/mL; P < 0.05; IGFBP-3: control 1048 ± 70 ng/mL vs. MNR 586 ± 84 
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TABLE 3.4 Effect of Maternal Nutrient Restriction beginning at E 6.5 of 
pregnancy on placental and fetal tissue weights at E 18.5. 
 
Control 
(n=24) 
80% MNR 
(n=8) 
70% MNR 
(n=9) 
60% MNR 
(n=7) 
Fetus    1397 ± 17    1149 ± 64a     894 ± 52a,b     967 ± 63a,b 
Placenta        95 ± 3        91 ± 5       72 ± 3a,b       78 ± 4a 
Heart          8 ± 1          6 ± 1a         5 ± 1a         5 ± 1a 
Lung        51 ± 1        39 ± 3a       29 ± 2a,b       32 ± 2a 
Liver        91 ± 2        69 ± 5a       46 ± 3a,b       50 ± 3a,b 
Gut        81 ± 1        67 ± 4a       48 ± 4a,b       55 ± 5a 
Kidney        12 ± 1          9 ± 1a         7 ± 1a         8 ± 1a 
Brain        69 ± 1        64 ± 3       56 ± 2a       58 ± 3a 
Carcass      977 ± 12      801 ± 4a     644 ± 38a,b     673 ± 50a 
Litter Size        13 ± 1        11 ± 1       11 ± 1       10 ± 1a 
Pregnant mothers were fed ad libitum (control) or 80%, 70% or 60% MNR 
beginning at E 6.5. At E 18.5, mothers were sacrificed and placenta and fetal 
tissues were weighed for each fetus for a mean litter value. The result, litter mean 
±SEM for ‘N’ number of litters, is expressed in mg. 
 
Superscripts (a = different from control ( P < 0.05); b = different from 80% MNR ( 
P < 0.05); c =  different from 70% MNR ( P < 0.05) among treatment groups 
indicate a significant difference in weight by one-way ANOVA (P < 0.05), 
followed by Tukey’s multiple comparisons test. 
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Figure 3.1 The effect of maternal nutrient restriction on circulating concentrations 
of the IGF system in the maternal and fetal plasma at E18.5. (A) Maternal plasma 
IGF-I concentrations (mean ± SEM) were 56 ± 12 ng/mL in controls (N=8) and 26 ± 4 
ng/mL in 70% MNR (N=8) (P<0.05). IGF-I concentrations were 55% lower in 70% 
MNR mothers (P < 0.05). (B) Maternal plasma concentrations (mean ± SEM) of IGFBP-
1, -2 and -3 in controls (N=8) and 70% MNR (N=8). In 70% MNR mothers, the IGFBP-1 
concentration of 899 ± 201 ng/mL (vs 68 ± 17 ng/mL in controls) and IGFBP-2 
concentration of 3,299 ± 432 ng/mL (vs 1648 ± 253 ng/mL in controls) were significantly 
higher (both P < 0.005), while IGFBP-3 concentration of 586 ± 84 ng/mL (vs 1048 ± 70 
ng/mL in controls) was significantly lower (P < 0.001). (C) Fetal plasma IGF-I 
concentrations (mean ± SEM) were 29 ± 3 ng/mL in controls (N=8) and 20 ± 2 ng/mL in 
70% MNR (N=8). IGF-I concentrations were 30% lower in 70% MNR fetuses (P < 0.05). 
(D) Fetal plasma concentrations (mean ± SEM) of IGFBP-1, -2 and -3 in controls (N=8) 
and 70% MNR (N=8). In 70% MNR fetuses, the IGFBP-1 concentration of 362 ± 70 
ng/mL (vs 197 ± 25 ng/mL in controls) and IGFBP-2 concentration of 2719 ± 170 ng/mL 
(vs 2194 ± 169 ng/mL in controls) were significantly higher (both P < 0.05), while 
IGFBP-3 concentration of 1475 ± 112 ng/mL (vs 1944 ± 111 ng/mL in controls) was 
significantly lower (P < 0.01).  
     
   
 
61
     
   
 
62
ng/mL; P < 0.001), whereas IGFBP-1 and IGFBP-2 concentrations were significantly 
increased (Fig. 3.1; IGFBP-1: control 68 ± 17 ng/mL vs. MNR 899 ± 201 ng/mL; P < 
0.005; IGFBP-2: control 1648 ± 253 ng/mL vs. MNR 3299 ± 432 ng/mL; P < 0.005). In 
fetal plasma, changes to concentrations of the IGF system peptides were similar to that of 
maternal plasma with lower IGF-I and IGFBP-3 concentrations and higher IGFBP-1 and 
IGFBP-2 concentrations in MNR fetuses compared to controls (Fig. 3.1; IGF-I: control 
29 ± 3 ng/mL vs. MNR 20 ± 2 ng/mL; P < 0.05; IGFBP-3: control 1944 ± 111 ng/mL vs. 
MNR 1475 ± 112 ng/mL; P < 0.01; IGFBP-1: control 197 ± 25 ng/mL vs. MNR 362 ± 70 
ng/mL; P < 0.05; IGFBP-2: control 2194 ± 169 ng/mL vs. MNR 2719 ± 170 ng/mL; P < 
0.05). The ratio of IGF-I to IGFBP-3 was similar between control and 70% MNR in both 
fetal and maternal plasma. Assays for IGF-II levels in plasma are unavailable for reliable 
estimates in the small volumes of mouse plasma. 
 
3.3.2.2 IGF system mRNAs in fetal tissues and placentae 
The expression levels of mRNAs encoding the IGF system in different fetal 
organs/tissues were performed to determine autocrine/paracrine changes of the system 
that correspond with changes in organ/tissue growth, and the organs/tissues that are 
responsible for the changes in fetal endocrine levels of the IGF system. IGF-I, -II, and 
IGFBP-1,-2,-3 mRNA levels were determined in heart, lung, liver, brain, carcass and 
placenta in control and 70% MNR litters using qRT-PCR. The liver demonstrated 
greatest response to MNR with significantly increased levels of IGFBP-1, IGFBP-2, and 
IGFBP-3 mRNAs (TABLE 3.5). Placenta, lung and brain demonstrated an increase in 
IGFBP-3 mRNA levels (TABLE 3.5). The placenta was the only organ that showed a 
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TABLE 3.5 Effect of 70% Maternal Nutrient Restriction beginning at E 6.5 of 
pregnancy on Insulin-Like Growth Factor (IGF) System mRNA levels at E 18.5 in 
placental and fetal tissues. 
 IGF-I IGF-II IGFBP-1 IGFBP-2 IGFBP-3 
Placenta 0.53 ± 0.12* 1.11 ± 0.07 0.64 ± 0.20 1.10 ± 0.16 1.76 ± 0.12* 
Heart 0.58 ± 0.08 1.04 ± 0.09 - - 1.24 ± 0.13 
Lung 0.71 ± 0.11 0.93 ± 0.09 1.85 ± 0.80 0.97 ± 0.21 2.22 ± 0.51* 
Liver 0.70 ± 0.10 1.04 ± 0.11 5.10 ± 1.86* 1.86 ± 0.33* 1.29 ± 0.08* 
Brain 0.80 ± 0.09 0.88 ± 0.09 2.29 ± 0.50 0.90 ± 0.08 1.48 ± 0.13* 
Carcass 0.76 ± 0.06 1.14 ± 0.10 - 1.60 ± 0.20 1.45 ± 0.15 
Pregnant mothers were fed ad libitum (control) or 70% MNR beginning at E 6.5.  At E 
18.5 mothers were sacrificed and placenta and fetal tissues collected and pooled by 
litter. The IGF system mRNA levels were measured by quantitative real-time PCR and 
corrected for the internal housekeeping gene, β2 macroglobulin. The relative mRNA 
levels of each tissue of 70% MNR group (N = 6 litters) are expressed relative to those 
of control group (N = 6 litters), which are assigned a value of one. 
 
* Indicates a significant fold-change between control and 70% MNR groups by Mann-
Whitney  Test (P < 0.05). 
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significant reduction in IGF-I mRNA level. In most fetal tissues, IGF-I mRNA levels 
were relatively lower, with no change in IGF-II mRNA levels (TABLE 3.5). At E11.5, 
the liver is the major source of hematopoietic cells during gestation as it is populated by 
hematopoietic stem cells and provides a developmental niche for the expansion, 
maturation and enucleation of primitive erythroid cells (22). Late in development, from 
approximately E16 onwards, the site of hematopoiesis shifts gradullay to the bone 
marrow, which is the definitive site where hematopoietic stem cells and progenitors of 
the adult hematopoietic system reside (22). In situ hybridization demonstrated IGF-I and -
II and IGFBP-1, -2 and -3 mRNAs to be expressed in hepatocytes and not in 
hematopoietic cells (Fig. 3.2 and Fig. 3.3) (Appendix Fig. 1.1, Fig 1.2 and Fig. 1.3).   
 
3.3.3 Effects of FGR on liver 
Fetal liver was demonstrated to be significantly affected by maternal 
undernutrition in terms of weight and IGF system expression. Analysis of liver structure 
was determined by immunohistochemistry of liver cell types at E18.5 (Fig. 3.4) and 
analysis of liver function by measurement of hepatocyte enzyme activity. 
Immunohistochemistry of the liver showed that IGFs and IGFBPs were localized in 
hepatocytes and not in hematopoietic cells. The percentage of hematopoietic cells as 
determined by ter-119 immunoreactivity was not different between MNR and controls, 
indicating that the proportion of hepatocytes and hematopoietic cells was maintained in 
FGR fetal livers and IGFBP expression increased in each hepatocyte during MNR (Fig. 
3.5A). Glycogen staining in MNR liver was significantly reduced compared to controls  
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Figure 3.2 Insulin-Like Growth Factor (IGF) System mRNA expression in fetal 
livers of control and 70% MNR at E 18.5. Autoradiography of in situ hybridization of 
IGF-I (A, B), IGF-II (C, D) in control (A, C) and 70% MNR (B, D). Images are captured 
by darkfield microscopy. White grains indicate location of IGF mRNA. Open arrows 
indicate representative hematopoietic cell clusters; closed arrows indicate representative 
hepatocytes. Note the hepatocytes of the control livers are filled with glycogen. Scale 
bars, 100 µm. 
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Figure 3.3 Insulin-Like Growth Factor (IGF) System mRNA expression in fetal 
livers of control and 70% MNR at E 18.5. Autoradiography of in situ hybridization of 
IGFBP-1 (A, B), IGFBP-2 (C, D), IGFBP-3 (E, F) in control (A, C, E) and 70% MNR 
(B, D, F). Images are captured by darkfield microscopy. White grains indicate location of 
IGF mRNA. Open arrows indicate representative hematopoietic cell clusters; closed 
arrows indicate representative hepatocytes. Note the hepatocytes of the control livers are 
filled with glycogen. Scale bars, 100 µm. 
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Figure 3.4 Representative photomicrographs of changes to fetal liver at E 18.5 
following 70% MNR. Cells positive for hematopoietic marker (A and B), ter119, in fetal 
livers of control (A) and 70% MNR (B). Glycogen (PAS) stained hepatic cells (C and D) 
in the control (C) and 70% MNR group (D). Cells positive for PCNA (E and F) in the 
control (E) and 70% MNR group (F). Apoptotic cells (G and H) in control (G) and 70% 
MNR (H). Arrows indicate positive markers. Scale bars, 100 µm. 
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Figure 3.5 Changes to fetal liver cells at E 18.5 following 70% MNR. (A) Cells 
positive for hematopoietic marker, ter119, (mean ± SEM) in fetal livers of control (N=8) 
and 70% MNR (N=8) showed no differences. (B) Percentage of glycogen (PAS) stained 
hepatic cells (mean ± SEM) in the 70% MNR group of 49 ± 5% (vs 75 ± 4% in control) 
was significantly reduced (P < 0.01). (C) Percentage of cells positive for PCNA (mean ± 
SEM) in the 70% MNR group of 17 ± 0.9% (vs 13 ± 0.9% in controls) was significantly 
increased (P < 0.01). (D) Percentage of apoptotic cells (mean ± SEM) demonstrated no 
differences. 
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(Fig. 3.5B; control 75 ± 4% vs. MNR 49 ± 5%; P < 0.001). Livers in MNR had a greater 
percentage of cells expressing the cell proliferation marker, PCNA, (Fig. 3.5C; control 13 
± 0.9% vs. MNR 17 ± 0.9%; P < 0.01), with no change in percentage of apoptotic cells 
(Fig 3.5D). Liver DNA and protein content (µg/mg wet weight) were not significantly 
different between groups (Appendix TABLE 1.1 and 1.2). Activity of 
phosphoenolpyruvate carboxykinase (PEPCK) and glucokinase were not different 
between control and 70% MNR fetal livers at E18.5. However, at six months, adult males 
demonstrated glucokinase (control 1.98 ± 0.09 µmol/min/g vs. MNR 1.47 ± 0.06 
µmol/min/g; P < 0.0005) activity was significantly lower in 70% MNR group, while 
PEPCK activity (control 0.039 ± 0.012 µmol/min/g vs. MNR 0.073 ± 0.009 µmol/min/g; 
P < 0.05) was significantly increased in the 70% MNR group. 
 
3.3.4 Glucose Intolerance 
At E18.5 fetal levels of glucose and insulin were measured to determine the 
exposure of fetal tissues to this important substrate and growth factor, respectively. At 
E18.5, both maternal (Fig. 3.6A; control 5.7 ± 0.3 mmol/L vs. MNR 3.3 ± 0.3 mmol/L; P 
< 0.001) and fetal blood glucose levels (Fig. 3.6A; control 3.7 ± 0.3 mmol/L vs. MNR 2.6 
± 0.2 mmol/L; P < 0.05) were significantly lower in the 70% MNR animals compared to 
controls, with a reduction in plasma insulin in both mother (Fig. 3.6B; control 692 ± 147 
pg/mL vs. MNR 56 ± 19 pg/mL; P < 0.005) and fetus (Fig. 3.6B; control 1615 ± 188 
pg/mL vs. MNR 546 ± 104 pg/mL; P < 0.001). Due to the reduction in fetal blood 
glucose and insulin levels with maternal undernutrition, we determined if there were 
structural changes to the fetal endocrine pancreas at E18.5. Tissue sections of whole  
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Figure 3.6 Changes to fetal endocrine pancreas structure at E 18.5 following 70% 
MNR. (A) Blood glucose levels (mean ± SEM) of control (N=12) and 70% MNR (N=9) 
mothers and control (N=8) and 70% MNR (N=8) litters. The blood glucose 
concentration, in 70% MNR mothers of 3.3 ± 0.3 mmol/L (vs  5.7 ± 0.3 mmol/L in 
controls) and 70% MNR fetuses of 2.6 ± 0.2 mmol/L (vs 3.7 ± 0.3 mmol/L in controls) 
were significantly lower (P < 0.0001) and (P < 0.05), respectively. (B) Plasma insulin 
concentrations (mean ± SEM) of control (N=6) and 70% MNR (N=6) mothers and 
control (N=6) and 70% MNR (N=6) litters. The plasma insulin concentration, in 70% 
MNR mothers of 56 ± 19 pg/mL (vs 692 ± 147 pg/mL in controls) and 70% MNR fetuses 
of 546 ± 104 pg/mL (vs 1615 ± 188 pg/mL in controls) were significantly reduced (P < 
0.005) and (P < 0.001), respectively. (C) Percentage of pancreas area staining positive for 
insulin (mean ± SEM) in control (N=8) and 70% MNR (N=7) fetuses. Insulin staining in 
the 70% MNR group of 6.2 ± 0.5 % (vs 10.2 ± 1.1% in controls) was significantly lower 
(P < 0.01). (D) Percentage of pancreas area staining positive for glucagon (mean ± SEM) 
in control (N=8) and 70% MNR (N=7) fetuses. Glucagon staining the in the 70% MNR 
group of 2.5 ± 0.4% (vs 3.9 ± 0.2% in controls) was significantly less (P < 0.01). 
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embryos were used to determine insulin and glucagon immunoreactivity, and expressed 
as percentage of the pancreas occupied by β- and α-cells respectively. MNR embryos 
demonstrated a significantly reduced insulin immunoreactivity (Fig. 3.6C; control 10.2 ± 
1.1 % vs. MNR 6.2 ± 0.5 %; P < 0.01), suggesting fewer beta cells in the fetal pancreas. 
A similar reduction was observed in glucagon immunoreactivity (Fig. 3.6D; control 3.9 ± 
0.2 % vs. MNR 2.5 ± 0.4 %; P < 0.01). These findings indicate that MNR impeded 
development of both types of endocrine cells in fetal pancreas. 
Studies of glucose tolerance were followed after birth to determine if there were 
long-term consequences to glucose metabolism following maternal undernutrition during 
gestation. At six months, adult male mice demonstrated glucose intolerance with a 
significantly increased area under the curve (AUC) for glucose (Fig. 3.7C; control 660 ± 
61 vs. MNR 1287 ± 128; P < 0.0001). There was no significant difference in body 
weights between controls and MNR (control 50.1 ± 5.0 g vs. MNR 51.8 ± 5.7 g). 
Pancreatic weights were not different between the two groups (control 331 ± 70 mg vs. 
MNR 286 ± 50 mg). Fasting glucose at time 0 of the glucose tolerance test was not 
different between the two groups, however, each subsequent 30 min time point 
demonstrated significantly higher blood glucose levels (Fig. 3.7A). Insulin levels 
measured at 60 min and 120 min during the glucose tolerance test were not significantly 
different (Fig. 3.7F). MNR females did not show glucose intolerance at six months (Fig. 
3.7B and D). 
Due to the changes to glucose tolerance at 6 months, the structure of the male 
endocrine pancreas were studied. At this time point, the β-cell mass of adult male MNR 
mice was significantly decreased (Fig. 3.8A; control 9.1 ± 1.6 mg vs. MNR 2.8 ± 1.1 mg;  
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Figure 3.7 Glucose tolerance testing at six months postnatal. (A) Blood glucose levels 
(mean ± SEM) of control (N=13) and 70% MNR (N=9) male mice during glucose 
tolerance testing. Blood glucose levels were higher in the 70% MNR males from 30 to 
120 minutes. (B) Blood glucose levels (mean ± SEM) of control (N=10) and 70% MNR 
(N=10) female mice during glucose tolerance testing, demonstrated no differences 
between groups. (C) Area under the curve (AUC) of the glucose tolerance test in 70% 
MNR male mice of 1287 ± 128 (vs 660 ± 61 in controls) was significantly elevated (P < 
0.0001). (D) Area under the curve (AUC) of the glucose tolerance test in 70% MNR 
female mice demonstrated no differences between groups. (E) Plasma insulin 
concentration (mean ± SEM) of male mice during glucose tolerance testing, demonstrated 
no differences between groups. 
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Figure 3.8 Adult male endocrine pancreas structure at six months postnatally, 
following 70% MNR in utero. (A) Beta cell mass (mean ± SEM) in control (N=13) and 
70% MNR (N=7) males. Beta cell mass in 70% MNR males of 2.8 ± 1.1 mg (vs 9.1 ± 1.6 
mg in controls) was significantly reduced (P < 0.05). (B) Alpha cell mass (mean ± SEM) 
in control (N=13) and 70% MNR (N=7) males. Alpha cell mass in 70% MNR males of 
0.18 ± 0.04 mg (vs 0.35 ± 0.06 mg in controls) was significantly reduced (P < 0.05). (C) 
Alpha cell area per islet area (mean ± SEM) in control (N=13) and 70% MNR (N=7) 
males. Alpha cell mass in 70% MNR males of 0.18 ± 0.04 mg (vs 0.35 ± 0.06 mg in 
controls) was significantly reduced (P < 0.05). (D) Area of islets (mean ± SEM) in 
control (N=13) and 70% MNR (N=7) males. Mean islet area in 70% MNR males of 
6,753 ± 2,123 µm2 (vs 12,373 ± 1,536 µm2 in controls) was significantly reduced (P < 
0.05). (E) Density of islets (mean ± SEM) per area of pancreas in control (N=13) and 
70% MNR (N=7) males. Islet density in 70% MNR males of 1.4 ± 0.2 islets/mm2 (vs 2.3 
± 0.1 islets/mm2 in controls) was significantly reduced (P < 0.005). 
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P < 0.05). The α-cell mass was also reduced (Fig. 3.8B; control 0.35 ± 0.06 mg vs. MNR 
0.18 ± 0.04 mg; P < 0.05). Interestingly, the proportion of islet area staining for glucagon 
was greater in 70% MNR male mice (Fig. 3.8C; control 4.2 ± 0.3 % vs. MNR 8.8 ± 2.0 
%; P < 0.01). In MNR male pancreases, the density of islets (Fig. 3.8E; control 2.3 ± 0.1 
islets/mm2 vs. MNR 1.4 ± 0.2 islets/mm2; P < 0.005), and mean area of islets were 
significantly reduced (Fig. 3.8D; control 12,373 ± 1,536 µm2 vs. MNR 6,753 ± 2,123; P < 
0.05). The size of each α-cell and β-cell were not significantly different between the two 
groups, suggesting that the reduction in α- and β-cell mass was due to fewer α- and β-
cells in 70% MNR males. Total pancreatic insulin content was not different between 
groups. This suggests MNR caused fewer endocrine cells to differentiate during 
development and beta cells were more affected than alpha cells. This reduction in 
endocrine cells carried through to adulthood contributing to development of glucose 
intolerance as adults. 
 
3.4 DISCUSSION 
This study showed that MNR in mice from E6.5 to E18.5 led to a reproducible 
FGR phenotype. MNR of 70% of normal caloric intake was the best model as it was most 
consistent without changing litter size and represents asymmetric human FGR. Increasing 
severity of MNR did not further reduce birth weight with 60% MNR. In MNR of 80%, 
fetal and organ weights (except for brain and placenta) were slightly less than controls. In 
70% MNR, weights were significantly lower than controls and 80% MNR mice. 
However, in 60% MNR, fetal weights were lower than controls but comparable to 80% 
MNR. This could be due to a reduction in litter size, which would increase limited 
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nutrient supply to surviving fetuses. Thus, the 70% MNR was chosen for further detailed 
studies.  This model led to findings of asymmetrical FGR with relative sparing of the 
brain, likely due to blood flow redistribution from less critical organs (liver, lung and gut) 
to more critical organs (brain, adrenals and heart) (23-27). Asymmetrical FGR occurs in 
humans when an insult, such as uteroplacental insufficiency or malnutrition, occurs in 
late second to third trimester (27, 28). Fetal and organ weights are simple measurements 
of growth, however they do not provide a true indication of how organ development has 
been affected by factors restricting fetal growth.  
The concentrations of IGF system proteins in fetal and maternal circulation in 
human FGR have been described previously (10). In most reports, circulating IGF-I and 
IGFBP-3 concentrations are decreased, whereas IGFBP-1 concentrations are increased, 
and IGF-II concentrations are variably altered. Tissues of origin and causes of these 
changes have not been determined in human subjects. Studies of blood and tissues in the 
mouse model should provide insight into these important questions. In 70% MNR 
fetuses, fetal weights were reduced without significant changes in tissue IGF-I mRNA 
levels except the placenta. IGF-I mRNA levels were lower in most organs. The reduction 
of circulating IGF-I may be due to overall changes in tissues and reflect fetal response 
due to reduction in nutrient availability and a signal to decrease growth. It also suggests 
that circulating IGF-I in the fetus may be contributed not only by the liver as in growing 
animals or adults (29-31) but also by other tissues. The circulating levels of IGFBP-3 
were reduced in 70% MNR fetuses similar to that of human FGR (10). Circulating 
IGFBP-3 is coupled to IGF-I and is usually decreased in human FGR (10), as IGF-I 
regulates its expression (32). IGFBP-3 mRNA expression was increased in the majority 
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of tissues, suggesting the importance of the autocrine/paracrine IGFBP-3 actions in FGR. 
Null mutation of Igf1 or Igf2 leads to a 40% reduction in fetal weight (11, 12) and Igf2 
null mice have smaller placentae and smaller fetuses, indicating its importance in 
placental and fetal development (11, 33-35). Human fetal serum IGF-II levels are not 
consistently correlated with birth weight, and do not tend to change with FGR (10). 
Therefore, it was not unexpected that MNR fetuses did not demonstrate changes to IGF-II 
transcript expression.  
Despite lack of change in hepatic IGF-I or IGF-II mRNA levels, the mouse fetus 
may have responded to MNR and restricted growth by enhancing levels of hepatic 
IGFBPs to inhibit IGF actions. Transgenic mouse models over-expressing IGFBPs 
demonstrate a FGR phenotype, with organ-specific changes in weight and function (13). 
Transgenic mice over-expressing human IGFBP-1 in the fetal liver are 18% smaller at 
birth, with relative sparing of placental weight (15). Elevated IGFBP-1 serum levels are 
negatively correlated to birth weight (10), and IGFBP-1 sequesters IGF-I and –II with 
greater affinity than either receptor, preventing either protein from signaling fetal growth 
(36). IGFBP-2 mRNA expression was increased in the livers of MNR fetuses, leading to 
increased circulating levels. The significant increase in circulating IGFBP-1 and IGFBP-2 
concentrations during MNR in the mouse mimics elevated circulating levels during 
human FGR and may contribute to the pathophysiology (37, 38). Studies of IGFBP-2 
implicate this role as being primarily inhibitory to IGF actions, as transgenic IGFBP-2 
mice demonstrate mild growth restriction and IGFBP-2 in vitro inhibited IGF-II mediated 
cell proliferation (39, 40). Our mouse model indicates that the source of increased 
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circulating IGFBPs is the liver suggesting that a similar pathophysiology occurs in 
humans. 
Elevated IGFBPs in MNR livers may explain the reduction of glycogen despite 
elevated levels of glucocorticoids in fetal circulation, which have previously been 
demonstrated to enhance glycogen deposition prior to birth (41). Recently, IGF-II has 
been proposed to be a major regulator of fetal hepatic glycogen synthesis (7). Igf2 
knockout mice demonstrate significantly less glycogen stores which correlated with a 
reduction in glycogen synthase, the rate-limiting enzyme in glycogen synthesis, despite 
normal levels of circulating insulin (42). This suggests the importance of IGF-II to fetal 
metabolism and that the reduction in liver glycogen in MNR fetuses may be due to a 
reduction in IGF-II action, by elevating hepatic IGFBPs. Increased proliferation of liver 
cells supports an immature liver in MNR fetuses, as fewer hepatocytes are differentiated 
to express enzymes for glycogen synthesis and hepatocyte precursor cells continue to 
proliferate. 
The elevation of circulating and tissue IGFBP expression may lead to impaired 
growth and development of the fetal pancreas. β-cell proliferation, differentiation and 
survival is dependent on IGF expression (43, 44). The elevated fetal IGFBPs may inhibit 
IGF action on the proliferation and maturation of β-cells (44). Decreases in total IGF 
availability may exist when apoptosis is high (43, 44). This is believed to be responsible 
for the wave of β-cell apoptosis in the neonatal rat observed 2 weeks postnatally and 
coincides with diminished pancreatic expression of IGF-II within the islets (45). A 
maternal low protein diet causes a decreased rate of fetal β-cell replication with increased 
incidence of apoptosis, which is associated with reduced expression of IGF-II within 
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islets (46). Therefore, the fetal availability of IGF-II may determine the number and 
function of adult β-cells. Similarly, altered expression of IGF or IGF binding proteins 
associated with FGR may cause a population of β-cells that are not equipped to 
adequately handle postnatal metabolic challenges (44). Transgenic IGFBP-1 mice were 
hyperglycemic, hyperinsulinemic and glucose intolerant with increased relative 
pancreatic weight. Pancreatic islets were significantly larger and more numerous, 
although pancreatic insulin content was reduce. Hyperglycemia in these mice may be 
explained by IGFBP-1 inhibiting the hypoglycemic effect of IGFs and the impaired 
pancreatic function may be a consequence of persistent hyperglycemia, which would also 
explain the insulin depletion (40). Therefore the intrauterine environment of 
hypoglycemia, low IGF levels with elevated IGFBPs may alter the development of the 
endocrine pancreas and its ultimate structure and function. 
At six months, FGR male mice developed impaired glucose tolerance although 
the insulin secretion was similar to control male mice. FGR mice showed catchup growth 
and weight that was similar to control mice at weaning and six months postnatally. There 
was a reduction in both α- and β-cell mass, however β-cell mass showed a greater 
reduction as evident by α-cells contributing to a greater proportion of islets. Similar 
changes in α-cells in islets have been demonstrated in human populations (47) and 
baboon models of type II diabetes (48) and may contribute to glucose intolerance (48, 
49). Several factors may contribute to reduction in β-cells following MNR during 
gestation. Low glucose levels may impede expression of Pdx-1, an inducer of early 
endocrine lineage cells in β-cells (44, 50). MNR during embryogenesis leads to low fetal 
glucose levels to limit Pdx-1 expression and the recruitment of endocrine cell precursors 
     
   
 
86
(43), as demonstrated by reduced α- and β-cells mass at E18.5. This may cause FGR 
infants to have limited β-cell mass as adults and predispose them to diabetes. During 
catch up growth, high glucose levels along with elevated saturated fatty acids, 
lipoproteins, and leptin may overwhelm β-cells inducing apoptosis and/or necrosis (51). 
High glucose concentrations in early postnatal life may play a critical role, as this has 
been shown to stimulate β-cell apoptosis (51, 52).  Increased β-cell apoptosis has been 
observed in humans with type 2 diabetes (53). The decrease in number of islets in 
pancreases of FGR males may be due to impaired development of pancreatic progenitor 
endocrine cells by MNR during gestation. The reduction in β-cell mass at six months in 
FGR males may result from reduced expression of IGFs or increased expression of 
IGFBPs during gestation and metabolic stress of catchup growth in FGR pups. Although 
pancreatic islet morphology was different in MNR males, plasma insulin levels were not 
different from controls during the glucose tolerance test. This suggests that there was 
insulin insensitivity. Glucokinase is an important hepatic “glucose sensor” as its activity 
to phosphorylate glucose to glucose-6-phosphate increases with elevated concentrations 
of blood glucose and insulin (54). In contrast, PEPCK catalyzes the rate-controlling step 
in gluconeogenesis, which allows cells to synthesize glucose from non-carbohydrate 
precursors. Insulin inhibits PEPCK expression and activity (55). Disruption of 
glucokinase activity (56-58) or overexpression of PEPCK (59, 60) demonstrates clinical 
signs consistent with type II diabetes mellitus in mice and humans (61, 62). Analysis of 
hepatic glucokinase and PEPCK activity demonstrates that despite adequate insulin 
release, glucokinase activity is low while PEPCK activity remains elevated in MNR 
males. This suggests that insulin may be ineffective at enhancing the activity of 
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glucokinase and suppressing the activity of PEPCK during glucose challenge and hence 
glucose continues to be released into the blood and is unable to be taken up into the 
hepatocytes. This may contribute to insulin insensitivity. 
In summary, 70% MNR in mice caused consistent FGR without impacting on 
litter size with an asymmetrical FGR phenotype similar to that observed in human FGR 
due to uteroplacental insufficiency. The livers were significantly smaller in MNR mainly 
due to reduction in glycogen stores without impacting hematopoiesis. MNR also 
increased the synthesis of IGFBPs, primarily IGFBP-1 and IGFBP-2, that would lead to 
reduced IGF actions by sequestering bioavailable IGFs and/or inhibiting IGF actions at 
the tissue level. The tissue IGFBP-3 biosynthesis was increased in the majority of tissues. 
During pregnancy, 70% MNR is associated with hypoinsulinemia and hypoglycemia in 
both maternal and fetal circulation, with a reduction in the proportion of α- and β-cells in 
fetal pancreatic islets. Deficits in islet endocrine cells continued postnatally and persisted 
at six months of age. FGR males demonstrated impaired glucose tolerance. Therefore, 
changes to insulin and IGF endocrine systems due to MNR during gestation may be 
associated with neonatal morbidity as well as predisposition to metabolic diseases in 
childhood or adulthood. 
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CHAPTER 4 
 
PULMONARY CONSEQUENCES IN THE OFFSPRING OF 
MATERNAL NUTRIENT RESTRICTION PREGNANCIES 
 
Manuscript prepared for Pediatric Research 
 
 
4.1 INTRODUCTION 
Suboptimal nutrition during fetal life can induce immediate and long-term 
alterations in the formation and function of many organs, including the lung (1). Fetal 
growth restriction (FGR) is a decrease in fetal growth that prevents a newborn from 
obtaining its optimal growth. Clinically, it is defined as a pregnancy in which estimated 
fetal weight is below the 10th percentile for gestational age (2) resulting in a small for 
gestational age newborn with birth weight less than 10th percentile for gestational age. 
Fetal growth restriction can have maternal, fetal or placental causes, however, the major 
pathophysiological condition that underlies most clinically relevant FGR is fetal 
undernutrition. In developed countries, placental insufficiency is the major etiology and it 
causes fetal undernutrition by impaired transfer of nutrients between mother and fetus 
due to placental disease despite an adequate supply in maternal circulation. In developing 
countries, poor maternal nutrition is the major etiology. FGR is associated with many 
adverse outcomes in multiple organ systems including the lungs, leading to poor 
respiratory function at all stages of postnatal life (3-7). Infants born prematurely are at 
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increased risk of lung diseases such as respiratory distress syndrome and 
bronchopulmonary dysplasia and fetal undernutrition may increase the severity and 
incidence of bronchopulmonary dysplasia (BPD) (8). Bronchopulmonary dysplasia is a 
disease observed primarily in very low birth weight (< 1 kg) preterm newborns (< 28 
weeks) (9). The lungs of BPD are characterized by extreme immaturity with fewer and 
larger alveoli, thickened, fibrotic alveolar walls and decreased dysmorphic capillaries 
(10). These structural changes are believed to reflect an arrest in lung development (9) 
with long term consequences (11, 12). Advances in treatment, including antenatal 
steroids, postnatal exogenous surfactant and newer ventilation techniques for neonates, 
have improved survival of increasingly premature infants (11, 12). Antenatal 
glucocorticoids improve outcomes in premature infants by accelerating maturation of 
type II alveolar epithelial cells and the components of surfactant they produce. 
FGR is an independent risk factor for the development of BPD suggesting that 
factors that control fetal somatic growth may have a significant impact on vulnerability to 
lung injury (13-16). The benefit of antenatal steroids to preterm fetuses who are FGR is 
questionable (9, 17-19), as FGR infants already have endogenously elevated 
glucocorticoid levels (17). In animal models, the administration of high dose 
glucocorticoids in newborns is used to recreate BPD (20, 21). High levels of 
glucocorticoids are known to inhibit cell proliferation by inhibiting DNA and protein 
synthesis, and this may contribute to the developmental arrest of lungs seen in infants and 
rodent models with BPD (20, 21). In human pregnancy, maternal cortisol concentrations 
are higher than in the fetus (17). This difference is maintained by 11β-hydroxysteroid 
dehydrogenase (11β-HSD) in the placenta, which controls the passage of cortisol from 
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mother to fetus. Two isoforms of 11β-HSD interconvert glucocorticoids with their 
inactive metabolites. 11β-HSD1 catalyzes bi-directional interconversion of cortisol and 
cortisone, but acts primarily as a reductase, converting inactive cortisone to active 
cortisol. 11β-HSD2 is a high-affinity unidirectional enzyme, catalyzing only the 
dehydrogenase reaction of cortisol into cortisone. Glucocorticoids are potent factors that 
influence tissue maturation in the fetus. However, both absence and excess of 
glucocorticoids are detrimental to normal fetal development. The intricate control of 
glucocorticoid action within fetal tissues by 11β-HSDs plays a critical role in normal fetal 
maturation, however FGR results when their control is disrupted. Alterations in the 
glucocorticoid hormone levels, glucocorticoid receptors and/or metabolizing enzymes 
have been implicated in developmental programming or developmental origins of health 
and disease. High levels of steroids to induce lung maturation in preterm FGR babies may 
harm rather than benefit, but the mechanism of how this occurs remains to be established.  
Developmental programming of the pulmonary system in FGR has been reported 
in humans (1) but has been poorly studied due to lack of appropriate animal models. Our 
mouse model of FGR is potentially suitable to study lung development during FGR and 
the mechanisms compromising long-term pulmonary function. To make comparable, 
clinically relevant observations of expression changes of the glucocorticoid system 
during fetal undernutrition and their impact on fetal growth, we generated a mouse model 
of FGR by maternal nutrient restriction (MNR) in which mothers were fed 70% of 
normal daily caloric intake during pregnancy (Chapter 3). We studied lung growth and 
development by determining overall changes to weight and structure, and lung maturation 
by surfactant protein expression. Postnatal measurements of lung mechanics were 
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performed to determine the impact of MNR on postnatal lung function. Our overall 
hypothesis is that fetal undernutrition compromises fetal lung development with long-
term adverse pulmonary function and elevated levels of fetal glucocorticoids contribute to 
this pathology. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Animals and Dietary Restriction Protocol 
Animal protocols were approved by the University Council on Animal Care of the 
University of Western Ontario and maintained in accordance with guidelines of the 
Canadian Council for Animal Care. Ten week-old virgin CD-1 females and stud males 
were obtained from Charles River Laboratories (Montreal, PQ, Canada). Mice were 
housed in standard shoe box cages in the Victoria Research Laboratories Vivarium 
(London ON, Canada) with a 12:12 light:dark cycle with water provided ad libitum. 
Female mice were housed singly with stud males in late afternoon and checked the 
following morning for presence of a vaginal plug, indicating embryonic day 0.5 (E0.5). 
Females were then housed individually and fed using feeding tubes with cage clips (Bio-
Serv, Frenchtown NJ, USA) and grain-based dustless precision pellets (#F0173, Bio-
Serv, Frenchtown NJ, USA) containing 20.7% protein, 4.0% fat, 6.7% ash, 59.6% 
carbohydrates, 4.0% fiber and 5.0% moisture ad libitum until E6.5. Feeds for control 
mice were pre-weighed each morning and remaining pellets weighed at the same time 
next day to establish average daily feed intake during pregnancy. From E6.5, mice were 
fed daily 70% (n = 9) by weight of average daily intake of control mice (n = 24). Mice 
were euthanized at E18.5 by carbon dioxide inhalation. Fetal tissues and lung were 
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dissected, weighed, and pooled by litter before flash freezing in liquid nitrogen. 
Individual maternal and pooled fetal bloods were obtained using heparinized capillary 
tubes (Fisher Scientific, Unionville ON, Canada). For newborn blood collection, pups 
were decapitated at 9AM on postnatal days 1 and 3 and blood was collected in the same 
manner as maternal and fetal blood. 
 
4.2.2 Quantitative real-time PCR (qRT-PCR) 
Total RNA from flash frozen control and 70% MNR fetal tissues were extracted 
using Trizol (Invitrogen, Burlington, ON) and purified with RNAeasy Mini Kit (Sigma, 
Maryland, USA), following the manufacturer’s instructions.  
SYBR green qRT-PCR was used to study mRNA expression in fetal lungs of SP-
A, -B, -C and -D and endogenous control gene, ribosomal protein L7 (RL7), and 
glucocorticoid receptor (GR), 11β-HSD1 and 28S endogenous control gene. Using 
reagents from Invitrogen (Burlington, ON), 1 µg of RNA was reversed transcribed (RT) 
using Superscript III and 500 ng of Oligo(dT) with 20U RNaseOUT in 21.5 µl final 
volume, followed by digestion of template RNA with 2U RNase H. Reactions were 
incubated at 70C, 10 min; 42C, 2 min; 70C, 15 min; 4C, 10 min and 37C, 20 
min. Platinum SYBR Green qPCR SuperMix-UDG with ROX (Invitrogen) was used as 
recommended with 200 µM of primers for SPs and RL7 and 600 µM for all others 
(Invitrogen; TABLE 4.1), mixed with 100 ng RT product in a total volume of 10 µl in 
triplicate. Thermal cycling conditions for surfactant protein (SP) and RL7 mRNA were 
95C, 10 min; 95C, 20 sec; 60C, 20 sec; 72C, 30 sec for 40 cycles. For 11β-HSD 
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1, GR and 28S, the conditions were as previously described (23). qRT-PCR data was 
divided by  
TABLE 4.1 Primer Sequences for SYBR Green Quantitative Real-Time PCR. 
Primer 
Name 
Primer Pair Sequence Fragment Size 
(bp) 
Ref 
SP-A 5’-ATCAAGTGCAATGGGACAGA-3’ 
5’-CTTTCTCCAGGCTCTCCCTT-3’ 
 
230 - 
SP-B 5’-GGCCTCACACTCAGGACTTC-3’ 
5’-GGACAAGGCCACAGACTAGC-3’ 
 
255 - 
SP-C 5’-CTCCACACCCACCTCTAAGC-3’ 
5’-GTTTCTACCGACCCTGTGGA-3’ 
 
161 - 
SP-D 5’-CCATGCTTGTCCTGCTTGTA-3’ 
5’-GTCCAGGTTCTCCAGCAGAG-3’ 
 
273 - 
RL7 5’-GGAGCTCATCTATGAGAAGGC-3’ 
5’-AAGACGAAGGAGCTGCAGAAC-3’ 
 
202 - 
GR 5’-GGAAGTTAATATTTGCCAATGGAC-
3’  
5’-CGCAGAAACCTTGACTGTAGC-3’ 
 
150 (22) 
28 S  5’- TTGAAAATCCGGGGGAGAG-3’ 
5’-ACATTGTTCCAACATGCCAG-3’ 
 
99 (22) 
11B HSD 1 5’-GTGTCTCGCTGCCTTGAACTC-3’ 
5’-TTTCCCGCCTTGACAATAAATT-3’  
101 (22) 
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endogenous control values and each litter was divided by the control mean, to determine 
fold-change in mRNA expression. 
 
4.2.3 Tissue Preparation 
Fetal mouse lungs were harvested at E18.5, fixed in 4% paraformaldehyde for 48 
hrs, and washed 3 times in PBS over 3 days.  Tissue were embedded in paraffin, 
sectioned at 3 µm and mounted onto Superfrost® slides (Fisher Scientific, Fairlawn, NJ). 
 
4.2.4 Immunofluorescence 
Sections were deparaffinized and rehydrated in a descending series of ethanol 
solutions. Tissue sections were blocked with Background Sniper Blocking Reagent 
(Biocare Medical, Concord, CA) for 10 min prior to application of mouse anti-SP-B to 
lung sections at RT for 1 hr (TABLE 4.2). Tissue sections were washed and incubated for 
30 min at RT with appropriate Alexa Fluor 568-conjugated IgG secondary antibody 
(1:200; Molecular Probes Inc., Eugene OR), counterstained with pre-mixed DAPI 
(Molecular Probes Inc.) and coverslipped with ProLong® Gold AntiFade Reagent 
(Molecular Probes Inc.). Omission of primary antibody served as controls for 
autofluorescence and nonspecific binding. Fluorescent images were captured and 
analyzed using a Carl Zeiss Axio Imager Z1 microscope equipped with AxioCamMR3 
camera and AxioVision Release 4.7.2 software. To determine the proportion of lung 
composed of type 2 alveolar cells in eight control and six MNR lungs, the number of cells  
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TABLE 4.2 Primary Antibodies used for Immunoflurescence (IF) and Western Blotting (WB). 
Dilution Antibody Host Catalogue # 
IF WB 
Source 
SP-A Rabbit - - 1:1000 gift from Dr. McCormick 
SP-B Mouse - 1:200 1:1000 gift from Dr. Possmayer/Suzuki 
proSP-C Rabbit WRAB-SPC - 1:1000 Seven Hills, Cincinnati, OH 
mSP-C Rabbit WRAB-MSPC - 1:1000 Seven Hills, Cincinnati, OH 
SP-D Mouse WMAB-1A10A9 - 1:1000 Seven Hills, Cincinnati, OH 
11β-HSD1 Goat AF3397 - 1:2000 R&D Systems Inc., Minneapolis, MN 
Pan-actin Mouse #MS-1295 - 1:7000 Thermo Fisher Scientific, Fermont, CA 
GAPDH Rabbit IMG-5567 - 1:5000 Imgenix, San Diego, CA 
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expressing SP-B per total number of cells were counted in 12 random fields of view at 
400x magnification. 
 
4.2.5 Lung Morphometry 
Fetal lungs were collected from eight control and six MNR fetuses and fixed in 
2.5% glutaraldehyde in 0.1 M phosphate buffer, and post fixed with 1% osmium tetroxide 
in 0.1 M phosphate buffer and dehydrated followed by transition through propylene 
oxide. Tissue samples were embedded in Polybed/ araldite and cured at 65C 
overnight. One micron sections were stained with toluidine blue. Total Lung Volume was 
determined by volume displacement (24). Sixteen random fields of view were taken with 
200x magnification using ImagePro Plus 4.5 (Media Cybernetics, Bethesda, MD). The 
area occupied by airspace was traced and expressed as a fraction of the total field of view. 
This fraction was multiplied by the volume of the lung to determine absolute volume of 
airspace in the E18.5 mouse lung. Areas occupied by airways and blood vessels were 
counted separately and excluded from calculation. 
Pooled fetal lungs from each litter were homogenized with protease inhibitors 
(Complete Mini, Roche Diagnostics, Mannheim, Germany) in phosphate buffer. For 
protein quantification, a sample aliquot was syringed three times and centrifuged at 
13,000 x g for 1 hr. Triplicate samples were quantified using BCA assay (Pierce; 
Rockford, IL). DNA quantification was performed by fluorometric DNA assay. An 
aliquot was centrifuged at 4000 x g for 5 min. The supernatant was diluted with 2 mM 
EDTA and Hoechst 33342 dye added (Molecular Probes; Eugene, OR). Duplicate 
measurements were obtained by fluorescence spectrophotometry (Fluoroskan Ascent FL, 
     
   
 
101
ThermoLab Systems, Milford, MA), and quantified against a standard curve generated 
with salmon testis DNA (Sigma-Aldrich, Oakville, ON).  
 
4.2.6 Corticosterone and ACTH ELISAs  
Plasma corticosterone was measured using the AssayMax Corticosterone ELISA 
Kit (AssayPro, St. Charles, MO) as per manufacturer’s instructions (Appendix 1.1.1). 
Plasma ACTH was quantified using a multiplexed bone metabolism mouse panel 1A 
biomarker immunoassay kit according to the manufacturer’s instruction (Milliplex, 
Millipore Corp, MA). A Bio-PlexTM 200 readout System was used (Bio-Rad 
Laboratories, Hercules, CA), which utilizes Luminex® xMAPTM fluorescent bead-based 
technology (Luminex Corp., Austin, TX). Levels were automatically calculated from 
standard curves using Bio-Plex Manager software (v.4.1.1, Bio-Rad).  
 
4.2.7 Western Blotting 
Surfactant protein expression was determined in the membrane fraction of fetal 
lungs. Membrane fractions were prepared from frozen tissue, homogenized in cold lysis 
buffer (0.25 M sucrose, 50 mM Tris-HCl, pH 7.4 with protease inhibitor cocktail) and 
centrifuged at 12,000 x g for 10 min. The supernatant was centrifuged at 100,000 x g for 
1 hr with the pellet resuspended in PBS. For 11β-HSD1, lung and placenta were prepared 
as previously described (25), and homogenates were used for Western blotting and 
enzyme activity assays. Protein content of lung and placental homogenates was 
determined by BCA assay (Pierce, Rockford, IL).   
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Western blotting was performed using 10-20 µg of total protein loaded into a 
12.5% SDS-PAGE gel, and electrophoresis performed at constant 100 V for 2 hrs. 
Protein was transferred to PVDF membrane for 1.5 hrs at constant 350 mAmp. After 
transfer, membranes were blocked with 5% skim milk in TBS for 1 hr at RT, then 
incubated with primary antibody overnight at 4C (TABLE 4.2). After washing, 
membranes were incubated with the appropriate peroxidase-labeled secondary antibody 
for 1 hr, washed and bands were visualized with Western Lighting Enhanced 
chemiluminescence detection reagents (Perkin-Elmer, Boston, MA). Blots were stripped 
and reprobed for mouse anti-pan-actin as a loading control for SPs and rabbit anti-
GAPDH for 11β-HSD1. Blot analysis was performed by densitometry using Alpha 
Imager and FluoroChem 8800 software (Alpha Innotech Corporation, San Leandro, CA). 
Bands of interest were normalized to loading control and values for each litter normalized 
to control mean, in order to determine fold-change in protein expression.  
 
4.2.8 11β-HSD1 Dehydrogenase Activity Assay 
11β-HSD1 dehydrogenase activities in placenta and lung homogenates were 
determined as previously described (25), with the following modifications. The 
conversion assay tubes contained tissue homogenate (0.1-0.2 g protein), 100,000 dpm 
[3H]-corticosterone, and final concentrations of non-radioactive corticosterone and 
cofactor NADP at 1 and 500 µM, respectively.  
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4.2.9 FlexiVent Measurements of Lung Mechanics  
Mice were weighed and injected with a Euthanyl dose of 110mg/kg. The mouse 
was exsanguinated by abdominal incision and locating and cutting abdominal blood 
vessels when the mouse was adequatedly anaesthetized as determined by toe pinch.  The 
neck was exposed and dissected with a small incision made in the trachea.  An 18G metal 
endotracheal tube was inserted and ligated with surgical silk.  The endotracheal tube was 
attached to the ventilator of the flexiVent system (Scireq, Montreal, Canada), with the 
mouse supine and thoracic cavity opened with connective tissues dissected away to 
determine changes to lung mechanics irrespective of tension contributed by the chest 
wall. The flexiVent was used to measure lung mechanics, including lung compliance 
(distensibility), lung resistance (obstruction of flow in relation to time), airway resistance 
(including both the large central and smaller peripheral airways), tissue damping (tissue 
resistance), tissue elastance, and tissue hysterisivity (ratio of the lungs ability to dissipate 
and conserve energy). The flexiVent technique involves 2 different perturbations, with 
the first determining whole-lung dynamic compliance and lung resistance by fitting the 
linear single-compartment model using multiple linear regression. The second 
perturbation distinguished central versus peripheral lung mechanics, reflecting the 
contributions of airways versus peripheral tissue, respectively. These measurements, 
which included airway resistance, tissue damping, tissue elastance, and tissue 
hysterisivity, were obtained using the forced oscillation technique that fits the constant 
phase model to input impedence.  
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4.2.10 Statistical Analysis 
All data are expressed as mean ± SEM. Parameters measured in control and 70% 
MNR animals were compared with Student’s non-paired two-tail t test. A Mann-Whitney 
test was performed to determine significantly different fold changes in the 70% MNR 
litters for Western blot densitometry and qRT-PCR. Significance was set at P < 0.05. 
 
4.3 RESULTS 
4.3.1 Effects of Fetal Growth restriction on Fetal Organ Weights 
Measurements of fetus and lung weights were recorded to determine the impact of 
maternal undernutrition. Fetal weights were significantly reduced in the MNR group (Fig. 
4.1A; Control: 1,396 ± 25 mg vs. MNR: 894 ± 52 mg; P < 0.0001). Lung weights were 
significantly reduced in the MNR group (Fig. 4.1B; Control: 52 ± 2 mg vs. MNR: 29 ± 2 
mg; P < 0.0001). Lung weights were disproportionately smaller compared to fetal 
weights in 70% MNR fetuses (Fig. 4.1C; control 3.70 ± 0.06, 70% MNR 3.15 ± 0.12, all 
values ×10-2; P < 0.0005).  
  
4.3.2 Effects of FGR on Lung Structure 
Fetal lung structure was analyzed at E18.5 to determine alterations during 
maternal undernutrition. Fetal lung volume was significantly less in 70% MNR (Fig. 
4.2A; control 33.5 ± 1.8 mm3 vs. MNR 25.3 ± 1.0 mm3; P < 0.005), with less lung 
parenchyma volume (Fig. 4.2A; control: 21.3 ± 1.2 mm3 vs. MNR 15.7 ± 1.6 mm3; P < 
0.05) however, airspace volume was maintained. The proportion of type 2 alveolar cells 
was significantly reduced in MNR lungs compared to controls (Fig. 2B; control 12.2 ±  
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Figure 4.1 The effect of maternal nutrient restriction on fetal weights at E18.5. (A) 
Fetal weight (mean ± SEM) in control (N=14) and 70% MNR (N=9) litters. In the 70% 
MNR fetuses, fetal weight of 894 ± 52 mg (vs 1,396 ± 25 mg in controls) was 
significantly less (P < 0.001). (B) Fetal lung weight (mean ± SEM) in control (N=14) and 
70% MNR (N=9) litters. In the 70% MNR fetuses, lung weight of 29 ± 2 mg (vs 52 ± 2 
mg in controls) was significantly reduced (P < 0.001). (C) Ratio of fetal lung weight to 
fetal body weight (mean ± SEM) in control (N=14) and 70% MNR (N=9) litters. In the 
70% MNR litters, the ratio of 3.15 ± 0.12 × 10-2 (vs 3.70 ± 0.06 × 10-2 in controls) was 
significantly reduced (P < 0.0005). 
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Figure 4.2 The effect of maternal nutrient restriction on fetal lung structure at 
E18.5. (A) Lung airspace and parenchyma volume (mean ± SEM) in control (N=8) and 
70% MNR (N=6) fetuses. In the 70% MNR fetuses, parenchyma volume of 15.7 ± 1.6 
mm3 (vs 21.3 ± 1.2 mm3 in controls) was significantly less (P < 0.05), with no change to 
airspace volume. (B) Percentage of type II alveolar cells (mean ± SEM) in control (N=8) 
and 70% MNR (N=6) fetal lungs. In the 70% MNR fetuses, the percentage of type II cells 
of 8.3 ± 0.6 % (vs 12.2 ± 0.6 % in controls) was significantly reduced (P < 0.001). (C) 
Representative fluorescent photomicrograph of control lung with SP-B staining. (D) 
Representative fluorescent photomicrograph of 70% MNR lung with SP-B staining. Scale 
bars, 100 µm. 
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0.6% vs. MNR 8.3 ± 0.6%; P < 0.001) with no change in DNA and protein content 
(µg/mg wet weight; Appendix TABLE 1.1 and 1.2). Type 2 alveolar cells produce the 
components of surfactant, important for increasing lung compliance during respiration 
postnatally. Surfactant proteins were analyzed to determine expression changes during 
maternal undernutrition. MNR lungs had lower levels of SP-A and -B mRNA with no 
changes in other SPs (Fig. 4.3A; fold change in MNR: SP-A: 0.57 ± 0.04; SP-B: 0.56 ± 
0.10; both P < 0.05). Western blotting for proteins demonstrated significantly lower 
levels of SP-A and precursor and mature forms of SP-C (Fig. 4.3B and C; fold change of 
SP-A in MNR: 0.55 ± 0.10; P < 0.05; proSP-C: 0.48 ± 0.07; P < 0.001; mSP-C: 0.62 ± 
0.08; P < 0.05). 
 
4.3.3 Effect of FGR on the glucocorticoid system  
Glucocorticoid levels are known to be an important regulartor of lung 
development during gestation; levels were measured at E18.5 to determine changes to 
expression during maternal undernutrition. Plasma corticosterone levels, the major 
glucocorticoid in rodents, were measured in mothers and their litters at E18.5. Plasma 
levels were significantly higher by 5-fold in 70% MNR mothers and their litters (Fig. 
4.4A; Mothers: control 150 ± 69 ng/mL vs. MNR 757 ± 195 ng/mL; P < 0.05; Fetus: 
control 182 ± 21 ng/mL vs. MNR 435 ± 74 ng/mL; P < 0.01). Corticosterone was 
measured in neonates at 1 and 3 postnatal days, with plasma levels normalizing to control 
levels (Fig. 4.4B). At E18.5, ACTH levels in 70% MNR maternal plasma were 
significantly increased (Fig. 4.4C; control 5 ± 1 pg/mL vs. MNR 15 ± 4 pg/mL; P <  
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Figure 4.3 The effect of maternal nutrient restriction on fetal surfactant protein 
expression at E18.5. (A) Fold change of surfactant protein (SP) transcript levels (mean ± 
SEM) in control (N=6) and 70% MNR (N=6) litters. In the 70% MNR litters, the fold 
change of SP-A of 0.57 ± 0.04 (vs 1.00 ± 0.08 in controls) and SP-B of 0.56 ± 0.10 mg 
(vs 1.00 ± 0.16 in controls) were significantly reduced (both P < 0.05). (B) 
Representative Western Blots for SP-A, SP-C (precursor (proSP-C) and mature forms 
(mSP-C)), SP-D and SP-B and action loading control in pooled fetal lung homogenates of 
mothers fed either control (C) or 70% MNR (N) during gestation. (C) Fold change of 
surfactant protein (SP) levels (mean ± SEM) in control (N=7) and 70% MNR (N=7) 
litters by densitometry. In the 70% MNR litters, the fold change of SP-A of 0.55 ± 0.06 
(vs 1.00 ± 0.10 in controls), the precursor form of SP-C of 0.48 ± 0.07 (vs 1.00 ± 0.15 in 
controls) and the mature form of SP-C of 0.62 ± 0.08 (vs 1.00 ± 0.11 in controls) were all 
significantly lower (P < 0.05, P < 0.001 and P < 0.05, respectively). 
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Figure 4.4 The effect of maternal nutrient restriction on circulating concentrations 
of corticosterone and ACTH in maternal and fetal at E18.5 and in neonatal plasma 
1 and 3 days following birth. (A) Maternal plasma corticosterone concentration (mean ± 
SEM) was 150 ± 69 ng/mL in controls (N=6) and 757 ± 195 ng/mL in 70% MNR (N=6). 
Corticosterone concentration was 5 times higher in 70% MNR mothers (P < 0.05). Fetal 
plasma corticosterone concentration (mean ± SEM) was 182 ± 21 ng/mL in controls 
(N=6) and 435 ± 74 ng/mL in 70% MNR (N=6). Corticosterone concentration was 2.4 
times higher in 70% MNR fetuses (P < 0.01). (B) Neonatal plasma corticosterone 
concentration (mean ± SEM) was not different between control (N=7) and 70% MNR 
(N=5) neonates at 1 and 3 days following birth. (C) Maternal plasma ACTH 
concentration (mean ± SEM) was 4.9 ± 1.0 pg/mL in controls (N=5) and 14.5 ± 3.7 
pg/mL in 70% MNR (N=6). ACTH concentration was 3 times higher in 70% MNR 
mothers (P < 0.05). Fetal plasma ACTH concentration (mean ± SEM) was 80.2 ± 10.3 
pg/mL in controls (N=6) and 20.9 ± 1.3 pg/mL in 70% MNR (N=6). ACTH 
concentration was 4 times less in 70% MNR fetuses (P < 0.01). 
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0.05), but significantly reduced in MNR fetal plasma (Fig. 4.4C; control 80 ± 10 pg/mL 
vs. MNR 21 ± 1 pg/mL; P < 0.0005).  
Regardless of elevated endocrine levels of glucocorticoids in the MNR fetuses, it 
is ultimately the expression of and activity of glucocorticoid metabolizing enzymes in the 
tissues and expression if the glucocorticoid receptor that determines the effect on tissue 
structure. In the 70% MNR, placental 11β-HSD1 dehydrogenase protein expression and 
activity was reduced (Fig. 4.5; MNR Protein fold change 0.75 ± 0.09; P < 0.05; Activity: 
control 7.23 ± 0.45 pmol/min/mg protein vs. MNR 6.00 ± 0.27 pmol/min/mg protein; P < 
0.05) with no change in mRNA expression (fold change in MNR: 1.48 ± 0.25; P > 0.05). 
No changes in the expression of GR (MNR mRNA fold change: 1.04 ± 0.29; P > 0.05) or 
11β-HSD1 dehydrogenase activity (MNR mRNA fold change: 1.07 ± 0.16; MNR Protein 
fold change 0.87 ± 0.08; MNR activity fold change 0.87 ± 0.12; all P > 0.05) were 
demonstrated in MNR fetal lung.  
 
4.3.4 Postnatal Pulmonary Function 
The Flexivent system was used to measure lung function at one and three months 
after birth to determine the longterm postnatal consequences of maternal undernutrition 
during gestataion. There were no differences in body weight between the control and 
experimental animals at one and three months postnatally. The combined cohort of males 
and females demonstrated significantly increased lung (TABLE 4.3; control 1.07 ± 0.07 
cm H2O·s/mL vs. MNR 1.48 ± 0.16 cm H2O·s/mL; P<0.05) and airway resistance 
(TABLE 4.3; control 0.42 ± 0.05 cm H2O·s/mL vs. MNR 0.54 ± 0.03 cm H2O·s/mL; 
P<0.05) with an increase in tissue elastance (control 68.1 ± 2.9 cm H2O/mL vs. MNR  
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Figure 4.5 The effect of maternal nutrient restriction on placental 11β-HSD1 
expression and activity. (A) Fold change of Placental 11β-HSD1 mRNA transcript 
expression (mean ± SEM) in control (N=6) and 70% MNR (N=6) litters did not differ 
between groups. (B) Fold change of placental 11β-HSD1 protein expression (mean ± 
SEM) in control (N=9) and 70% MNR (N=7) litters by densitometry. In the 70% MNR 
litters, the fold change of 11β-HSD1 of 0.75 ± 0.09 (vs 1.00 ± 0.07 in controls) was 
significantly reduced (both P < 0.05). (C) Placental 11β-HSD1 protein activity (mean ± 
SEM) in control (N=9) and 70% MNR (N=7) litters. In the 70% MNR litters, the activity 
of 11β-HSD1 of 6.00 ± 0.27 pmol/min/mg protein (vs 7.23 ± 0.45 in controls) was 
significantly reduced (both P < 0.05). 
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TABLE 4.3 Lung function measurements in control and maternal nutrient restricted mice at one and three months postnatally. 
One Month Postnatal    
 ALL MALE FEMALE 
 Control 70% MNR Control 70% MNR Control 70% MNR 
Resistance 
(cmH2O·s/mL) 
    1.07 ± 0.07     1.48 ± 0.16*     1.15 ± 0.11     1.20 ± 0.17     0.99 ± 0.08     1.77 ± 2.11** 
Compliance 
(mL/cmH2O) 
  0.014 ± 0.001   0.012 ± 0.001   0.014 ± 0.001   0.014 ± 0.001   0.014 ± 0.001   0.010 ± 0.001*** 
Airway Resistance 
(cmH2O·s/mL) 
    0.42 ± 0.05     0.54 ± 0.03*     0.47 ± 0.09     0.50 ± 0.04     0.37 ± 0.03     0.59 ± 0.06** 
Inertance 
(cmH2O·s·s/mL) 
0.0015 ± 0.0003 0.0022 ± 0.0004 0.0012 ± 0.0005 0.0013 ± 0.0005 0.0019 ± 0.0001 0.0032 ± 0.0005* 
Tissue Damping 
(cmH2O/mL) 
    10.5 ± 1.0     14.4 ± 1.8     11.7 ± 1.7     11.3 ± 1.6       9.3 ± 0.8     17.6 ± 2.7* 
       
Three Months Postnatal     
 ALL MALE FEMALE 
 Control 70% MNR Control 70% MNR Control 70% MNR 
Resistance  
(cmH2O·s/mL) 
    0.46 ± 0.02     0.63 ± 0.03***     0.46 ± 0.04     0.62 ± 0.07     0.45 ± 0.03     0.65 ± 0.04** 
Compliance  
(mL/cmH2O) 
  0.026 ± 0.001   0.021 ± 0.001*   0.023 ± 0.002   0.023 ± 0.003   0.030 ± 0.001   0.019 ± 0.001*** 
Airway Resistance 
(cmH2O·s/mL) 
    0.20 ± 0.01     0.30 ± 0.03*     0.20 ± 0.02     0.30 ± 0.08     0.21 ± 0.03     0.30 ± 0.02 
Inertance  
(cmH2O·s·s/mL) 
0.0009 ± 0.0001 0.0010 ± 0.0001 0.0007 ± 0.0001 0.0009 ± 0.0002 0.0012 ± 0.0002 0.0012 ± 0.0001 
Tissue Damping 
(cmH2O/mL) 
      4.6 ± 0.2       6.2 ± 0.3***       4.6 ± 0.3       5.9 ± 0.7       4.6 ± 0.2       6.5 ± 0.3*** 
       
Pregnant mothers were fed ad libitum (control) or 70% MNR from E 6.5. Following birth, 70% MNR pups were cross-fostered to control mothers and fed ad 
libitum after weaning. The SCIREQ flexiVent system measured lung function (mean ± SEM) at 1 and 3 months postnatally. ‘All’ compasses both male and 
female genders of the cohort. ‘Male’ and ‘female’ is analysis of cohort members separately by gender.  
 
Significant differences between control and 70% MNR among the entire cohort, male and female gender is indicated by * P < 0.05; ** P < 0.01; *** P < 0.005  
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89.0 ± 8.1 cm H2O/mL; P<0.05). However, once the cohort was divided by gender, the 
MNR males did not demonstrate any significant differences in pulmonary function from 
the control males. At three months the increase in lung resistance in 70% MNR females 
was maintained, however the increase in airway resistance had resolved. Male MNR mice 
did not demonstrate any differences in lung function measurements at three months 
(TABLE 4.3).  
 
4.4 DISCUSSION 
Elevated glucocorticoid level is important in preparing the fetus for birth and 
postnatal life, as it stimulates differentiation and maturation of organ systems. This has 
led to its administration to mothers with threatened preterm labour prior to 34 weeks 
gestation and has resulted in greatly improve neonatal outcomes. However, repeated 
dosing with antenatal glucocorticoids has been shown to cause FGR in animal models 
and possibly humans (26-28) as glucocorticoids can inhibit DNA replication and protein 
synthesis (29). Prolonged and elevated fetal glucocorticoid levels may inhibit the growth 
and development of glucocorticoid sensitive tissues such as the lung. In this study, we 
demonstrated that MNR significantly reduced fetal lung weights more than the fetal 
weight as the ratio of lung weight to fetal weight was significantly reduced. Despite the 
significantly lower weight of the MNR fetal lung, the proportion of cells and proteins per 
milligram of wet lung weight was not different between groups. Therefore the size and 
protein content of MNR lung cells were not different from controls, but the overall 
reduction in the number of MNR cells in the lung contributed to the reduced MNR lung 
weight. Our MNR growth restricted neonates from FGR pregnancies were born at term 
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and did not demonstrate respiratory difficulties after birth, therefore it is not an 
appropropriate model for bronchopulmonary dysplasia (BPD). However, our MNR 
mouse model may be a valuable model to study the changes to lung structure during FGR 
and the long-term consequences of impaired lung function postnatally, as there are 
currently no adequate models to study this organ system following FGR. 
The 11β-hydroxysteroid dehydrogenase (11β-HSD) enzymes in the placenta have 
been implicated as one of the key components in the pathogenesis of FGR due to its 
primary function in maintaining the glucocorticoid barrier, buffering the fetus from high 
maternal glucocorticoid levels by metabolizing corticosterone in the placenta and in fetal 
tissues. Dysfunction of these enzymes can lead to the elevated fetal glucocorticoid levels 
causing FGR. In human fetal growth, the activity of 11β-HSD2 is positively correlated to 
birth weight, with its activity reduced in FGR pregnancies (17). In the mouse after E16.5, 
11β-HSD2 expression declines and is no longer detectable in the fetal component of the 
mouse placenta, the labyrinth, or the fetal lung (22). In placenta from FGR mice, the 
expression of 11β-HSD1, which can act as a reductase or dehydrogenase, is high at E18.5 
in the labyrinth layer and in vitro acts predominantly as a dehydrogenase (25). In the 70% 
MNR placenta, 11β-HSD1 protein expression and dehydrogenase activity were reduced, 
which is similar to 11β-HSD2 levels and activity reported in human FGR. With elevated 
corticosterone levels in the mother and reduced corticosterone metabolism in the 
placenta, more maternal corticosterone can enter the 70% MNR fetuses to impair fetal 
growth. Subsequently, high fetal corticosterone levels exert negative feedback on fetal 
pituitary ACTH release and inhibit the activity of the fetal HPA axis prior to parturition. 
Therefore, during pregnancy, the FGR fetus loses the ability to regulate its own plasma 
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levels of corticosterone due to the transfer of maternal corticosterone. Once the FGR 
fetus is born, the ability to control its circulating levels of corticosterone is reestablished. 
Despite the elevated levels of corticosterone in the fetal plasma, the expression of 
glucocorticoid receptor (GR) and the expression and activity of 11β-HSD1 did not 
change to compensate for the elevated plasma levels of glucocorticoids. Thus, the fetal 
lung was not protected from the effects of greatly elevated plasma corticosteroids in 
FGR. 
 Mouse models with genetic disruption of the corticotrophin releasing hormone 
(CRH) (30) or glucocorticoid receptor (GR) (31) demonstrate fetal lungs characterized by 
loss of cellularity and thinning of saccules and cell differentiation, indicating that 
glucocorticoids are essential to achieve anatomic maturation. Conversely, highly elevated 
glucocorticoids in the fetus impair lung development. In 70% MNR fetuses in which 
circulating levels of corticosterone were highly elevated, the lungs showed the volume of 
airspace maintained with less parenchymal volume. These changes in lung structure 
together with a disproportionately smaller lungs compared to the fetus support the 
growing evidence that FGR leads to developmental alterations in lung structure that 
impair lung function at birth and possibly postnatally. In a cohort of carunclectomized 
sheep, FGR fetuses in late gestation demonstrated lung growth sparing, with an increased 
number of air spaces and reduction in gas exchange surface density (32). Postnatal FGR 
lambs at 8 weeks had evidence of increased blood-air barrier thickness, likely due to 
edema and/or deposition of increased amounts of extracellular matrix, which may 
permanently reduce lung compliance (1). A similar long-term functional consequence of 
FGR was demonstrated in our mouse model of female FGR adults.  
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Our study, in combination with other FGR models demonstrating aberrant 
surfactant protein expression, questions the benefit of administering exogenous 
glucocorticoids to mothers with FGR in which circulating levels are already increased in 
both mother and fetus. Sheep fetuses that are growth restricted by carunclectomy 
demonstrated SP-A and -B gene expression was inversely related to plasma cortisol 
concentration with reduced lung SP-A, -B and –C protein and mRNA expression (33). 
Maternal undernutrition in rats impaired surface tension-lowering properties of fetal lung 
extracts and slowed prenatal and postnatal maturation of alveolar type II cells in offspring 
(34). A hypoxic preterm mouse model of FGR also demonstrated lower levels of SP-A, -
B and -C mRNA (35). Thus, our data further supports previous reports that FGR alters 
surfactant and the expression of surfactant proteins during gestation. Additional 
exogenous glucocorticoids given to mothers with FGR may not enhance the development 
of the surfactant system, but suppress/inhibit the surfactant system by enhanced 
endogenous corticosteroid exposure of the fetus. The most intriguing finding in our study 
was the reduction of SP-A at both the mRNA and protein levels in our 70% MNR fetal 
lungs. Maternal protein restriction in rats has previously demonstrated a reduction in fetal 
lung SP-A during gestation (36, 37). Synthesis of SP-A in vitro has a biphasic response to 
glucocorticoids (38); at low glucocorticoid concentrations, SP-A expression is enhanced, 
but at high concentrations, it is inhibited. Recently, Islam and Mendelson reported that 
the glucocorticoid receptor inhibits SP-A gene expression in human type II cells and this 
inhibition can be enhanced by glucocorticoid treatment. The mechanism involves the 
induction of histone deacetylases with increased binding to the SP-A promoter to cause a 
closed chromatin structure that blocks gene expression (39). Changes to the epigenetic 
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gene regulation of SP-A may have long lasting effects, which could program SP-A 
expression beyond gestation and into postnatal life.  
A large number of randomized controlled trials have demonstrated that prenatal 
glucocorticoid treatment reduced the risk of respiratory distress syndrome (RDS) in 
premature human infants, generally between 28 and 32 weeks gestation (40), with greater 
effect observed in females. The presence of surfactant in amniotic fluid of males appears 
two weeks later than in females (41), with male amniotic fluid cortisol concentrations 
significantly lower than females (41). This reduction in cortisol does not seem to be due 
to cortisol deficiency, since exogenous glucocorticoid administration failed to correct the 
male deficit in lung maturation (42, 43). In rodents, fetal lung growth peaks earlier in 
females than males (44) with more epithelial cells and lamellar bodies per type II alveolar 
cell in female fetal rat lung than male (45). Female fetal rat, mouse, rabbit, sheep and 
human lungs begin synthesis of surfactant phospholipid earlier than male fetuses (46-48), 
however, surfactant levels are equivalent between genders at term (49).  
Androgens have been implicated to act as antagonists to glucocorticoids (49). 
Exogenous androgen treatment stimulates tissue and cell growth, by stimulating mitosis 
of type II cells and fibroblasts in cell culture, while blocking their differentiation (44). 
Pregnant rabbits treated with dihydrotestosterone (DHT) showed delayed spontaneous 
and dexamethasone-stimulated surfactant production by both male and female fetuses 
(44, 50, 51), while treatment of fetal rabbits with the antiandrogen Flutamide inhibited 
the delay in surfactant production by raising the male surfactant phospholipid values to be 
equivalent to females, with no effect on the females (50). A dose-response relationship is 
noted between surfactant production and levels of androgen the fetuses were exposed to 
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as a result of their position in utero in litter-bearing rodents (50). Among males, there 
were no siginificant differences in surfactant production, whereas all levels were low 
compared to females (50). In females, those in utero placed between two females had the 
highest surfactant level, those females between two males had the lowest levels, and 
those with only one male neighbor had intermediate levels (50). Androgens and estrogens 
have been shown to exert inhibitory and stimulatory effects, respectively (52). Maternal 
administration of estrogen accelerates lung maturation and stimulates surfactant 
production in the fetal rabbit and rat (53, 54); with prenatal estrogen deprivation 
impairing alveolar formation and fluid clearance in neonatal piglets (55). Adult female 
rodents have more and smaller alveoli than males and the formation and maintenance is 
dependent on estrogens (56) and the estrogen receptor (ER) α and ERβ (57) as genetic 
deletion of ERα or ERβ decreases the number and increases the size of alveoli in mice 
with changes more prominent in females than males (57, 58). Therefore, it is possible that 
androgens in male MNR mice may protect the male lungs from prolonged, elevated 
levels of corticosterone, and therefore no long term impact on lung mechanics was 
detectable at one or three months postnatally.  The converse was likely true for females. 
We expected the changes in lung mechanics of FGR females at 1 month to be reversed 
when tested at 3 months, due to the initiation of puberty and the stimulatory effects of 
estrogen on lung development and maintenance. However, the deficit in lung function 
remained unchanged in the FGR female cohort at 3 months, this suggests the insult from 
MNR in utero persists despite the positive effects of circulating estrogen.  
The influence of gender and sex hormones lung development are particularly 
significant for preterm infants (49). The origin of gender-based differences may 
     
   
 
124
ultimately lie at the chromosomal level, with the role of sex chromosomes in lung 
development to be elucidated. Surfactant production in male and female chick embryos, 
in which sex karyotype is reversed such that if the homogametic sex (i.e. ZZ) is male, 
male surfactant production increases earlier than in females with males responsive earlier 
to treatment with glucocorticoids in ovo than females (59). Therefore, regardless of sex 
hormones, it may ultimately be the interaction of elevated corticosterone or MNR with 
the sex chromosome complement in females may be responsible for the postnatal 
consequences of compromised lung mechanics. The heterogametic sex is at a 
disadvantage for the timing of lung development and suggests a biologic advantage in 
having two complete sex chromosomes (49). However, during FGR, this may become a 
disadvantage.    
In summary, during FGR, maternal glucocorticoids enter the fetal circulation due 
to both high levels in the mother and reduced metabolism in the placenta. This causes the 
FGR fetus to be exposed to prolonged elevated levels of glucocorticoid, which may 
inhibit optimal development of glucocorticoid sensitive tissues, such as the lung. The 
elevated corticosterone and the other endocrine disturbances that occur during MNR were 
associated with reduced volumes of lung parenchyma with no change in airspace volume 
and reduction of surfactant protein-A, -C and possibly -B expression. These structural 
and biochemical changes may be associated with neonatal morbidity or predisposition to 
diseases in childhood or adulthood. Measurement of pulmonary mechanics in the 
offsprings at one and three months postnatally demonstrated a reduction in lung function, 
only in females. This study questions the benefit of administering antenatal 
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glucocorticoids to preterm FGR infants, as our study suggests that this may have 
deleterious effects on lung development both in short term as well as long term. 
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CHAPTER 5 
 
CHANGES IN PLACENTAL STRUCTURE AND 
FUNCTION BY MATERNAL UNDERNUTRITION IN A 
MOUSE MODEL OF FETAL GROWTH RESTRICTION  
 
Manuscript prepared for Placenta 
 
5.1 INTRODUCTION 
The placenta forms an important interface between the mother and fetus, adapting 
nutrient supply to the demands of the fetus while buffering changes in the maternal 
compartment. The ability of the placenta to adjust to the needs of the fetus depends on 
size, morphology, blood flow and transporter abundance of the placenta in conjunction 
with the synthesis and metabolism of nutrients and hormones by the placenta (1). If the 
placental supply of nutrients is compromised, the placenta adapts to enhance nutrient 
transport for maintaining fetal growth as demonstrated in humans (2, 3) and animal 
models (4), such that placental efficiency (grams of fetus supported per gram of placenta) 
increases.  
If the placenta fails to adapt and meet the required nutrient transfer to the fetus for 
growth, fetal growth restriction (FGR), may ensue. FGR is defined as a decrease in fetal 
growth rate that prevents a newborn from obtaining his or her optimal growth potential. 
FGR affects 3-10% of human pregnancies, is associated with high perinatal mortality and 
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morbidity (5, 6), and is associated with an increase risk of diseases in adulthood. FGR 
can be reproduced in experimental animals by maternal undernutrition, and is used to 
study pathophysiology in the fetus and placenta during FGR (7). The mouse is a valuable 
animal model for FGR research since it is a mammalian species with genetic makeup, 
biochemical pathways, cell types and physiology similar to humans (7). In particular, the 
mouse, which is amenable to genetic manipulation, has a hemochorial placenta that is 
functionally similar to humans, with many cell types having equivalent properties (8). 
The fetal compartment of a mouse placenta consists of the labyrinth zone, which contains 
fetal and maternal blood vessels for nutrient exchange, and the junctional zone, which 
stores glycogen and produces hormones. The junctional zone rests on the decidualized 
endometrium of the uterus. 
Insulin-like growth factor-II (IGF-II) is a major placental regulator of nutrient 
transfer to the fetus, placental growth and development. Placental efficiency increases 
with Igf2 gene deletion selectively in the mouse placenta (Igf2P0); at E16, more glucose 
and amino acids are transferred to the fetus per gram of placenta with upregulation of 
specific transporters in the placenta (9). These changes are not present when Igf2 is 
deleted in all fetal tissues, including the placenta (Igf2 null); there is a disproportionate 
decrease in labyrinth zone with hypoplasia and disturbances in cell differentiation in the 
junctional zone (10). Both forms of Igf2 deletion demonstrate reduced placental surface 
area and increased barrier thickness, with changes more severe in the Igf2 null (10). IGF-
II production in the fetal compartment is presumed to be a genetic signal to the placenta 
to enhance fetal growth, as the Igf2 null placenta fails to increase its efficiency when fetal 
IGF-II is removed (11). 
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IGF-II is an important member of the IGF system during embryonic and fetal 
development, and is an important mediator of placental structure and function (8); other 
members of this system can alter the activity of IGF-II. The IGF system includes IGF-I 
and IGF-II signaling peptides, two cell surface receptors, IGF-1R and IGF-2R, and six 
binding proteins, IGFBP-1 to IGFBP-6. The majority of effects of IGF-I and -II are 
mediated by binding to IGF-1R. IGF-II binding to the insulin receptor A (INSRA) 
isoform also mediates cell mitogenesis as this isoform is highly expressed during 
gestation (12, 13), as opposed to the insulin receptor B isoform which is highly expressed 
postnatally and mediates the metabolic effects of insulin with little affinity for IGF-II (12, 
13).  In contrast, IGF-2R binds only IGF-II and clears IGF-II from the plasma, decreasing 
its bioavailability. Six high-affinity IGF binding proteins regulate the availability of IGF-
I and -II to fetal tissues, protecting them from degradation in circulation and inhibiting 
IGF-I and -II from binding to their receptors (14). The IGF-I and -II peptides are 
produced widely by the fetus and placenta, and it is believed that the paracrine production 
of IGFBPs determines which cell types will be targeted for the growth promoting actions 
of IGFs (15).  
The insulin-like growth factor (IGF) system is the principal regulator of normal 
fetal and placental growth as it directs cell proliferation, differentiation, migration, and 
aggregation during gestation (15). Many transgenic and knockout mice targeting this 
system have demonstrated aberrant fetal and/or placental growth and development. The 
IGF system is present in most fetal tissues and its expression is coupled to nutrient supply 
to ensure that fetal growth is adequate relative to the amount of nutrients available (15). 
Alterations in fetal nutrient supply can change the expression of this system in a tissue 
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specific manner to regulate not only overall fetal growth, but the growth and development 
of individual fetal organs and placenta. 
This study was designed to investigate how maternal nutrient restriction (MNR) 
affects the structure and function of the murine placenta. The tissue morphology and 
expression of IGF system mRNAs were examined in the placenta of control and MNR 
litters at 18.5 days of pregnancy as mouse fetuses undergo rapid growth. Based on 
previous studies, we hypothesized that reduction of maternal nutrient supply would cause 
the placenta to maintain an adequate supply of nutrients to sustain fetal growth via up-
regulation of IGF system genes. 
 
5.2 MATERIALS AND METHODS 
5.2.1 Animals and Dietary Restriction Protocol 
Protocols on Animal Care were approved by the University Council on Animal 
Care at the University of Western Ontario, in accordance with guidelines of the Canadian 
Council for Animal Care. Ten week-old virgin CD-1 females and stud males were 
obtained from Charles River Laboratories (Montreal, PQ, Canada). Mice were housed at 
the Lawson Health Research Institute Vivarium (London ON, Canada) with 12:12 
light:dark cycle and water provided ad libitum. Female mice were housed singly with 
stud males in late afternoon and checked the following morning for vaginal plugs, 
indicating embryonic day 0.5 (E0.5). Females were housed individually and fed grain-
based dustless precision pellets (#F0173, Bio-Serv, Frenchtown NJ, USA) containing 
20.7% protein, 4.0% fat, 6.7% ash, 59.6% carbohydrates, 4.0% fiber and 5.0% moisture 
ad libitum using feeding tubes with cage clips (Bio-Serv, Frenchtown NJ, USA) until 
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E6.5. Feeds for control mice were pre-weighed each morning and remaining pellets 
weighed at same time each day to establish average daily feed intake during pregnancy. 
From E6.5, MNR mice (n = 21) were fed daily 70% by weight of the average daily intake 
of control mice (n = 14). Mice were euthanized at E18.5 by carbon dioxide inhalation. 
Fetuses were removed and weighed, placentae trimmed of membranes and yolk sac were 
dissected, weighed, and flash frozen in liquid nitrogen and stored at -80C.  
 
5.2.2 Stereology 
Stereology was performed as outlined previously (16) with minor modifications. 
Weights were recorded for all randomly selected placentae from six litters for each group. 
Placentae were sectioned at 5 µm thickness and stained with hematoxylin and eosin. 
Cross sections of mouse placentae were imaged using 5× objective of a Carl Zeiss 
Axio Imager Z1 and AxioCamHR3. AxioVision, Release 4.7.2 Software was used to 
combine individual fields of view enabling a complete view of tissue section. 
StereoInvestigator Software (MicroBrightField Bioscience, Inc., Williston, VT) was used 
for all stereology measurements. Using the Cavalieri Estimator probe (MicroBrightField 
Bioscience, Inc., Williston, VT), a 100 µm grid was superimposed over the cross section 
and two different markers used to count points falling on the Junctional Zone and 
Labyrinth Zone of the mouse placenta. (The absolute placental volume is defined as the 
sum of the junctional and labyrinth zone volumes.) Shrinkage during the paraffin-
embedding process was accounted for as previously described (16).  
Resin sections 1 µm thick at the placental midline were used to resolve the 
labyrinth vasculature in detail. A 63× oil objective lens on the Carl Zeiss Axio Imager Z1 
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and AxioCamHR3 was used to randomly capture 12 fields of view within the labyrinth 
zone, and to determine the volume densities, surface densities, length densities and 
interhemal membrane thickness as previously described (16).  
Theoretical diffusion capacity was calculated by dividing mean surface area of the 
fetal and maternal interhemal membrane by its thickness then multiplying by the Krogh 
diffusion coefficient for oxygen, as described previously (16). Specific diffusion capacity 
is an estimate of oxygen diffusion in terms of fetal requirements, obtained by theoretical 
diffusion capacity per mg of fetal weight. 
 
5.2.3 Quantitative Real-Time PCR 
Total RNA from flash frozen control and MNR placentae, pooled by litter, were 
extracted using Trizol (Invitrogen, Burlington, ON) and purified with the RNAeasy Mini 
Kit (Sigma, Maryland, USA), following the manufacturer’s instructions.  
SYBR Green qRT-PCR was used to study mRNA expression of glucose 
transporters, Glut-1 and -3, System A sodium-dependent neutral amino acid transporters 
isoforms, Slc38a1, -2 and -4, and System L amino acid transporter isoforms, Lat-1 and-2. 
Using reagents from Invitrogen, 1 µg of RNA from the placenta was reverse transcribed 
(RT) using Superscript III and 500 ng of Oligo(dT) with 20 U RNaseOUT in a 21.5 µl 
final volume, followed by digestion of the template RNA with 2 U RNase H. Reactions 
were incubated at 70C, 10 min; 42C, 2 min; 70C, 15 min; 4C, 10 min and 37C, 
20 min. Specific primers (TABLE 5.1) were purchased from Invitrogen. Platinum SYBR 
Green qPCR SuperMix-UDG with ROX (Invitrogen) was used as recommended with 200 
µM of primers, mixed with 100 ng RT product in a total volume of 10 µl in triplicate.  
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TABLE 5.1 Primer Sequences for SYBR Green quantitative Real-Time PCR. 
Primer 
Name 
Primer Pair Sequence Fragment 
Size (bp) 
Reference 
Glut-1 CCAGCTGGGAATCGTCGTT (F) 
CAAGTCTGCATTGCCCATGAT (R) 
76 (17) 
Glut-3 CTCTTCAGGTCACCCAACTACGT (F) 
CCGCGTCCTTGAAGATTCC (R) 
121 (17) 
Lat-1 GCTGTGGACTTCGGGAACTACC (F)  
CCACACACAGCCAGTTGAAGAA (R) 
291 AY162432/ 
GI:27227810 
Lat-2 CTCTTCACATGCCTCTCCAC (F)  
TACACGACCACACACATC (R) 
379 AY162433/ 
GI:27227860 
Slc38A1 TGCAGAACACTGGGGCGAT (F)  
GTGTAGCCAAGATACCCCAGG (R) 
195 NM_134086/  
GI:142381438 
Slc38A3 CGAATCATGCCCACTGACAA (F)  
AACCGCAGCGAAACAAAGG (R) 
71 (18) 
Slc38A4 AGGGTGCTGAGAAATGCCAA (F)  
GACCTCAGGGTGGCAGACAA (R) 
100 (18) 
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Thermal cycling conditions were 50C, 2 min; 95C, 20 sec; 60C, 20 sec; 72C, 30 
sec for 40 cycles. A Mann-Whitney test was performed to determine if the fold-change of 
MNR litters was significantly different from controls. 
 
5.2.4 Microvillous Membrane (MVM) Extraction 
Pooled placentae from each litter were trimmed of fetal membranes and umbilical 
cords, chopped into small pieces and rinsed three times in HT saline (1.8 g NaCl in 10 
mM HEPES-Tris). Placentae were homogenized in Buffer D (250 mM sucrose in 10 mM 
HEPES-Tris) for 30 sec at 15,000 rpm. A homogenate sample was reserved for alkaline 
phosphatase enrichment to assess final MVM extract purity. The homogenate was 
centrifuged at 3,000× g for 10 min at 4C to remove nuclei and large debris. Resulting 
supernatant was centrifuged at 14,000× g for 30 min to pellet the crude membrane 
fraction of the homogenate and resuspended in Buffer D with magnesium chloride to 
isolate the MVM fraction. Precipitates were discarded following a 2,500× g spin for 10 
min at 4C and the MVM fraction in the supernatant concentrated at 100,000× g. Protein 
concentration was determined by BCA assay. Purity of MVM extract was assessed by 
MVM/homogenate alkaline phosphatase enrichment ratio, and was found to be 16 ± 2 
fold (n = 14). 
 
5.2.5 Western Blots 
Glucose transporter isoforms GLUT1 and GLUT3 protein levels were analyzed in 
placental MVM extract using Western blotting (TABLE 5.2). In brief, 15 µg of total 
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TABLE 5.2 Primary Antibodies used for Immunohistochemistry (IHC) and Western Blotting 
(WB). 
Dilution Antibody Host Catalogue # 
IHC WB 
Source 
IGF-I Rabbit #RB-9240-P 1:10 - Labvision Corp., Fremont, CA 
IGF-II Rabbit PAAL1 1:15 - GroPep, Adelaide SA, Australia 
IGFBP-1 Goat Sc-6072 1:400 - Santa Cruz Biotech Inc., Santa Cruz, CA 
IGFBP-2 Rabbit #06-107 1:750 - Upstate Biotech Inc., Lake Placid, NY 
IGFBP-3 Rabbit DSL-R00534 1:750 - Diagnostic Systems Laboratories, Inc., Webster, TX 
GLUT1 Rabbit 07-1401 - 1:4000 Millipore, Temecula, CA, USA 
GLUT3 Rabbit AB1344 - 1:2000 Millipore, Temecula, CA, USA 
Pan-actin Mouse #MS-1295 - 1:7000 Thermo Fisher Scientific, Fermont, CA 
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protein was loaded onto 10% SDS-PAGE gels, and electrophoresis was performed at 
constant 100 V for 2 h. Protein was transferred onto PVDF membranes for 1.5 h at 
constant 350 mAmp and blocked with 5% Carnation non-fat powdered milk in TBS for 1 
h at RT. Membranes were incubated with primary antibodies overnight at 4C, washed, 
and incubated with appropriate secondary peroxidase-labeled IgG for 1 h. After washing, 
bands were visualized using Western Lighting Enhanced Chemiluminescence (ECL) 
detection reagents (Perkin-Elmer, Boston, MA). Blots were stripped and reprobed for 
pan-actin as a loading control. Analysis was performed by densitometry using an Alpha 
Imager and FluoroChem 8800 software (Alpha Innotech Corporation, San Leandro, CA). 
A Mann-Whitney test was performed to determine if the fold-change in MNR litters was 
significantly different from controls. 
 
5.2.6 Tissue Preparation 
Placentae were harvested at E18.5, fixed in 4% paraformaldehyde for 48 h, 
bisected, then washed 3 times in PBS over 3 days.  Tissue specimens were embedded in 
paraffin, sectioned at 5 µm and mounted onto Superfrost® slides (Fisher Scientific, 
Fairlawn, NJ). 
 
5.2.7 Immunohistochemistry 
Sections were deparaffinized and rehydrated in descending series of ethanol 
solutions. Endogenous peroxidase was quenched with 3% H2O2, blocked using Avidin 
and Biotin kit (Biocare Medical, Concord, CA) and the Background Sniper Universal 
Blocking Reagent (Biocare Medical) as per manufacturer’s instructions. Tissue sections 
     
  
140
were incubated with primary antibodies against IGF-I, -II and IGFBP-1, -2 and -3 
overnight at 4C (TABLE 5.2). Slides were incubated for 30 min at RT with appropriate 
secondary IgG. After washing, sections were incubated for 30 min at RT in peroxidase-
conjugated avidin–biotin–complex (Vectastain Elite ABC kit; Vector Laboratories Inc, 
Burlingame, CA) and DAB (Cardassian Diaminobenzidine Chromogen Kit; Biocare 
Medical, Walnut Creek, CA) was applied. Tissue sections were counterstained with 
methyl green (DakoCytomation Inc., Carpinteria, CA).  Preabsorbed negative controls 
were performed with each antibody. 
 
5.2.8 In situ Hybridization (ISH) 
Placenta sections from control and MNR groups were analyzed for IGF-I, IGF-II, 
IGFBP-1, IGFBP-2 and IGFBP-3 mRNA expression by in situ hybridization using 35S-
labelled antisense riboprobes as described (8). The 35S-labelled antisense and sense cRNA 
probes were generated from cDNAs (TABLE 5.3) using a Promega Riboprobe 
Combination System SP6/T7 kit (Promega Corp., Madison, WI) and 35S-UTP (Perkin 
Elmer, Waltham, MA). In situ hybridization was performed as previously outlined (8) 
(Appendix 1.1.2). The slides were viewed under both dark- and bright fields, using a 
Carl Zeiss Axio Imager Z1 and appropriate photomicrographs were obtained at 400× 
magnifications using AxioCamHR3 and AxioVision Release 4.7.2 software.  
Quantification was performed on eight control and eight MNR placentae. For the 
IGF system, 12 random fields of view were taken in the labyrinth zone of the placenta 
from each animal. Using Carl Zeiss Automeasure Plus Software, IGF-I, IGF-II, IGFBP-2 
and IGFBP-3 mRNA abundance per cell was quantified by counting total grains and  
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TABLE 5.3 cDNA Vectors for generating cRNA probes for insitu hybridization of Igf 
System RNA. 
Restriction Site AntiSense                           
Probe 
Target
(gi #) 
Size 
(bp) AS S 
Vector Origin Ref 
Plp-I 23820972 800 NotI BamHI pCR
®II-
TOPO 
Dr. James Cross 
(University of 
Calgary) 
(19) 
mIgf-1 33612736 271 XhoI EcoRV pBluescript LION 
imaGenes                        
(Berlin, Germany) - 
mIgf-2 170172554 468 EcoR I Sst I pBluescript KS 
Dr. Graeme Bell 
(University of 
Chicago) 
(20) 
rIgfbp-1 6981079 1477 Kpln XhoI pGEM 7Zf Matt Rechler (21) 
rIgfbp-2 148747420 585 HindIII EcoR I pGEM 3z Matt Rechler (21) 
rIgfbp-3 6981083 905 EcoRI SmaI pGEM 3z 
Dr. Adrian H. 
Herington 
(University of 
Melbourne) 
(22) 
The nucleotide sequence homology between rat and mouse IGFBP-1 to -3 cDNAs is 90-94%. 
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dividing by number of cells, in each field of view at 400× magnification. For Plp-1, a 
cross-section of the midline placenta was generated using 10× objective and combined in 
AxioVision Release 4.7.2 software. Cells in junctional zone were manually counted and 
those expressing Plp-1 were classified as spongiotrophoblast cells (19). 
 
5.2.9 Placental Transport Assays of Radiolabeled Solutes 
Pregnant mice at E19 were anesthetized by intraperitoneal injection of 0.03 
mL/10 g of ketamine and xylazine at concentrations of 4 mg/mL and 1 mg/mL, 
respectively. A neck incision was made, and jugular vein exposed. A 100 µl bolus of PBS 
containing 3.5 µCi 14C-methyl-aminoisobutyric acid (MeAIB) or 3.5µCi 14C-methyl-D-
glucose with 70 µCi 51Cr-EDTA was injected into the jugular vein. Four minutes after 
injection, animals were killed and pups removed by hysterectomy. Fetuses, placentae and 
100 µl maternal blood were placed in 4 ml of Scintisafe and beta or gamma radiation 
counted. Radioactive counts in each fetus were expressed relative to counts in maternal 
blood sample and used to calculate the amount of radioisotope transferred per gram of 
placenta or per gram of fetus for each feto-placental unit in the litter. Average values for 
each litter were normalized to the mean of the control group to express the resulting fold 
change in solute transport. 
The fetal accumulation of radioisotope expressed relative to placental gives a 
relative measure of placental transfer of solute. The fetal accumulation of radioisotope 
expressed relative to fetal weight gives a relative measure of the amount of solute 
received by the fetus. Data for placental transfer assays were collected from four control 
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and eight MNR litters for 51Cr-EDTA; eight control and 12 MNR litters for 14C-methyl-
D-glucose; six control and seven MNR litters for 14C-MeAIB.  
 
5.2.10 Statistics 
All data are expressed as mean ± SEM. Parameters in control and MNR animals 
were compared with Student’s non-paired two-tailed t test, unless stated otherwise. For 
radioactive solute studies, t test was performed prior to normalization to the control mean. 
Significance was set at P < 0.05. 
 
5.3 RESULTS 
5.3.1 Fetal and Placental Weights at E 18.5 
Placental and fetal weights were measured at E18.5 to determine the effect of 
maternal undernutrition during gestation. The MNR group demonstrated significantly 
reduced placental weights (Fig. 5.1A; Control: 94 ± 2 mg vs. MNR: 86 ± 2 mg; P < 0.05), 
fetal weights (Fig. 5.1B; Control: 1482 ± 27 mg vs. MNR: 969 ± 30 mg; P < 0.001) and 
placental efficiency (Fig. 5.1C; Control 15 ± 1 vs. MNR 11 ± 1: P < 0.001) compared to 
control. 
 
5.3.2 Absolute Volumes 
Whole placental weight was reduced during maternal undernutrition, however this 
does not indicate how the structure of the placenta adapted to a reduced supply of 
maternal substrates. Stereology was employed to measure alterations to placental  
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Figure 5.1 The effect of 70% maternal nutrient restriction on fetal and placental 
weight and placental efficiency at E18.5. (A) Placental weight (mean ± SEM) in control 
(N=14) and 70% MNR (N=21) litters. In 70% MNR litters, the placental weight of 86 ± 2 
mg (vs 94 ± 2 mg in controls) was significantly lower (P < 0.05). (B) Fetal weight (mean 
± SEM) in control (N=14) and 70% MNR (N=21) litters. In 70% MNR litters, the fetal 
weight of 969 ± 30 mg (vs 1482 ± 27 mg in controls) was significantly less (P < 0.001). 
(C) Placental efficiency (mean ± SEM) in control (N=14) and 70% MNR (N=21) litters. 
In 70% MNR litters, placental efficiency of 11 ± 1 (vs 15 ± 1 in controls) was 
significantly reduced (P < 0.001). 
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structure following maternal undernutrition. The absolute volume, defined in our study as 
combined junctional and labyrinth zone volume, was significantly less in the MNR group 
(Fig. 5.2A; Control: 0.129 ± 0.008 vs. MNR: 0.081 ± 0.005 cm3; P < 0.0005), with both 
zones significantly reduced (Fig. 5.2A; LZ, Control: 0.081 ± 0.005 vs. MNR: 0.058 ± 
0.003 cm3, P < 0.005; JZ, Control: 0.048 ± 0.004 vs. MNR: 0.022 ± 0.003 cm3, P < 
0.0005). The junctional zone contributed significantly less to absolute volume in MNR 
placenta (Fig. 5.2B; Control: 37 ± 2% vs. MNR: 27 ± 2%; P < 0.005). 
 
5.3.3 Junctional Zone Study 
Stereology indicated a reduction in the volume of the junctional zone; further 
studies were performed to determine changes to the cell population residing in this zone. 
The junctional zone contained fewer total cells in the MNR group compared to control 
(Fig. 5.3A; Control: 4375 ± 232 vs. MNR: 2411 ± 184; P < 0.00005), with both glycogen 
cells (GC) and spongiotrophoblast cells (SpT) significantly reduced (Fig. 5.3B; SpT, 
Control: 2883 ± 159 vs. MNR: 1874 ± 138, P < 0.0005; GC, Control: 1492 ± 193 vs. 
MNR: 537 ± 93, P < 0.001). Proportion of glycogen cells was significantly less in the 
MNR group (Fig. 5.3C; Control: 33 ± 3% vs. MNR: 22 ± 3% mg; P < 0.05). 
 
5.3.4 Labyrinth Volumes 
Stereology measurements indicated that the volume of the labyrinth zone was 
significantly reduced following maternal undernutrition, but its volume was relatively 
spared at the expense of the volume of the junctional zone. Further stereology  
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Figure 5.2 The effect of 70% maternal nutrient restriction on placental volumes and 
the proportion of Junctional and Labyrinth Zones of the placenta at E18.5. (A) 
Representative cross-section at placental midline of control placenta. (B) Representative 
cross-section at placental midline of 70% MNR placenta. (C) Placental volume (mean ± 
SEM) in control (N=6) and 70% MNR (N=7) placentas. In 70% MNR placenta, the 
placental volume of 0.081 ± 0.005 cm3 (vs 0.129 ± 0.008 cm3 in control) was 
significantly reduced (P < 0.0005), as well as the volume of the labyrinth of 0.058 ± 
0.003 cm3 (vs 0.081 ± 0.005 cm3 in controls) and junctional zone 0.022 ± 0.003 cm3 (vs 
0.048 ± 0.004 cm3 in controls) were both significantly reduced (P < 0.005 and P < 
0.0005, respectively). (D) Proportion of labyrinth (mean ± SEM) and junctional zone 
(mean ± SEM) in control (N=6) and 70% MNR (N=7) placentas. In the 70% MNR 
placenta, the proportion of the labyrinth of 73 ± 2% (vs 63 ± 2% in controls) was 
significantly increased at the expense of the junctional zone of 27 ± 2% (vs 37 ± 2% in 
controls) (P < 0.005). 
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Figure 5.3 The effect of maternal nutrient restriction on total cell numbers and the 
proportion of difference cell types in the junctional zone of the placenta at E18.5. 
(A) Total number of cells in the junctional zone (mean ± SEM) at the placental midline in 
control (N=7) and 70% MNR (N=7) placentas. In the 70% MNR placentas, the total 
number of cells of 2411 ± 184 (vs 4375 ± 232 in controls) was significantly reduced (P < 
0.00005). (B) Cell counts (mean ± SEM) of spongiotrophoblasts (SpT) and glycogen 
cells (GC) at the placental midline in control (N=7) and 70% MNR (N=7) placentas. In 
the 70% MNR placentas, the number of spongiotrophoblast cells of 1874 ± 138 (vs 2883 
± 159 in controls) and glycogen cells of 537 ± 93 (vs 1492 ± 193 in control) were 
significantly reduced (P < 0.005 and P < 0.001, respectively). (C) Percentage (mean ± 
SEM) of spongiotrophoblast and glycogen cells in the junctional zone at the placental 
midline in control (N=7) and 70% MNR (N=7) placentas. In the 70% MNR placentas, the 
percentage of the glycogen cells of 22 ± 3% (vs 33 ± 3% in controls) in the junctional 
zone was significantly reduced (P < 0.05). 
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measurements were performed to determine subtle changes to the maternal and fetal 
vasculature of the labyrinth zone, responsible for substrate exchange between the two 
circulations. Labyrinth volume composed of fetal capillaries was not significantly 
different between groups, while volume of maternal blood spaces and trophoblast were 
significantly reduced (Fig. 5.4A; MBS, Control: 0.015 ± 0.001 vs. MNR: 0.008 ± 0.001 
cm3, P < 0.001; Trophoblast, Control: 0.050 ± 0.003 vs. MNR: 0.035 ± 0.002 cm3, P < 
0.005). Therefore, the percentage of labyrinth composed of fetal capillaries was 
significantly increased (Fig. 5.4B; Control: 19 ± 1% vs. MNR: 22 ± 1%, P < 0.05), the 
maternal blood space was significantly reduced (Fig. 5.4B; Control: 19 ± 1% vs. MNR: 
15 ± 1%, P < 0.005) and the trophoblast was not different. MNR placenta had a 
significant increase in interhemal distance (Fig. 5.4C; Control: 3.4 ± 0.1 µm vs. MNR: 
3.9 ± 0.1 µm; P < 0.005). The fetal capillary surface area and maternal surface area were 
significantly reduced in the MNR group (Fig. 5.4D; FC, Control: 54.9 ± 5.7 vs. MNR: 
39.4 ± 2.2 m2, P < 0.05; MBS, Control: 68.5 ± 4.6 vs. MNR: 51.7 ± 3.9 m2, P < 0.05). 
Length of fetal capillaries in MNR placenta was significantly less (Fig. 5.4E; Control: 
198.6 ± 21.9 m vs. MNR: 126.1 ± 7.4 m, P < 0.05) and diameter was significantly 
increased (Fig. 5.4F; Control: 9.9 ± 0.3 µm vs. MNR: 11.2 ± 0.4 µm, P < 0.05). 
 
5.3.5 Theoretical Diffusional Capacity 
Measurements performed by stereology of the maternal and fetal vasculature in 
the labyrinth zone allowed estimation of the theoretical diffusion capacity of the control 
and MNR placentas. Theoretical diffusion capacity was significantly reduced in MNR 
animals (Fig. 5.4G; Control: 0.032 ± 0.003 vs. MNR: 0.020 ± 0.01, P < 0.01), however  
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Figure 5.4 The effect of maternal nutrient restriction on dimensions of fetal 
capillaries and diffusion capacity in the labyrinth zone of the placenta at E 18.5. (A) 
Volume (mean ± SEM) of fetal capillaries (FC), maternal blood space (MBS), and 
trophoblast in control (N=6) and 70% MNR (N=6) placentas. In the 70% MNR placentas, 
the volume of the MBS of 0.008 ± 0.001 cm3 (vs 0.015 ± 0.001 cm3 in controls) and 
trophoblast of 0.035 ± 0.002 cm3 (vs 0.050 ± 0.003 cm3) were significantly reduced (P < 
0.001 and P < 0.005, respectively) with no difference in FC volume. (B) Percentage 
(mean ± SEM) of labyrinth composed of FC, MBS, and trophoblast in control (N=6) and 
70% MNR (N=6) placentas. In the 70% MNR placentas, the percentage of FC volume of 
22 ± 1% (vs 19 ± 1% in controls) was significantly increased (P < 0.05) and the 
percentage of MBS volume of 15 ± 1% (vs 19 ± 1% in controls) was significantly 
reduced (P < 0.005), with no difference in the percentage of trophoblast volume. (C) 
Interhemal distance (mean ± SEM) in control (N=6) and 70% MNR (N=6) placentas. In 
the 70% MNR placentas, interhemal distance of 3.9 ± 0.1 µm (vs 3.4 ± 0.1 µm in 
controls) was significantly increased (P < 0.005). (D) Surface area (mean ± SEM) of FC 
and MBS in control (N=6) and 70% MNR (N=6) placentas. In 70% MNR placentas, 
surface area of the FC of 39.4 ± 2.2 m2 (vs 54.9 ± 5.7 m2 in controls) and MBS of 51.7 ± 
3.9 m2 (vs 68.5 ± 4.6 m2 in controls) were significantly reduced (both P < 0.05). (E) 
Length (mean ± SEM) of FC in control (N=6) and 70% MNR (N=6) placentas. In the 
70% MNR placentas, FC length of 126.1 ± 7.4 m (vs 198.6 ± 21.9 m in controls) was 
significantly reduced (P < 0.05). (F) Diameter (mean ± SEM) of FC in control (N=6) and 
70% MNR (N=6) placentas. In the 70% MNR placentas, FC diameter of 11.2 ± 0.4 µm 
(vs 9.9 ± 0.3 µm in controls) was significantly increased (P < 0.05). (G) Theoretical 
diffusion capacity (mean ± SEM) in control (N=6) and 70% MNR (N=6) placentas. In the 
70% MNR placentas, the theoretical diffusion capacity of 0.020 ± 0.01 cm2·min-1·kPa-
1
·10-2 (vs 0.032 ± 0.003 cm2·min-1·kPa-1·10-2 in controls) was significantly reduced (P < 
0.01). (H) Specific diffusion capacity (mean ± SEM) in control (N=6) and 70% MNR 
(N=6) placentas, was not different between groups. 
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when expressed in weight as grams of fetus, the diffusion capacity was appropriate for 
weight of the fetus, with no difference between groups (Fig. 5.4H). 
 
5.3.6 IGF System 
The IGF system has been implicated to have a significant role in promoting 
development and function of the murine placenta (8). The expression of the system was 
analyzed specifically in the labyrinth zone during maternal undernurition. MNR placentae 
demonstrated significantly increased mRNA expression of IGF-II (Fig. 5.5 E&G; 
Control: 10 ± 2 vs. MNR: 19 ± 3 grains/cell, P < 0.05), IGFBP-2 (Fig. 5.5 M&O; 
Control: 23 ± 1 vs. MNR: 40 ± 4 grains/cell, P < 0.001) and IGFBP-3 (Fig. 5.5 Q&S; 
Control: 21 ± 1 vs. MNR: 41 ± 2 grains/cell, P < 0.001), with no significant differences in 
IGF-I expression. IGFBP-1 expression was localized to the yolk sac with strong 
expression in the cuboidal epithelium lining, the non-vascular spaces in the allantoic plate 
and appeared greater in MNR placenta though not quantified.  
 
5.3.7 Transporter Studies 
Stereology allowed measurement of placental structure, but did not indicate 
changes to the placental function of nutrient transport. Transfer studies of radiolabelled 
substrates from the maternal to fetal circulation were performed to measure the function 
of the placenta during maternal undernutrition. Analysis of solute transfer per gram of 
placenta for each radiolabelled substrate demonstrated no significant differences between 
control and MNR groups for MeAIB. However transport of EDTA (Fig. 5.6A; MNR 0.05  
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Figure 5.5 The effect of maternal nutrient restriction on placental IGF System 
Expression at E18.5. In situ hybridization of IGF-I (A and C), IGF-II (E and G), 
IGFBP-1 (I and K), IGFBP-2 (M and O), and IGFBP-3 (Q and S) of control (A, E, I, M 
and Q) and 70% MNR (C, G, K, O and S) placentas. Immunohistochemistry of IGF-I (B 
and D), IGF-2 (F and H), IGFBP-1 (J and L), IGFBP-2 (N and P), and IGFBP-3 (R and 
T) of control (B, F, J, N and R) and 70% MNR (D, H, L, P and T) placentas. (U) Counts 
of IGF System mRNA grains per cell (mean ± SEM) in the labyrinth from control (N=8) 
and 70% MNR (N=8) placentas. In the 70% MNR placentas, transcript expression of 
IGF-II of 19 ± 3 (vs 10 ± 2 in controls), IGFBP-2 of 40 ± 4 (vs 23 ± 1 in controls) and 
IGFBP-3 of 41 ± 2 (vs 21 ± 1 in controls) were significantly elevated (P < 0.05, P < 0.001 
and P < 0.001, respectively). Bars, 100 µm. 
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Figure 5.6 The effect of maternal nutrient restriction on placental transfer of solutes 
at E18.5. (A) Fold change of EDTA, glucose and MeAIB transfer to fetus per gram of 
placenta (mean ± SEM) in control (N =4, 8, 6, respectively) and 70% MNR (N=8, 12, 7, 
respectively) litters. In the 70% MNR placentas, the transfer of EDTA of 0.49 ± 0.05 (vs 
1.00 ± 0.10 in controls) and glucose of 0.52 ± 0.08 (vs 1.00 ± 0.15 in controls) was 
significantly reduced (P < 0.001 and P < 0.01, respectively). (B) Fold change of EDTA, 
glucose and MeAIB transfer to fetus per gram of fetus (mean ± SEM) in control (N =4, 8, 
6, respectively) and 70% MNR (N=8, 12, 7, respectively) litters. In the 70% MNR 
fetuses, the accumulation of EDTA of 0.63 ± 0.05 (vs 1.00 ± 0.10 in controls) was 
significantly reduced (P < 0.005), but MeAIB accumulation per gram of fetus of 2.24 ± 
0.46 (vs 1.00 ± 0.25 in controls) was significantly increased (P < 0.05). 
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fold change 0.49 ± 0.05, P < 0.001) and glucose (Fig. 5.6A; MNR 0.52 ± 0.08 fold 
change, P < 0.01) was significantly reduced in MNR group. When normalized to fetal 
weight, the fetus received less EDTA per gram than controls (Fig. 5.6B; MNR fold 
change 0.63 ± 0.05, P < 0.005), however more MeAIB (Fig. 5.6B; MNR fold change 
1.44 ± 0.25, P < 0.05), with no significant differences in glucose. No significant 
differences were demonstrated in mRNA expression of Glut-1 and -3, Lat-1 and-2, and 
Slc38a1, -2 and -4 and at the protein level of GLUT-1 and GLUT-3 in the microvillous 
membrane (MVM) (Appendix Fig. 1.4). 
 
5.4 DISCUSSION 
This study demonstrated that 70% MNR adversely affects the structure and 
function of the placenta to adequately supply nutrients to the growing fetus. In contrast to 
previous studies (2-4), we showed that a relatively mild reduction of maternal nutrient 
supply (70% of controls), caused a reduction in placental efficiency and impairment of 
solute transport that was inefficient relative to the weight of the fetus. Previously, we 
have shown that the 70% MNR mouse model of FGR demonstrated the most severe 
asymmetrical FGR phenotype when compared to 80% and 60% MNR (Chapter 3). Coan 
et al., recently published a placental study in a 80% MNR mouse model, which according 
to our previous data, may not be severe enough to induce a consistent FGR phenotype, as 
many fetal weight parameters were similar to control (23). 
Fetal weight was reduced to a greater extent than placental weight, suggesting that 
during MNR, the placenta was relatively spared compared to the fetus as maternal 
nutrient supply was utilized to support placental metabolism, growth and development 
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first. In a previous study, we demonstrated that transgenic mice overexpressing hepatic 
hIGFBP-1 were growth-restricted at birth with increased placental weight and reduced 
placental efficiency near term similar to the current MNR model (24). The placental 
changes may be the direct effects of IGFBP-1 on placental growth or may be 
compensatory changes designed to increase passage of nutrients to the growth-restricted 
fetus (24). Previously, we demonstrated increased IGFBP-1 expression in MNR fetal 
liver, and hence elevated circulating IGFBP-1 may be a fetal distress signal to the 
placenta to increase growth to supply more nutrients to the fetus [submitted]. Placental 
weight that was proportionately greater relative to fetal weight may be a compensatory 
mechanism to increase nutrient supply in utero, but may increase the long-term risk of 
disease as a high placental to birth weight ratio has been associated with elevated blood 
pressure and increased prevalence of coronary heart disease and impaired glucose 
tolerance (25-27). 
To further study MNR placental structure, the volume of each placental layer and 
changes to the cellular composition were analyzed. The labyrinth zone contains fetal 
capillaries (FC) and maternal blood spaces (MBS) that are separated by two layers of 
syncytiotrophoblast and cytotrophoblast epithelium as well as fetal capillary endothelium 
and its supporting mesenchyme (16). The junctional zone is composed of three principal 
cell types, the spongiotrophoblasts, glycogen cells and secondary giant cells that rest on 
the decidualized endometrium of the uterus (16). Significant reductions in both placental 
zones were demonstrated, but the junctional zone was disproportionately reduced 
compared to the labyrinth zone, suggesting that the labyrinth was spared to maintain 
survival of the fetus and placenta. The junctional zone is the least understood of the 
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placental layers, however, it is critically important for fetal survival as demonstrated by 
embryonic lethality of the Mash2 knockout mouse, which lacked a junctional zone (28). 
Analysis of the junctional zone demonstrated reductions of both spongiotrophoblast and 
glycogen cells, however, there was a greater decline in the population of glycogen cells. 
These junctional zone changes are similar to those described by Lopez et al. where 
glycogen cells were disproportionately reduced in the placenta of Igf2 null mice (29). 
Previous studies utilized glycogen vacuoles to identify glycogen cells and could not 
differentiate whether glycogen cell reduction is due to less glycogen synthesis or 
disturbed glycogen cell differentiation. Using Plp-1 mRNA as a specific molecular 
identifier of glycogen cells, we demonstrated less glycogen cell differentiation during 
MNR (19). The function of the glycogen cell is unclear, but the stored glycogen may be 
used as an energy source for the placenta itself or may be stored to support fetal growth, 
as there are high demands on maternal resources at term (30). The lack of glycogen cells 
in our MNR model supports the theory of glycogen being stored to support fetal growth, 
as at E18.5, fetal growth was compromised more than placental growth.  
The absolute volume of the labyrinth zone was significantly reduced in the MNR 
placenta, with the vasculature demonstrating fine differences in structure. The absolute 
volume of fetal capillaries was spared, but at the expense of volume reductions in the 
maternal blood spaces and placenta trophoblast and interstitium.  The relative increase in 
the proportion of MNR labyrinth composed of fetal capillary suggests that the fetal 
circulatory component was attempting to compensate by vasodilatation to increase blood 
flow and extract more nutrients from the mother. In contrast, the reduction of the 
maternal blood space volume may be a maternal response to limit nutrient transfer to the 
     
  
162
fetus by constricting blood flow through the placenta. Our results support the changes to 
the placenta seen in MNR guinea pigs (31) and are consistent with stereological studies 
of human FGR placentae (32, 33). Reduced surface area for exchange and increased 
barrier thickness between maternal and fetal circulations suggest an impedance to transfer 
of solutes across the placenta with FGR. 
Simple diffusion of EDTA was significantly reduced in keeping with the 
stereology data. Glucose transport was significantly reduced per gram of placenta, but 
was appropriate per gram of fetus. Glucose is an important substrate for growth in late 
gestation as fetal weight is correlated specifically to the supply of glucose. Our data 
demonstrating no changes to mRNA and protein levels with MNR are consistent with 
human studies of FGR placentae (34, 35). System A is a ubiquitous Na+-dependent 
transport system used by small neutral amino acids (glutamine, glycine, and serine) and 
consists of three different isoforms SNAT-1 (ATA-1), SNAT-2 (ATA-2) and SNAT-4 
(ATA-3) in human and rodent placenta (36).  MeAIB is a System A specific substrate, 
particularly for SNAT-2 (36). The placental transport of MeAIB per gram of placenta 
was not different between groups with no change in SNAT mRNA expression. However, 
significantly more MeAIB accumulated in growth restricted MNR fetuses indicating a 
potential mechanism to increase fetal growth or energy stores prior to birth. The reduced 
permeability of EDTA and increased MeAIB accumulation in the fetus may be 
complementary, such that reduced passive permeability of MNR placenta may lower the 
back flux of small molecules (e.g. EDTA) down their concentration gradient from fetal to 
maternal circulation (10) and result in increased net flux of actively transported amino 
acids across the MNR placenta to the fetus and accumulation of MeAIB (10).  
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Analysis of the insulin-like growth factor system expression in the labyrinth layer 
suggests an intriguing paracrine mechanism by which the placenta altered growth and 
differentiation in the event of MNR. The cellular sites of expression of the respective 
mRNAs of the IGF system were similar to those previously described (8). IGF-II mRNA 
was highly expressed in the labyrinth layer of the MNR placenta compared to the control 
and is consistent with several previous studies which reported increased placental 
expression of IGF-II mRNA in human (37, 38) and animal models of FGR (39, 40). IGF-
II gene transcription may be increased in an attempt to compensate for growth restriction, 
as IGF-II over-expression caused by relaxation of imprinting (41) or disruption of the 
IGF-2R clearance receptor lead to placentomegaly (42). Alternatively, increased 
expression may be an attempt by the placenta to overcome the inhibitory actions of 
elevated IGFBP expression. Our model supports the latter hypothesis. IGFBP-2 mRNA 
was highly expressed in the labyrinth layer in the MNR placenta, specifically in the 
trophoblast and capillary endothelium. Although IGFBP-2 actions on the placenta is yet 
unknown, its expression tends to be increased in fetal circulation of FGR humans and 
animal models, and suggests to be a causal factor of decreased growth (43). IGFBP-2 
may have specific effects on the placenta as it has a higher affinity for IGF-II over IGF-I, 
as IGF-II is the main promoter of growth and differentiation of the placenta. IGFBP-3 
was localized to the mesenchyme of the labyrinth and its expression was increased in 
MNR placentae. Similarly, the function of IGFBP-3 in the placenta is unknown, but it 
may suppress IGF effects as shown in placental fibroblasts (44). Many of the 
morphological changes in the MNR labyrinth and junctional zones are similar to those 
seen in the Igf2 null mutant mouse placentae (10), and overall suggest an impairment of 
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IGF-II action in the MNR placenta. Thus, resultant phenotype of the placenta in MNR 
indicates that despite increased expression of IGF-II mRNA, the concomitant increase of 
IGFBPs may inhibit IGF-II actions on placental development 
In conclusion, our MNR mouse model of FGR demonstrated many changes to 
placental vasculature that have been documented in human cases of FGR. Our model 
demonstrates a failure of the placenta to adapt to MNR, as placental efficiency in terms of 
weight is reduced while the specific transport of substrates crossing the placenta by 
diffusion, facilitated diffusion and active transport do not correspond to the amounts 
necessary to sustain fetal growth. Although the role of IGF-II has been demonstrated to 
be an important regulator of placental development and function, the role of its main 
regulators, the IGFBPs, have yet to be established in the pathophysiology of FGR and the 
placenta. Our model demonstrated important changes in placental IGFBP expression and 
may serve as an important model system to determine the interaction of IGFBPs on IGF-
II placental action during FGR with subsequent changes in placental structure and 
function.  
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CHAPTER 6 
THESIS DISCUSSION 
6.1 THE MODEL 
Our model of fetal growth restriction (FGR) in mice demonstrated many of the 
phenotypic characteristics of human FGR. The variations in fetal morphometry indicated 
that the mouse model was consistent with an asymmetric form of FGR (1). The primary 
regulators of fetal growth, the IGF and glucocorticoid systems, demonstrated expression 
changes consistent with those seen in human FGR neonates. The circulating IGF-1 and 
IGFBP-3 were decreased, and IGFBP-1 elevated (2). Tissue expression of murine IGF 
system mRNAs were consistent with humans as the liver being the main site of 
production during gestation for these peptides (3). The glucocorticoid system 
demonstrated elevated circulating levels of corticosterone (4, 5) in the fetus with 
decreased dehydrogenase metabolism to inactive metabolites in the placenta as seen in 
human FGR (2). Maternal total caloric restriction in the mouse caused similar changes to 
organ structure compared to those demonstrated in human FGR fetuses. In the liver, 
glycogen storage was reduced (6); in the lung, airspaces were enlarged consistent with 
bronchopulmonary dysplasia following human FGR complicating prematurity (7-12); and 
in the placenta, the vascular structure demonstrated reduced surface area of fetal 
capillaries and maternal blood space, with increased thickness of the exchange barrier 
between the maternal and fetal circulations. These changes correspond to vascular 
changes in human FGR placentas uncomplicated by pre-eclampsia (13). Our mouse 
model showed evidence of catch-up growth and developmental programming of chronic 
diseases in adulthood in a gender specific manner. The catch-up growth the in MNR 
     
  
169
mouse offspring was completed by three weeks postnatally and MNR adults remained the 
same weight as controls by six months postnatally. The accelerated accretion of mass in 
our MNR postnatal animals occurred without subjecting the pups to high fat diets (14) or 
abundant calories postnatally (15) and long-term disease occurred despite having the 
same food allocation as the control pups. Evidence of developmental programming 
occurred in our male FGR mice that demonstrated postnatal glucose intolerance, whereas 
female FGR mice demonstrated impairment in postnatal lung function.  
The important advantage of a mouse model of FGR is the ability to utilize genetic 
manipulation (knockout or transgenic) to address phenotypic or functional role of specific 
genes to delineate mechanistic contribution in vivo. Epigenetic alterations to DNA are 
hypothesized to be an important mechanism responsible for developmental programming 
of fetal tissues following FGR (16-18). The IGF and the glucocorticoid systems are 
important in these epigenetic changes. Components of the IGF system, IGF-II in humans, 
and IGF-II and IGF2R in the mouse, are imprinted in utero (19). Persistent epigenetic 
changes to IGF-II have been demonstrated in humans following maternal malnutrition 
(20) and genetic alteration of IGF-II (21) or IGF2R (22, 23) in mice demonstrated 
alterations in placental and fetal growth. In utero, glucocorticoids can alter DNA 
methylation, particularly at the GR promoter (18), which may persist after birth to alter 
adult gene expression (18). Glucocorticoid overexposure during late gestation in rats has 
been linked to demethylation of the GR promoter and increased GR gene expression in 
the kidneys of offspring during adulthood, contributing to the development of 
hypertension (18, 24). However, little is known about the effects of hormones on histone 
modifications during gestation (18); it is likely that changes in the fetal endocrine 
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environment through maternal dietary manipulation and placental insufficiency lead to 
histone modifications (18, 24-26), as has been demonstrated in adult tissues (27). A 
mouse model of FGR with long-term compromised function of the pancreas and lung, 
which are highly sensitive to alterations of fetal IGF expression and elevated 
glucocorticoid exposure, provides an opportunity to determine the epigenetic alterations 
and their contribution to the pathophysiology of developmental programming. 
Despite the similarities our FGR mouse model has to human FGR, the mouse 
model has some disadvantages. A major limitation of the rodent model in fetal 
development research is that they are born with a relatively immature central nervous 
system and endocrine/paracrine systems that continue to mature during the weaning 
period (28). This may be an important reason why we were not able to demonstrate long 
term neurologic or neurobehavioral adverse outcomes in our model. Rodents are also 
litter-bearing, which may question their relevance to human pregnancy. In the first thesis 
chapter, the mouse model appeared to reduce its litter size with increasing severity of 
maternal nutrient restriction, allowing the potentially more hardy fetuses to survive with 
less severe growth restriction. Humans do not have a similar mechanism of reducing the 
severity of FGR. Despite the entire litter of maternally nutrient restricted fetuses and 
placentae developing in the same uterus, the supply of nutrients to the fetus may be 
variable (29), as blood flow may be preferentially diverted to some fetuses at the expense 
of others, possibly due to the position in the uterine horn (30). This caveat was addressed 
in the thesis by collecting tissues from all fetuses in the litter and combining them into a 
single sample, to give an overall indication of tissue changes. However, this technique 
precluded the ability to detect fetal sex differences in tissue expression. A caveat of our 
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mouse model, which does not occur in the rat, is the lack of 11β-HSD2 beginning at E16 
(31). In rats and humans, 11β-HSD2 continues to be expressed until term (32) and 
changes to expression or activity have been demonstrated to contribute to the severity of 
FGR (2). In our initial hypothesis, that IGFs and glucocorticoids are the primary 
regulators of fetal growth, we anticipated globally altered gene expression of these 
systems in each fetal tissue during maternal nutrient restriction. However, each tissue 
responded variably to maternal undernutrition. In the IGF system, some tissues 
demonstrated no changes to any component of the IGF system assayed (e.g. heart and 
carcass), other tissues elevated the expression of binding proteins (e.g. lung, liver and 
brain), while other tissues reduced the expression of IGF-I and increased the expression 
of binding proteins (e.g. placenta). Similar varied responses to maternal undernutrition 
were demonstrated in the glucocorticoid system, circulating glucocorticoids were 
elevated in the maternal and fetal plasma. However, the dehydrogenase activity of 11β-
HSD1 was reduced in the placenta, but did not change in the lung; nor did the expression 
of the glucocorticoid receptor change in these tissues. This indicates that there was no 
global tissue response to hormonal changes with substrate reductions that occurred during 
fetal undernutrition. Each fetal tissue had a unique response and mechanism that adapted 
to maternal undernutrition to preserve fetal viability. Despite these differences, our mouse 
model provides a good representation of human FGR to be used for studies involving 
fetal programming, gender differences and disruption to fetal vasculature.  
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6.2 COMMON ETIOLOGY/PATHOPHYSIOLOGY 
In the organ systems studied, common features that may provide clues to the 
overall pathophysiology of FGR are noted. Two themes that arise across the organ 
systems studied in the thesis are the disruption FGR causes to the fetal vasculature and 
the sexual dimorphism that occurs in organ function in adulthood following FGR. 
 
6.2.1 Importance of Fetal Vasculature 
Abnormal vascular development has been implicated in many organs affected by 
FGR. During FGR, an adaptive response alters the circulation to divert nutrient rich blood 
away from the trunk (compromising the liver, muscle, gut and lung) to sustain brain and 
heart metabolism (33-39). The loss of blood flow to trunk organs during development 
may permanently compromise circulation to that organ and its function (40). Low 
perfusion could result in vascular remodeling, oxidative stress, apoptosis, and 
proliferation of vascular smooth muscle, which contribute to the development of 
cardiovascular disease (40). Furthermore, abnormal vascularization has been detected in 
the pancreas, in the lung (41, 42), and the cardiovascular system following FGR (43). 
Therefore, disruption to the fetal vasculature may be a common pathophysiology in the 
long-term consequences of fetal programming. 
The primary system mediating vessel growth is the vascular endothelial growth 
factor (VEGF) system. VEGFs are crucial regulators of vascular development during 
embryogenesis (vasculogenesis) and blood vessel formation (angiogenesis) in the adult 
(44). Five VEGF ligands, which occur in several different splice variants and processed 
forms have been identified (44). VEGF binds with high affinity to transmembrane 
     
  
173
tyrosine kinase receptors, VEGFR1 and VEGFR2, which are expressed on vascular 
endothelium (44). VEGFR2 is the dominant receptor involved in vasculogenesis and 
angiogenesis as it signals endothelial cell proliferation, migration, and survival (44). 
Negative regulation of VEGFR2 is exerted, at least in part, by an alternatively spliced 
soluble VEGFR1 variant that binds to VEGF and prevents VEGF binding to VEGFR2 
(44). In the placenta, elevated production of the soluble VEGFR1 variant (sFlt1) and 
consequent immobilization of VEGF and decreased VEGFR2 signaling is implicated in 
preclampsia (45). Preeclampsia causes placental insufficiency, which in turn leads to fetal 
undernutrition. However, if elevated sFlt1 production is associated with preclampsia and 
altered placental vasculature, it is possible that fetal tissues may also be producing 
elevated sFlt1 levels. Regardless of the fetal nutrition status, the possible disturbance to 
the fetal vasculature throughout the body due to less VEGF may cause the development 
of small and immature organs characteristic of FGR.  
Glucocorticoids and IGFs have been demonstrated to influence the expression of 
the VEGF system. Glucocorticoids inhibit blood vessel development and VEGF 
expression (46-49). Deletion of fetal 11β-HSD2 and exposure of the fetus and placenta to 
high levels of maternal glucocorticoids result in reduced fetal and placental growth at 
E18, with impaired capillary development and reduced VEGF mRNA in the labyrinth 
zone of the placenta (50). Increased placental glucocorticoid exposure may inhibit VEGF 
expression which is a key factor for placental vascular remodeling (51, 52). In contrast, 
insulin and IGFs potentiate and increase the expression of the VEGF system. IGF-I may 
also be permissive to VEGF action, as VEGF can stimulate endothelial cell proliferation 
only if there is sufficient IGF-I (53). IGFs can directly stimulate the proliferation of 
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endothelial cells and blood vessel formation (54) and insulin is considered to be a growth 
factor for endothelial cells (55). Therefore, low insulin and IGF levels with elevated 
glucocorticoid levels during FGR may be responsible for reduced VEGF and 
vascularization of fetal organs with stunted tissue growth and development. 
The clinical importance of appropriate expression of growth factors mediating 
angiogenesis is supported by the reduced mRNA and protein expression of vascular 
endothelial growth factor (VEGF) and its receptors in lung tissue from infants with BPD 
(56-58). Reduced expression of VEGF signaling components in BPD suggests that the 
disruption of pulmonary vasculature may be an underlying cause of poor alveolarization 
(56-58). Specifically, inhibiting the VEGFR2 receptor by pharmacological approaches 
during the neonatal period of alveolarization in rats, caused hypoplastic lungs with a 
reduction in capillaries and distended underdeveloped alveoli (59). Conversely, many 
animal models using adverse lung stimuli to disrupt alveolarization demonstrate reduced 
expression of VEGFR2, which may contribute to inhibition of alveolar formation (60-62). 
The mechanism by which VEGFR2 expression is reduced in these models is unknown, 
but appears to be related to the elevated exposure of fetal lungs to glucocorticoids. 
The islet cells of the endocrine pancreas highly express VEGF, which likely 
maintains the dense network of islet microvessels (63-65). VEGFR2 is expressed by the 
endothelial cells and pancreatic ductal cells during fetal development (66). VEGF is 
mitogenic for the pancreatic ductal epithelium (which contain ß cell precursors) (67), and 
the blood vessels provide inductive signals for endocrine pancreas development (68). 
This implicates VEGF as having a potential role in organogenesis of the endocrine 
pancreas and its population of islets (69). FGR rat fetuses of mothers fed an 8% low 
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protein diet throughout pregnancy developed small islets due to less islet cell proliferation 
and more apoptosis with impaired insulin secretion (70). LP fetuses had reduced islet 
blood vessel density, with fewer islet cells producing VEGF and VEGFR2 (70). 
However, the pancreatic duct cells had enhanced expression of VEGFR2, suggesting 
upregulation of VEGFR2 production in duct cells in response to the fewer islet cells 
induced by LP (70). This mechanism for enhancing islet neogenesis was insufficient as 
VEGF production by LP endocrine cells was too low (70). 
Normalizing appropriate VEGF expression in fetal tissues during organ 
development may be an important key to acquiring normal tissue structure and function, 
as well as to offset the development of disease in adulthood. Understanding the 
interaction of the VEGF system with the common mediators of tissue growth and 
development, such as the glucocorticoid and IGF system, may help uncover important 
clues to the impairment to fetal organs that occur during FGR. 
 
6.2.2 Gender Differences of Long-Term Disease 
Sex specific differences in disease prevalence are known to occur in the human 
population. Generally, the effects of poor fetal growth are more obvious in males 
following FGR (71-73). Our mouse model may be an important model system for 
studying gender differences to disease following FGR. Our model demonstrated sex-
specific changes in glucose metabolism and lung function in postnatal life, with 
implications in determining fetal response to stress, antenatal glucocorticoid treatment 
and developmental programming. 
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In utero, it is known that the IGF and glucocorticoid system demonstrates gender 
differences. Despite no difference in fetal cord blood cortisol levels, female fetuses have 
reduced 11β-HSD2 activity compared to male fetuses (74), suggesting placental 
glucocorticoid metabolism differs according to fetal gender. Similar gender differences 
have been observed in the mouse placenta (75) and human kidney (76). Differences in 
glucocorticoid metabolism between genders may contribute to reduced sensitivity of male 
fetuses to the effects of glucocorticoids; as prenatal glucocorticoid treatment is less 
effective in preventing respiratory distress syndrome in male fetuses compared to females 
(77). The mechanisms for each gender to cope with glucocorticoid exposure may explain 
the resulting differences in fetal programming in males and females. The IGF axis is 
known to have gender differences in expression. IGF-II (78), IGFBP-1 (79) and growth 
hormone (GH) (80) concentrations are higher from the umbilical cord serum in male 
neonates than those in females. However, cord plasma IGF-I and IGFBP-3 are higher in 
female neonates than in males (79, 80). Glucocorticoids and IGFs may be involved in the 
development of chronic diseases such as insulin resistance in adulthood following FGR 
(3, 32) as they may alter the structure and function of the pancreas (81), liver (82) and 
lung (83, 84) during development, and components of the IGF and glucocorticoid 
systems are expressed differently between genders. Gender-specific expression changes 
in the glucocorticoid and IGF system during FGR may determine sex specific adaptations 
to fetal growth via these mediators, and establish mechanisms for the differential 
incidence of long-term disease risk between genders.  
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6.3 FUTURE DIRECTIONS  
6.3.1 Four Core Genotype Mouse Model 
Many of the differences in the incidences of disease across genders, such as 
hypertension (85), autoimmune disease (86), alcohol abuse (87), which were previously 
attributed to sex hormones may be due to the presence or absence of Y chromosome or 
additional X chromosome. Genetic female (e.g. XX) and genetic male (e.g. XY) cells 
have a different number of X and Y genes (88). These genomic differences may cause 
sex differences in which cells function, both in sex specific organs and organs throughout 
in the body (88). Recently, Arnold et al. developed the four core genotype model in 
which sex chromosome complement (XX vs. XY) is unrelated to the gonadal sex in mice 
(89). These mice were produced by a two-step genetic manipulation: the Sry gene (which 
determines the presence of testes) was deleted from the Y chromosome (90), and a 
functional Sry transgene was inserted onto an autosome, driven by its own promoter (91). 
Therefore, testes determination was transferred from the Y chromosome to an autosome; 
the Y chromosome and the number of X chromosomes were no longer correlated with 
gonadal sex (89). The four genotypes are XX gonadal males or females, and XY gonadal 
males or females (Fig. 6.1). The model allows determination of the differences in 
phenotype caused by sex chromosome complement (XX vs. XY), different effects of 
ovarian and testicular hormones, and the interactive effects of sex chromosomes and 
gonadal hormones (89). The four core genotype model would allow dissection of the 
etiology of dimorphic disease prevalence following FGR.  
Maternal nutrient restriction in the fore core genotype model, to compare the 
development of insulin resistance between XX and XY females, as well as between XX  
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Figure 6.1 Four Core Genotype Model. Four core genotype mice are a result of 
breeding a XX female with a XY-Sry male that has the Sry gene on an autosome 
chromosome. Pink mice represent phenotypic females, with female gonads and their 
associated secretions. Blue mice represent phenotypic males with male gonads and their 
associated secretion as a result of the Sry gene on an autosome chromosome. Genotypic 
sex chromosome complement is represented by the chromosomes depicted in the centre 
of the mouse. Doubled headed arrows indicate comparisons made between genders with 
single headed arrows indicating the relevance of the comparison. Y-Sry is a Y 
chromosome with the Sry gene deleted. Adapted from Arnold et al. (89) 
     
  
179
     
  
180
and XY males, would determine if insulin resistance was due to the sex chromosome 
compliment inherited by the cells. If the XY males and the XY females developed insulin 
resistance, this may be due to the presence of the Y chromosome or absence of the 
additional X chromosome (89) (Fig. 6.1). This may also occur in the etiology for 
compromised pulmonary function in fetal growth restricted females. If the development 
of insulin resistance or reduced pulmonary compliance is determined to be a result of sex 
chromosomes, other mouse strains, which vary in the number (or segments) of X and Y 
chromosomes, will be needed to determine whether developmental programming is 
caused by X or Y genes (89). Since epigenetics has been implicated as a mechanism for 
long-term programming of adult diseases following FGR, and if sex chromosomes are 
also implicated, imprinted X genes may be further studied. In females, the XX 
complement inherits the genomic imprint of both maternal and paternal X chromosomes, 
however in females with an XY sex chromosome compliment, only the maternal X 
chromosome imprint is expressed (89). Comparisons between the XX and XY females 
may give clues to the imprinted genes involved. Mosaicism may be implicated as a 
mechanism for gender differences; mosaicism will cause XX mice to express alleles of 
the maternal X chromosome in half their cells and alleles from the paternal X 
chromosomes in the other half (89). The greater diversity of X-linked genes in XX 
offspring could protect against environmental challenges more than in XY offspring (92).  
Alternatively, our maternal nutrient restriction regime can be inflicted on the four 
core genotype model and the development of long-term diseases between XX males and 
XY females can be compared. If insulin resistance is detectable in males with an XX 
chromosome complement and if insulin resistance is not detectable in the XY females, 
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the development of insulin resistance may rely on the secretion of gonadal hormones (89) 
(Fig. 6.1). FGR has been implicated in altering production of sex hormones as well as 
sexual development (33, 34). Therefore, maternal nutrientrestriction in the four core 
genotype model may verify the role of gonadal hormones in the development of insulin 
resistance or decreased lung compliance following FGR. 
Utilization of the four core genotype model in conjunction with our maternal 
nutrient restriction regime may determine an understanding of why adult diseases are 
more prevalent in one gender following FGR. 
 
6.3.2 Maternal Supplements to Normalize Fetal Vasculature  
Targeting components mediating fetal vasculature development may be essential 
for mitigating the severity of postnatal complications following FGR. The VEGF system 
in particular is central for vascular and tissue development and most importantly, seems 
amendable to maternal nutrient supplementation. 
 
6.3.2.1 Maternal Supplementation of Taurine 
 
Taurine was one of the amino acids most reduced in fetal serum in the LP diet 
model (70). It is a sulfur-containing amino acid, highly concentrated in the islets (93); it 
stimulates insulin release by fetal ß cells in vitro (94). Taurine supplementation in vivo 
and in vitro can reverse many of the impairments caused by a low protein diet during 
fetal and neonatal life. Establishing taurine to typical levels in the fetal blood circulation 
by supplementing LP mothers during gestation normalized fetal insulin secretion, islet 
and ß cell mass, apoptotic and low proliferative rates of the pancreatic endocrine cells 
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(95, 96). Taurine may have normalized the endocrine pancreas by restoring the number 
islet cells expressing VEGF and VEGFR2 and reversing the reduced blood vessel volume 
density and number of fetal islets induced by the LP diet (70, 96). However, VEGFR2 
expression in the pancreatic duct cells remained elevated (70). This study suggests that 
taurine normalizes or enhances the expression of VEGF and VEGFR2 in islet cells (70) 
and prevents vascular changes to the islets during a LP maternal diet (70). The 
mechanism in which taurine affects VEGF and VEGFR2 expression is not understood, 
however, taurine may increase VEGF expression and stimulate islet vascularization, 
which in turn controls ß cells in the fetal endocrine pancreas (70). 
Alternatively, taurine may protect endothelial cells from apoptosis due to 
cytotoxic stimuli, high glucose or IL-2 mediated cell injury (97-99). The supplementation 
of taurine to an inappropriate maternal diet may reduce the need for taurine production 
from cysteine. To produce taurine, cysteine must be processed through the transulfuration 
pathway, which also produces homocysteine byproducts that have adverse effects on 
endothelial cell function (70, 100). Taurine enhances growth factor production, as 
supplementation to LP dams during gestation restored normal IGF-II expression in fetal 
islet cells (95), which may be stimulatory factors of endothelial cell proliferation and 
blood vessel formation (53, 54). 
 
6.3.2.2 Maternal Supplementation of Retinoic Acid (RA)  
 
Retinoic acid (RA) supplementation in postnatal animal models has demonstrated 
promising results to reverse the effects of adverse stimuli on lung development and 
enhance the formation of alveoli. The ability of retinoic acid (RA) to induce alveolar 
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regeneration represents a potential means for preventing or reversing the loss of gas-
exchange surface area in the lung (101). Rats treated with elastase to destroy the alveoli 
greatly reduced the surface area for gas exchange (102). Administration of all-trans-RA 
for 12 days restored the size and surface area of alveoli (102). Similar results using RA 
have been obtained in other animal models with restoration of the gas-exchange surface 
area (103-108). Dexamethasone treatment in newborn rodents has been used to generate 
reduced gas-exchange surface areas, with enlarged and fewer alveoli (107, 108). 
Treatment of 4 week old rats with all-trans-RA induced a partial recovery and in 6 week 
old mice a full recovery was obtained (107, 108). Human BPD has many characteristics 
of dexamethasone treated newborn rodents and it has been associated with low serum RA 
levels (109). Postnatally, three weekly doses with RA is one of few interventions found to 
significantly reduce incidence of BPD in extremely low birthweight infants (50, 110) and 
may have therapeutic implications in adults with emphysema (28, 101). The mechanism 
by which RA induces alveoli formation and antagonizes the effects of glucocorticoids is 
unknown. Affymetrix oligonucleotide arrays were used to identify gene expression 
changes in the neonatal mouse lung following treatment with dexamethasone to reduce 
alveolarization (111). Dexamethasone reduces VEGFR2 expression by 2.1 fold, which 
may contribute to loss of alveolar septae (111). Lung VEGFR2 expression is elevated 1.2 
fold by all-trans-RA and decreased only 1.3 fold in lungs treated with all-trans-RA plus 
dexamethasone (111). In vitro studies have demonstrated RA enhances angiogenesis and 
VEGFR2 expression, but the mechanism remains unknown (29). These studies suggest 
RA may reverse the effects of dexamethasone on alveolarization by increasing the 
expression of VEGFR2. 
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Taurine and retinoic acid supplementation demonstrate that a single nutrient may 
restore normal vascular cues during development and potentially restore organ function. 
Studies that supplement low calorie or low protein maternal diets with these nutrients 
should consider studying the effects of supplementation on various fetal organs and 
determine if vascularization is restored. Studying common fetal tissue responses to 
maternal undernutrition and their restoration with nutrient supplements may indicate 
mechanisms and pathways disrupted during FGR and may identify common targets 
among fetal organs to restore function and prevent adverse long-term fetal programming. 
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6.4 CONCLUSIONS 
In conclusion, our mouse model using maternal nutrient restriction closely mimics 
the adaptations in the endocrine/paracrine system regulating fetal growth, tissue structure 
and function demonstrated in human FGR. This thesis demonstrates the impact and 
adaptation of maternal nutrient restriction on a murine model and provides insight into 
the pathophysiological mechanisms of FGR in humans.  This model is clinically relevant, 
as the nutrient deficient environment of the fetus during gestation caused a hormonal 
milieu not conducive to optimal fetal growth and development, consisting of elevated 
circulating glucocorticoids and reduced bioavailability of IGFs. This caused growth 
alterations similar to asymmetric FGR and long-term programming of insulin resistance 
in males, consistent with observations in other animal models and humans. The lung was 
adversely affected during gestation in a nutrient deficient environment as it developed 
proportionately smaller to the size of the fetus with alterations to its structure. 
Importantly, the gestational changes in the lung may lead to compromised postnatal 
pulmonary function in females. The placenta failed to adapt to maternal nutrient 
restriction by increasing the efficiency by which it transports nutrients and substrates to 
the fetus, regardless of reduced overall placental weight and volume. This failure to adapt 
may implicate the placenta as contributing to the pathophysiology to fetal growth 
restriction.  
There are many benefits and disadvantages to using a mouse as a model of FGR. 
The potential benefit of genetic manipulation during this period in science when advances 
into the understanding of epigenetic alterations and the long term implications has great 
benefit to neonatal health management and approaches to chronic diseases in adulthood. 
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This mouse model also raises many important questions regarding gender and long-term 
disease risk following FGR, as well as the impact on vasculature in all FGR organs, as 
potential areas to study and manipulate for understanding the mechanisms involved in 
FGR and long-term disease risk. This mouse model of FGR may assist in identifying new 
targets and mechanisms that occur in fetal tissues to adapt fetal growth during periods of 
a compromised intrauterine environment and develop new techniques to mitigate changes 
in fetal tissues to restore normal development prior to birth and long-term disease risk. 
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APPENDIX 
1.1 ADDITIONAL METHODS 
1.1.1 Insulin, Corticosterone and ACTH ELISA 
Plasma insulin was measured in mothers and E18.5 fetuses and six month adult 
males using a Crystal Chem Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem, 
Downers Grove, IL). In brief, a standard curve was generated with two fold dilutions. 
Five micro litres of mother, fetal or adult male plasma sample was added per well with 95 
µl of diluent and were incubated for 2 hrs at room temperature. The microplate was 
washed and 100 µl of horse radish peroxidase-conjugated anti-insulin was added to each 
well and incubated for 30 min. The microplated was washed before adding 100 µl of 
3,3’,5,5’-tetramethylbenzidine (TMB) substrate solution and incubating for 40 min. Stop 
solution was added to each well and the absorbance of colour reaction was read a 
wavelength of 450 nm in a plate reader. The intra- and interassay coefficients of variation 
were ≤ 10.0% and ≤ 10.0% respectively, with a minimum detectable dose of insulin of 
0.10 ng/ml.  
Plasma corticosterone was measured in mothers and E18.5 fetuses using an 
AssayMax Corticosterone ELISA Kit (AssayPro, St. Charles, MO). In brief, a standard 
curve was generated with four fold dilutions. Twenty-five micro litres of mother or fetal 
plasma sample was added per well and 25 µl of biotinylated corticosterone was added 
immediately afterwards and the solutions were incubated for 2 hrs at room temperature. 
The microplate was washed and 50 µl of Streptavidin-Peroxidase to each well and 
incubated for 30 min. The microplated was washed before adding 50 µl of Chromogen 
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Substrate and incubating for 10 min. Stop solution was added to each well and the 
absorbance of colour reaction was read a wavelength of 450 nm in a plate reader. The 
intra- and interassay coefficients of variation were 5.0% and 7.0% respectively, with a 
minimum detectable dose of Corticosterone of 40 pg/ml.  
Plasma ACTH was quantfied in maternal and pooled fetal mouse plasma using 
multiplexed bone metabolism mouse panel 1A biomarker immunoassay kits (cat. No. 
MBN1A-41K) according to manufacturers’ instruction (Milliplex, Millipore Corp, MA). 
A Bio-PlexTM 200 readout System was used (Bio-Rad Laboratories, Hercules, CA), 
which utilizes Luminex® xMAPTM fluorescent bead-based technology (Luminex Corp., 
Austin, TX). Levels were automatically calculated from standard curves using Bio-Plex 
Manager software (v.4.1.1, Bio-Rad). 
 
1.1.2 In situ Hybridization Protocol 
Liver and placental sections from control and maternal NR groups were analyzed 
for Igf-1, Igf-2, Igfbp-1, Igfbp-2 and Igfbp-3 mRNA expression by in situ hybridization 
using 35S-labelled antisense riboprobes with the 35S-labelled antisense and sense cRNA 
probes were generated from the cDNAs (listed in Tables 3.2 and Table 5.3) using a 
Promega Riboprobe Combination System SP6/T7 kit (Promega Corp., Madison, WI) and 
35S-UTP (Perkin Elmer, Waltham, MA). 
Tissue sections, mounted on Superfrost® slides (Fisher Scientific, Fairlawn, NJ), 
were deparaffinized, rehydrated in descending ethanol series (l00%, 90%, and 70%), and 
incubated in the following solutions: 0.2% Triton-X 100 in PBS for 1 hr, proteinase-K 
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(0.2 U/ml) for 30 min at 37 C and acetic anhydride (0.25%) in triethanolamine buffer 
(Sigma, St. Louis, MO) for 10 min. 
The sections were then dehydrated in ascending ethanol series and prehybridized 
with  prehybridization buffer (0.3 M NaC1, 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 X 
Denhardt’s solution, 500 µg/ml yeast transfer RNA, 100 µg/ml denatured salmon sperm 
DNA, 0.1% SDS, 100 mM dithiothrietol, and 50% formamide) at 45 C for 2 hrs. 
Following prehybridization, tissue sections were hybridized overnight at 45 °C–
65 °C with 35S-labelled antisense riboprobes specific for each IGF or PLP-I mRNA 
(radiolabeled to a specific activity of ≥ l09 cpm/ml and used at a concentration of 10 X l06 
cpm/ml) in 1 x hybridization buffer (prehybridization buffer with 10% dextran sulfate) 
overnight at 55 °C. Excess probe was washed twice with 2X SSC with 10 mM DTT and 
the prehybridization buffer was applied to the slides for 10 min at the same temperature 
as the probe hybridization temperature. Tissue sections were treated with RNAse (10 
mg/250 mL) to cleave unhybridized probe. Tissue sections then underwent washes in 
decreasing salt buffers (2.0× SSC to 0.1× SSC) at specific temperatures for each probe. 
Tissue sections were then dehydrated in ascending ethanol series and exposed to 
x-ray film (XAR, Kodak) for 24 hrs. The duration for exposure to photoemulsion was 
judged by the autoradiographic intensity of the sections on x-ray film. The slides were 
coated with photoemulsion (NTB-3 nuclear track emulsion, Eastman Kodak, Rochester, 
NY) and exposed at 4 °C for 1-16 weeks, under dessicating conditions.  
The photoemulsion was developed with a D-19 developer (Kodak), fixed, stained 
with Harris’s hematoxylin and eosin, and mounted with Permount® (Fisher Scientific). 
The specificity of in situ hybridization was demonstrated by the absence of hybridization 
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signal when adjacent tissue sections were subjected to identical in situ hybridization 
procedures with radiolabeled sense RNA probes. 
The slides were viewed under both dark- and brightfields, using a Carl Zeiss Axio 
Imager Z1 (Zeiss, City, Country) and appropriate photomicrographs were obtained at 40× 
magnifications using AxioCamHR3 and the AxioVision Release 4.7.2 software.  
 
1.1.3 Apotag Staining for Apoptotic Cells 
Liver tissue sections were prepared and deparaffinized in decreasing 
concentrations of ethanol. Apoptotic cells were detected using an Apoptag Kit from 
Chemicon International. Briefly, tissue sections were then immersed in 0.4 U/mL of 
Proteinase K in PBS for 20 min at room temperature, then washed four times in deionized 
water. Slides were quenched in 3% H2O2 in methanol for 10 min at room temperature and 
then washed in deionized water. Slides were then incubated in equilibration buffer for 1 
hr, before incubating with TdT enzyme at a dilution of 1:3 at 37 C in a humidified 
chamber for 1 hr. The reaction was stopped with Stop/Wash Buffer and slides were 
washed in deionized water. Anti-D.I.G conjugate was applied to the slides and incubated 
at room temperature for 30 min in a humidified chamber. DAB was used to detect the 
enzymatic reaction product and tissue was counterstained with Methyl Green 
(DakoCytomation Inc., Carpinteria, CA).  Specificity of the staining product was verified 
by generating a positive control slide by inititally incubating the liver sections in DNAse 
1 (Invitrogen) in TBS/MgSO4 for 30 min in a humidified chamber at 37 ‘C. Negative 
Control slides were generated by omitting the TdT enzyme incubation step.  
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1.1.4 Periodic Acid Schiff (PAS) Stain 
To determine the glycogen content present in the liver of the control and 70% NR 
fetuses, PAS staining was performed using the PISSARRO-PAS Stain Kit (Biocare 
Medical, Walnut Creek, CA). Liver tissue sections were prepared and deparaffinized in 
decreasing concentrations of ethanol. Tissue sections were oxidized in PISSARRO 
Periodic Acid Solution for 10 min then rinsed four times in distilled water. Liver sections 
were then placed in PISSARRO Schiff’s Reagent for 15 min. Slides were counterstained 
with CAT Hematoxylin then mounted with Permount and coverslipped. 
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1.2 ADDITIONAL RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 1.1 Effect of Maternal Nutrient Restriction beginning at E 6.5 of 
pregnancy on placental and fetal tissue DNA content at E 18.5. 
 
Control  
(n=10) 
70% MNR  
(n=10) 
Placenta                1.19 ± 0.10                0.67 ± 0.08* 
Lung                6.93 ± 0.38                7.10 ± 0.91 
Liver                3.69 ± 0.23                3.00 ± 0.39 
Brain                4.40 ± 0.36                4.06 ± 0.34 
Pregnant mothers were fed ad libitum (control) or 70% MNR beginning at E 6.5. 
At E 18.5, mothers were sacrificed and placenta and fetal tissues were weighed 
for each fetus for a mean litter value. The result, litter mean ± SEM for ‘N’ 
number of litters, is expressed in µg/mg. 
 
Significant differences from control (*P < 0.05). 
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TABLE 1.2 Effect of Maternal Nutrient Restriction beginning at E 6.5 of 
pregnancy on placental and fetal tissue protein content at E 18.5. 
 
Control  
(n=10) 
70% MNR  
(n=10) 
Placenta              33.54 ± 1.41              30.12 ± 2.38 
Lung              62.05 ± 7.00              72.22 ± 8.81 
Liver              52.87 ± 6.31              68.00 ± 10.77 
Brain              68.96 ± 10.31              50.92 ± 5.50 
Pregnant mothers were fed ad libitum (control) or 70% MNR beginning at E 6.5. 
At E 18.5, mothers were sacrificed and placenta and fetal tissues were weighed 
for each fetus for a mean litter value. The result, litter mean ± SEM for ‘N’ 
number of litters, is expressed in µg/mg. 
 
Significant differences from control (*P < 0.05). 
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Figure 1.1 Insulin-Like Growth Factor (IGF) System mRNA expression in livers of 
control fetuses at E 18.5. AntiSense controls of autoradiography in situ hybridization of 
IGF-I (A), IGF-II (C) and IGFBP-2 (E) and sense controls of IGF-I (B), IGF-II (D) and 
IGFBP-2 (F). Images are captured by darkfield microscopy and white grains indicate the 
location of mRNA signal. Scale bars, 100 µm. 
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Figure 1.2 Insulin-Like Growth Factor (IGF) System protein expression in fetal 
livers of control and 70% MNR at E 18.5. Immunohistochemistry of IGF-I (A, B), 
IGF-II (C, D) in control (A, C) and 70% MNR (B, D). Images are captured by darkfield 
microscopy. White grains indicate location of IGF mRNA. Open arrows indicate 
representative hematopoietic cell clusters; closed arrows indicate representative 
hepatocytes. Note the hepatocytes of the control livers are filled with glycogen. Scale 
bars, 100 µm. 
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Figure 1.3 Insulin-Like Growth Factor (IGF) System protein expression in fetal 
livers of control and 70% MNR at E 18.5. Immunohistochemistry of IGFBP-1 (A, B), 
IGFBP-2 (C, D), IGFBP-3 (E, F) in control (A, C, E) and 70% MNR (B, D, F). Images 
are captured by brightfield microscopy. DAB staining indicates location of IGFBP 
proteinA. Open arrows indicate representative hematopoietic cell clusters; closed arrows 
indicate representative hepatocytes. Note the hepatocytes of the control livers are filled 
with glycogen. Scale bars, 100 µm. 
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Figure 1.4 Nutrient transporter expression in placenta of control and 70% MNR at 
E 18.5. (A) Expression of nutrient transporter mRNA measured by quantitative Real-
Time PCR (P > 0.05). (B) Expression of nutrient transporter protein determined by 
Western Blotting and measured by densitometry (P > 0.05). 
 
 
 
 
 
 
 
     
  
209
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
      
  
210 
 
 
 
 
 
 
 
 
 
 
 
The UNIVERSITY of  WESTERN ONTARIO - COUNCIL ON ANIMAL CARE 
1.3 ANIMAL USE PROTOCOL 
For New, Full Renewal (5th Year) or Pilot Animal Use Projects 
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http://www.uwo.ca/animal/website/AUS/Content/Forms.htm 
 Acute  Non-recovery Surgery, 
Euthanasia for Tissue Collection 
 Breeding for 
Research F. 6 
Choose maximum level within this study  Teaching H. Add.  1 
C 
 Chronic  Long Term (i.e. 
nutrition), Recovery Study (i.e. post 
surgery) 
 Wildlife Study H. Add. 2 
Check All Species Used 
Within this Protocol 
 Bird  Cat   Dog   Fish  Frog  Guinea Pig  Hamster  
Mouse  NHP 
  Pig  Rabbit  Rat   Squirrel  Sheep   Other, explain       
Major Study Elements Checklist  
What are the major events involving animals in this project? 
In addition to all mandatory sections, complete all specified sections beside each checked element 
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Pick all that apply Complete  Related Section Pick all that apply 
Complete 
 Related 
Section 
 Agent Use –  Non Hazardous      Drugs   Other F.2  Euthanasia F. 1 
 Agent Use -     Hazardous  Biological F.2 &  H. Ad.3  Fasting F. 3 & 7 
 Anaesthesia  F.2, 3 & 5  Genetic Mutation, i.e. transgenic, knockout F. 8 
 Antibody Production F. 2 – 5,  H. Ad. 3 – Sched. 3  Injections F. 2 
 Behavioural Study F. 5  Model Creation F. 9 
 Breeding F. 6  Observation / Monitoring F. 5 
 Capture F. 5  Radiation – i.e. CT, MRI, PET, X-ray F.2& H Ad.3 
 Collection -     Blood       F. 7  Surgery – Recovery F. 2 ,3,5 
 Collection -     Tissue   Other, i.e. urine F. 9  Surgery – Non-recovery F. 2 & 3 
 Diagnostic Imaging F. 9 & H. Ad. 3  Treatment F. 5 
 Dietary Manipulation F. 5   
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B. PROJECT LAY SUMMARY - Mandatory Completion Required 
Describe your project concisely in lay terms at a Grade 9 level using 40 words or less per 
question 
– Avoid technical and scientific terms – 
The Project Lay Summary is a CCAC required element to ensure committee lay member comprehension. 
1. Project’s Purpose 
Develop animal models of Fetal Growth Restriction (FGR) using dietary restrictions and uterine artery ligation  
2. Expected Benefit 
FGR is associated with higher fetal morbidity and mortality with other diseases in later life linked to this condition 
3. Reason for Using Animals 
Mechanistic studies investigating the molecular events inthe fetus and placenta can be studied only in animal models 
4. Reason for Using Species Mice--gene targeting and transgenic techniques available;  
                                                       Rats--uterine artery ligation and dietary  experiments previously established 
                                                       Guinea Pigs--prenatal developers unlike mice and rats 
 
 
 
 
 
 
 
 
C. RESEARCH STAFF & THEIR TRAINING REQUIREMENTS – Omitted from Thesis 
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D.  PROJECT OVERVIEW - Mandatory Completion Required 
Provide a BRIEF overview of your project. 
Use Section E. for Animal Number Justification, and  F. & G. for Experimental Details 
1. Rationale 
The intrauterine environment is the predominate factor that regulates the development and function of the placenta, which (under 
conditions of hypoxia and/or poor nutrition) lead to fetal morbidity and mortality.  There is also evidence linking FGR to postnatal 
diseases such as diabetes and high blood pressure, suggesting a fetal programming effect 
2. Hypothesis 
Animal models of FGR generated by maternal nutrient restriction and/or uteroplacental restriction are relevant to human FGR and 
its outcomes, and are robust models to study the mechanisms that underlie the pathophysiology of FGR and developmental 
programming 
3. Objective(s) 
To generate animal models of FGR that are relevant to the human.  This in turn will allow us to determine the structural and 
functional changes in placentae and to also identify epigenetic changes either in candidate genes or globally in the whole genome 
4. Approach/Research Plan –  Brief Summary only 
FGR will be developed by two methodologies--by uterine artery ligation and by maternal dietary manipulation (global nutrient 
restriction) 
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E. ANIMAL NUMBER JUSTIFICATION BY EXPERIMENTAL GROUP– TWO OPTIONS 
– 
Mandatory Completion Required 
i. Describe possible replacement, refinement and/or reduction alternatives to animal use, and 
offer justification if these are not to be employed, or a description of efforts to find such 
alternatives. 
Replacement--the focus of this study is the pathophysiology of FGR, from which the placenta is the key organ in the disease 
process.  Thus we have chosen rodents as they have the physiology required but are considered a lower evolutionary species.   
Refinement--the model of uterine artery ligation has been demonstrated successfully for rats and guinea pigs; dietary restriction 
has been demonstrated successfully for all three rodent species 
Reduction--ANOVA will be used for the majority of the analyses and thus each component of the study has been assigned a 
number to reach statistical significance 
ii.  Indicate how you have determined your animal numbers by breaking their use down into 
experimental groups including controls – Label each group with a numeric identifier, i.e. 1, 2, 3  
OR Option 2 – Use the following table to describe animal number per experimental group justification – If more 
than 4 groups are involved, reopen this file, then complete for additional groups, providing a different numeric 
Group ID # for each 
Experimental Group ID #  
MGNR  
←Use Experimental Group  ID # (column directly left) to assign group to details in Sections 
F & G, 
 right hand column 
Name of Experimental Group 
&/or Species or Strain 
Mouse Global Nutrient Restriction 
Total Animal Numbers per 
Experimental Group 
60 
Subgroup Animal Numbers n=10 for each subgroup (100% 70% PR) per strain 
Other Animal Number 
Related Detail 
Males required for breeding 
Extra females may be required for cases of premature delivery or failure to conceive 
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F.  EXPERIMENTAL DETAILS - Mandatory Completion Required 
Using the groups you have indicated in Section E., provide details of all experiments, events & 
procedures involving animals in each of the groups. 
 Use the right-hand column to connect the ‘event’ with the specific group(s) identified in 
Section E. 
F. 1. Animal Use Endpoints – Mandatory Completion for All Projects 
“In experiments involving animals, any actual or potential pain, distress, or discomfort should be minimized or 
alleviated by choosing the earliest endpoint that is compatible with the scientific objectives of the research.  Selection 
of this endpoint by the investigator should involve consultation with the lab animal vet and the animal care 
committee.” CCAC General Guideline 
For SOP detail go to http://www.uwo.ca/animal/website/VS/Content/SOPs.htm 
Identify 
Section E 
Experiment
al Group 
 ID #s 
Involving  
This 
Element 
Experimental 
Endpoints 
Mice--e18.5 
Rats--e21.5  
Guinea Pigs--e58 
 
 All  Or  
 ID #s 
      
Pick all that will be followed 
 #320 Euthanasia  
 #321-Criteria for Early Euthanasia-Rodents 
 #322-Criteria for Early Euthanasia-Non-
Rodents 
 Other Criteria, please explain below 
 All Or  
 ID #s 
      
Euthanasia 
SOPs If ‘Other Criteria’, explain  
       
Pick All Euthanasia Methods That Will Be Followed & Provide Euthanasia Related Agent Use Detail 
Below 
Euthanasia 
Method 
 Animals Not Euthanized 
 Barbiturate Overdose 
 CO2 
 Decapitation under Anaesthesia 
Agent 
Name 
Sodium 
Pentobarbi
tal 
Dose 
110 mg/kg 
Route 
IP 
Volume 
0.5 ml 
 All Or 
  ID #s 
GPUAL 
GPGNR 
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 *Decapitation with No Anaesthesia* 
 Cervical Dislocation with Anaesthesia 
 *Cervical Dislocation with No 
Anaesthesia* 
 Other Method(s), Anaesthetized - 
explain 
 *Other Method(s), Awake* - explain 
If ‘Other Method(s)’, explain  
 CO2 followed by exsanguination of dams for optimal 
blood collection in mice and rats 
 Pups from guinea pig dams will be given additional 
sodium pentobarbital directly if not sufficient from 
dam, followed by exsanguination 
 All Or  
ID #s 
      
Scientific 
Justification 
If Method Type Has An Asterisk *, Provide Scientific Justification 
This method is to be performed only on unborn fetuses extracted from the uterus of euthanized 
dam for mice and rats 
 
 All  Or  
 ID #s 
      
 
 
F. 2.  Agent Use  
 No Agent Use (Go to F 3.) 
NON HAZARDOUS AGENTS INCLUDING DRUGS 
 
Does this 
agent have 
potential to 
cause pain 
or 
pronounced 
debilitation? 
Identify 
Section E. 
Experiment
al 
Group ID #s 
Involving  
This Agent 
 
F. 3. Anaesthesia or Surgery or Recovery Projects  
 No Surgery or Anaesthesia or Recovery Elements (Go to F 4.) 
Identify 
Section E. 
Experimental 
Group ID #s 
Involving 
This Element 
Fasting 
Involved? 
 Yes   
No If Yes, provide justification & duration detail       
 All  or 
 ID #s RUAL 
& GPUAL 
Post Op 
Care 
Care Person(s) Steven Dixon 
                           Animal Technician to be hired 
for WVB animals 
Contact # x55067/473-5057 
                   TBA 
 
 All  or 
 ID #s RUAL 
& GPUAL 
SOPs Pick all that will be followed  
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 330-Post-operative Care-Rodent 
 331-Post-operative/Post-Anaesthetic Care-
Level 1 
 332-Post-operative/Post-Anaesthetic Care-
Level 2 
 333-Post-operative/Post-Anaesthetic Care-
Level 3 
 334-Post-operative/Post-Anaesthetic Care- 
Level 4 
 343-Surgical Prep/Rodent/Recovery Surgery 
 350-Rodent Anaesthesia/Halothane/Induction 
Chamber 
 Other, please explain        
 All  or 
 ID #s RUAL 
& GPUAL 
Surgery or 
Procedure 
Location 
Institution 
 
WVB 
Room # 
 
TBA 
 Overnight Surgery/Recovery in non-approved 
area.  If clicked, provide scientific justification: 
      
 All  or 
 ID #s RUAL 
& GPUAL 
Recovery 
Location 
Institution 
 
WVB 
Room # 
TBA 
When will animals be returned  
to the main facility? Upon full recovery 
 All  or 
 ID #s RUAL 
& GPUAL 
Other 
Related 
Detail 
      
 
 
F. 4. Antibody Production 
 No Antibody Production (Go to F.5.) 
 
F. 5. Monitoring or Chronic Projects – i.e. Post-op, Feed, Drug and/or Disease Induction 
Studies 
 No Monitoring or Chronic Elements (Go to F 6.) 
Identify 
Section E. 
Experimental 
Group ID #s 
Involving  
This Element 
Monitoring  
Criteria 
Pick all that will be followed 
 100-Monitoring/Tumour Growth in Rodents 
 310-Holding Period Post Admission  
 Other,  please explain        
 All  or 
ID #s       
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Monitoring 
Type 
 Weight   Food Intake  Behaviour  Urine Output  Other, explain Muscle mass of 
mothers on nutrient restriction 
 All  or 
ID #s       
Monitoring 
Frequency 
Pick all that apply to this project:  
 Hourly    Twice Daily    Daily   
 Weekly  Other, please explain 
If other, or multiple frequencies chosen, please 
provide detail:   
      
 All  or 
ID #s       
Monitoring 
Personnel 
Care Person(s) Steven Dixon 
Animal Technician for WVB TBA Contact #  x55067, 473-5057  
 All  or 
ID #s       
Monitoring 
Records  
Will animal monitoring records be kept 
with the animal? 
 Yes or   No 
If ‘No’, identify monitoring record location 
 LHSC-VRL A7-144 
TBA WVB 
 All  or 
ID #s       
Other Related 
Monitoring 
Detail 
      
 
F. 6  Breeding  
 No breeding elements (Go to F.7) 
I. Indicate Breeding Type    Breeding for research within this protocol   
 Breeding for research NOT within this protocol 
Complete for All Breeding Elements 
II. Provide justification for maintaining a 
breeding colony 
Breeding only for experimental use; no continued colonies required 
III. Provide justification for breeding 
numbers 
Quote animal  numbers within Section G. 
Animal Requirements 
Males required for breeding (n=10 for each species) 
Extra females may be required for cases of premature delivery or failure to 
conceive 
60 females for mice and rats, but 120 Guinea pig females required due to smaller 
litter size  
IV. List procedures used in the breeding 
colony 
      
V. Number estimation and use of surplus Surplus Number Estimate:       
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animals ( those not required for experimental 
programs, or retired breeders) 
Surplus Use:       
VI. Breeding colony location, if different 
from research housing. 
      
VII. Research associates directly involved 
in the care of animals in this breeding 
colony 
Name:         Contact #:        Email:       
Name:         Contact #:        Email:       
Breeding for External Protocols Only 
VIII. List External Protocol Researcher(s)                                         
IX. List External Protocol Numbers                                                              
 
F. 7. Blood Collection 
 No Blood Collection (Go to F.8.) 
Identify 
Section E. 
Experimental 
Group ID #s 
Involving  
This Element 
 
F. 8  Genetically Altered Animal Information 
 No Genetically Altered Animals Used (Go to F. 9.) 
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F. 9. Procedural Description - Mandatory Completion for All Projects 
P
r
o
c
e
d
u
r
e
 
N
u
m
b
e
r
 
Minus the details presented in Section F. 1. through F. 8, 
 provide a detailed procedural description of all animal-related 
events  
Does this 
procedure 
have 
potential 
to cause  
pain or 
pronounce
d 
debilitatio
n? 
Identify 
Section E. 
Experiment
al 
Group ID #s 
Involving  
This 
Procedure 
1 
Female mice will be bred with male mice and presence of a vaginal plug will be marked as gestational day 
0.5.  Mice will be randomly assigned to one of 3 groups--100% (control), protein restricted diet  (8.1%), or 
70% Nutrition (starting on gestational day 6.5).  Food consumption will be monitored daily using special 
diet and feeders obtained from Bio-Serv to determine the average daily intake of food for each gestational 
day.  Mice in the Protein Restricted group will be allowed to eat the special diet ad libitum.  On gestational 
day 18.5 mice will be euthanized for tissue collection from fetuses.  This procedure is performed in both 
strains (CD-1 and c57bl6) to identify strain specific results. 
 Yes 
 No 
 All  or 
ID#s 
MGNR 
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G. ANIMAL REQUIREMENTS - Mandatory Completion Required 
Detail all animal requirements including, species, strain, age/weight, sex, housing, dietary and 
animal total details for the Upcoming Year Only 
*Use bottom row of this section to add more detail to any column*  
Researcher must provide scientific justification for overnight animal housing in non-approved areas, i.e. labs, & receive AUS 
approval:   
Use Section F. 3 for surgery related housing & bottom of this section  for all other housing justification  
Animal Housing 
See Drop-downs for complete listing 
Abbreviations:     
CBM=Centre for Brain & Mind          HSACF=Health Sciences Animal Care Facility 
LHRI=Lawson Health Research Institute, St. Joe’s 
LHSC-UC=University Campus  LHSC-SS=South Street 
LHSC-VRL=Victoria Research Lab  LRCP=London Regional Cancer Program 
RACF= Robarts Barrier Facility  REB= Robarts Experimental Barrier  
WVB=West Valley Bldg 
Specie
s 
Strain 
&/or 
Other 
Species 
Detail 
For 
Genetic 
Mutation 
Use F. 8 
For 
Details 
Age or 
Weigh
t 
Sex 
Housing 
Location 
Use/Lab 
Location 
Room 
# 
If Specialized 
Housing 
Required,  i.e. 
barrier, lab, Field 
Study, Other  
Provide Details  
Used in 
Breeding 
? 
Speci
al 
Dietar
y 
Detail
s 
Complet
e 
only if 
Standar
d diet is 
not 
adequat
e 
1 Year 
Total  
Animal 
Number
s 
Require
d 
Mouse cd-1 8 wks Female LHSC-VRL Same as Housing A7-143 
      Yes Details below 60 
Mouse cd-1 8 wks Male LHSC-VRL Same as Housing A7-143 
      Yes       10 
Mouse c57bl6 8 wks Female LHSC-VRL Same as Housing A7-143 
      Yes Details below 60 
Mouse c57bl6 8 wks Male LHSC-VRL Same as Housing A7-143 
      Yes       10 
Non-approved  
Housing 
Justification 
      
Other  Animal  Specially formulated feeds and feeders obtained from Bio-Serv to facilitate accurate measurements of 
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Requirement Detail daily food intake of control groups for GNR groups 
Vitamin C supplementation will be provided in the drinking water for guinea pigs 
 
 
H. ADDENDA 
 Addendum  1 – Teaching ONLY  No Teaching Elements 
 
 Addendum  2 – Wildlife Study 
ONLY  No Wildlife Study Elements 
 
Addendum 3 - Hazardous &/or Biological Agent Use  ONLY – Occupational Health and Safety 
 No Hazardous &/or Biological Agent Use 
University of Western Ontario  
Animal Use Protocol Safety Form 
For further information, please contact J. Stanley - 
jstanle2@uwo.ca 
Protocol Title:  Animal Models and Mechanisms of 
Fetal Growth Restriction 
 Approved:  June 10, 2003             OHS Use Only 
Permit Number Issued:        
 
 
Approvals -   Please Sign & Date Below 
Principal Investigator 
Print Name   V. Han 
Signature  
Protocol Title 
Animal Models and Mechanisms of Fetal 
Growth Restriction 
Date 
mm/dd/yy 
    06/15/06 
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The UNIVERSITY of WESTERN ONTARIO – UNIVERSITY COUNCIL ON ANIMAL CARE 
 
1.4 MAJOR MODIFICATION PROTOCOL FORM  
 
I. DECLARATION 
 
1. I believe that the proposed animal use conforms to my stated objectives, will advance knowledge and will 
employ the best methods on the smallest number of animals to obtain valid information. 
2. I believe that, wherever possible, all procedures having the potential to cause pain or stress have been 
refined and/or reduced to minimize animal discomfort. 
3. I confirm that the experimental method accurately describes ALL the proposed animal use.  I accept 
responsibility for procedures performed on animals in this project.  All procedures will be carried out by, 
or under the guidance of trained and competent personnel using recognized techniques. 
4. All animals in this project will be used in compliance with the regulations of The Animals for Research Act 
of the province of Ontario, the guidelines of the Canadian Council on Animal Care and the policies and 
procedures of the University of Western Ontario Council on Animal Care. 
5. I am aware that the data provided in this protocol will be entered into the Animal Research Protocol 
Management System and submitted to the Canadian Council on Animal Care. 
6. I will ensure that any individual, who will perform any procedure(s) as described in this protocol, will 
complete all related mandatory training and will be familiar with the contents of this document. 
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Authorization - Please Sign & Date Below 
Project Title - Please repeat title used on page 1 Fetal Growth Restriction:  Mechanisms and Outcomes      
Principal Investigator or Course Director 
Print Name -  Dr. Victor Han 
 
 
 
Signature -      
Date                             
mm/dd/yy  
06/15/06 
 
AUS Office Use Only 
APPROVAL OF ANIMAL USE SUBCOMMITTEE 
 
Signature of Reviewing Veterinarian -             Date -   
                                                                            mm/dd/yy                                  
                                                                             
                                                                                /      / 
 
Signature of AUS Chair -                  
Date -
                                                                                        
mm/dd/yy                                                                                          
 
                                                                                            /     
/ 
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A. INVESTIGATOR DECLARATION – Mandatory Completion 
I.     All animals used in this research project will be cared for in accordance with the recommendations of the Canadian  
       Council on Animal Care and the requirements of the provincial legislation entitled, "The Animals for Research Act," of 
the 
       Province of Ontario.  
II.    I confirm that this Animal Use Protocol accurately represents the proposed animal use.  
III.   I accept responsibility for procedures performed on animals in this project. 
IV.   I will ensure that any individual who will perform any animal-related procedure(s) within this protocol will complete all 
       related mandatory training AND will be made familiar with the contents of this document. 
1. I  support the above declaration -  YES      Today’s Date mm/dd/yy: 03/10/09 
2. By checking ‘YES’  in this section, I authorize the submission of this form and its electronic delivery to aus@uwo.ca     
      YES     NO  
3. I authorize Steven Dixon (PI Designate) to submit this form and to receive a copy of authorization via email on my 
behalf.   
      Today’s Date (mm/dd/yy): 03/10/09 
AUS APPROVAL - AUS Office Use Only  - 
Veterinary  Authorization by  Click Here 
Authorization Date (mm/dd/yy)        
Signature: 
AUS Committee Signature: 
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B. PROTOCOL / INVESTIGATOR / FUNDING INFORMATION - Mandatory Completion  
B.1. PROTOCOL INFORMATION  
Protocol Number: 2006-095-
08 Protocol Title:  Animal Models and Mechanisms of Fetal Growth Restriction 
B.2. INVESTIGATOR CONTACT INFORMATION 
Principal Investigator Full Name:  Dr. Victor Han Email Address: vhan@uwo.ca Office / Lab Phone: 58306 
B.3. FUNDING SOURCE INFORMATION  
 NO NEW/CHANGES TO Funding Information (Go to C.) 
 
 
C. PROTOCOL OVERVIEW – CHANGES AND/OR ADDITIONS TO THE ANIMAL USE PROTOCOL 
Mandatory Completion 
1.1 Please provide justification for proposed  changes outlined in this Protocol Modification 
The placenta is a key component regulating the growth of the fetus in utero.  This modification is designed to measure 
which mechanisms of transplacental transport are being affected (simple diffusion, facilitated diffusion and active 
transport). 
1.2. IDENTIFY ALL CHANGES AND/OR ADDITIONS TO THE ORIGINAL ANIMAL USE PROTOCOL USING THIS CHECKLIST    
CHECK ALL CHANGES AND/OR ADDITIONS PER SPECIES & 
COMPLETE  IDENTIFIED SECTIONS Species  
Type 
Use Type 
Pick All 
 That Apply 
Category of 
Invasiveness 
(CI) Procedure Type Section Required Procedure Type 
Section 
Required 
Mouse Chronic   
 Acute C 
 Adverse Consequences 
 Agent Use – Non-
Hazards 
 Agent Use – Hazardous 
 Anesthesia 
 Animal Requirements 
 Antibody Production 
 Behavioural  
F 
L.1.1 
L.1.2 & 9 
L.2 
G 
L.3 
E 
L.4 
 Genotyping 
 Glossary of Terms 
 Groups  
 Location – Housing & 
Use 
 Imaging 
 Model Creation 
 Monitoring 
E 
D 
D 
H 
L.1.2 & 9 
E 
J 
A 
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 Blood Collection  
 Breeding 
 Collection -  Other 
Tissue 
 Dietary Manipulation 
 Euthanasia 
 Facility Transfer 
 Funding - New 
 Genetically Altered 
Animals 
L.5 
E 
E 
I 
H.4 
B 
L.6 
 PI Designate 
Authorization 
 Procedures 
 Protocol Transfer 
 Staff &  Their Training 
 Surgical Procedures 
 Teaching & Training 
 Title – Protocol / 
Funding 
 Wildlife Field Study 
E 
G.3 
K 
L.2 
L.7 
B 
L.8 
 
D. LAY SUMMARY, GLOSSARY OF TERMS, SCIENTIFIC OBJECTIVES & PROCEDURAL OVERVIEW 
D.2. GLOSSARY OF TERMS & SPECIALIZED EQUIPMENT 
 No NEW / CHANGES TO Glossary of Terms and/or Specialized Equipment and/or Group Flow Charts and/or 
Timelines 
 
E. PROCEDURAL OUTLINE –  Mandatory Completion 
 NO NEW/CHANGES TO Procedural Outline (Go to F.) 
Provide a concise description of the procedural events experienced by the animals in each experiment.  The intent is to 
chronologically order, name and briefly describe the procedural events that animals of each experimental cohort will 
experience. The species-specific events should be presented numerically in chronological number.  Indicate the 
experimental groups experiencing each procedural event and evaluate the procedure-specific potential to cause pain.  
P
r
o
c
e
d
u
r
e
 
N
u
m
b
e
r
 
SPECIES 
& Sect. D 
5.1 
Group  
ID# 
Potenti
al 
 To 
Cause 
 Pain or 
Distres
s 
PROCEDUR
E 
NAME 
Short Description of the Experimental Procedure  
1 
Mouse 
ID# 
MGNR 
 Yes 
 No 
Radiotracer 
infusion 
Pregnant mice are anaesthetized with midazolam and ketamine/xylazine.  After 
exposing maternal jugular vein, 1.3 kBq of a radiotracer in 100ul of saline (0.9% w/v) 
is injected into the vein.  Pregnant mum is then euthanized by cervical dislocation 2 
minutes after injection.  Pups are removed from the mother and euthanized by 
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F. ADVERSE CONSEQUENCES -  Mandatory Completion 
 NO NEW/CHANGES TO Adverse Consequences (Go to G.) 
 
 
G. 4-YEAR TOTAL ANIMAL REQUIREMENTS – Mandatory Completion 
 NO NEW/CHANGES TO 4-Year Animal Requirements (Go to H.) 
 
G.3. PROTOCOL TRANSFER OF PREVIOUSLY USED ANIMALS – Complete if Sect. G.2. Animal Source = 
Protocol Transfer-Citywide involving previously used animals (See Instruction Pages iii & iv) 
 NO NEW/CHANGES TO Protocol Transfers - Go to H. 
 
H. ANIMAL HOUSING & USE LOCATION REQUIREMENTS – Mandatory Completion 
 NO NEW/CHANGES TO Animal Housing & Use Location Requirements - Go to I. 
 NO NEW/CHANGES TO Citywide &/or External Facility Animal Transfers - Go to I. 
 
I. EUTHANASIA INCLUDING CRITERIA FOR EARLY EUTHANASIA & EXPERIMENTAL 
ENDPOINTS  
Mandatory Completion 
 NO NEW/CHANGES TO Euthanasia Including Criteria for Early Euthanasia & Experimental Endpoints - Go to 
J. 
 
J. MONITORING – Mandatory Completion 
 NO NEW/CHANGES TO Monitoring - Go to K. 
decapitation.  Tissues are then collected from the pups for further analysis. 
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K. RESEARCH STAFF & THEIR TRAINING REQUIREMENTS – Mandatory Completion 
Complete for ALL Staff Working  Within This Specific Protocol  
 NO NEW/CHANGES TO Research Staff & Their Training Requirements - Go to L. 
 
L. ADDENDA – Complete as Indicated within Section C.2. 
L.1.  AGENT / DRUG USE – NON-HAZARDOUS & HAZARDOUS 
 NO NEW/CHANGES TO Agent / Drug Use - Go to L.2 
L.1.1. AGENT USE – NON-HAZARDOUS ONLY 
 NO NEW/CHANGES TO Non-Hazardous Agent / Drug Use - Go to L.1.2 
 
L.1.2. AGENT USE – HAZARDOUS  
 NO NEW/CHANGES TO Hazardous Agent / Drug Use - Go to L.2 
Provide detailed hazardous agent (Biological, Recombinant DNA, Viral Vectors, Chemical, Nuclear, Radiation, Laser, MRI, 
X-Ray Devices, Hazardous Drug, Hazardous Species, and Hazardous Hormone) use per species AND complete Addendum 
L.9. 
SPECIES 
& SECT. 
D 5.1 
GROUP 
ID# 
HAZARDOU
S 
AGENT 
TYPE  
HAZARDOUS 
AGENT 
NAME 
PAIN or 
DISTRESS 
POTENTIA
L 
 
DOSE 
 
ROUTE VOLUME FREQUENCY 
PERMIT 
REGISTRY # 
Mouse 
 
ID# MGNR 
Nuclear Substance
If Other, 
      
14C-Inulin 
 Yes 
 No 
 
Uncertain 
1.3 kBq IV 100ul Once HAN1003rev2 
As Above 
 
ID#       
Nuclear Substance
If Other, 
      
14C-methyl-D-
glucose 
 Yes 
 No 
 
Uncertain 
1.3 kBq IV 100ul Once HAN1003rev2 
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As Above 
 
ID#       
Nuclear Substance
If Other, 
      
14C-MeAIB 
 Yes 
 No 
 
Uncertain 
1.3 kBq IV 100ul Once HAN1003rev2 
 
L.2. ANESTHESIA OR SURGERY OR RECOVERY PROJECTS  
 NO NEW/CHANGES TO Anesthesia, Surgery or Recovery - Go to L.3 
Provide detailed anesthesia, surgery and/or recovery information per species. Ensure procedural outline from pre-op 
through to post-op including timelines, monitoring, drug administration, wound closure & suture removal.  If surgery 
and/or anesthetic procedural outlines were previously detailed within Sect. E, provide Sect. E Row # as reference rather 
than repeating detail here. 
See Instructions Pages for SOP Titles. 
SPECIES 
& SECT 
D.5 
GROUP 
ID# 
SURGICAL 
AND/OR 
ANESTHETI
C  
TYPE & 
NAME  
OUTLINE SURGERY 
Pre-op to Post-op 
Timelines, Wound Closure 
Suture Removal, or 
Provide Sect. E Row # 
FASTING
? 
IF ‘YES’, 
DURATION 
ANESTHETI
C 
TYPE & 
NAME 
OUTLINE ANESTHETIC 
REGIME 
Depth, Duration, 
Frequency, Monitoring, 
or 
Provide Sect. E Row # 
POST-OP 
CARE SOPs  
FOLLOWED 
 
SURGICAL & 
RECOVERY 
LOCATIONS 
Buildings & 
Room #s 
Mouse 
 
ID# 
MGNR 
Type:
Non-Recovery
Name: 
      
 SOP 343 & 
Surgical Outline: 
Sect E Row 1 
 Yes  
 No 
Duration: 
      
Type:  
Injectible 
Agent 
Name: 
Midazolam 
+ 
Ketamine/X
ylazine 
  SOP 350 & 
Anesthetic Regime: 
      
 SOP 
330  
 SOP 
331 
 SOP 
332 
 SOP 
333 
 SOP 
334 
Surgery – 
Bldg & Rm# 
VRL A5-108 
Recovery –
Bldg & Rm# 
N/A 
 
L.3. ANTIBODY PRODUCTION 
 NO NEW/CHANGES TO Antibody Production - Go to L.4 
 
L.4. BLOOD COLLECTION 
 NO NEW/CHANGES TO Blood Collection - Go to L.5 
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L.5.  BREEDING  
 NO NEW/CHANGES TO Breeding - Go to L.6 
 
L.6. GENETICALLY ALTERED ANIMAL REQUIREMENTS 
 NO NEW/CHANGES TO Genetically Altered Animal Requirements - Go to L.7 
 
L.7. TEACHING 
 NO NEW/CHANGES TO Teaching - Go to L.8 
 
L.8.   WILDLIFE FIELD STUDY  
 NO NEW/CHANGES TO Wildlife Study - Go to L.9 
 
L.9.  OCCUPATIONAL HEALTH & SAFETY FORM – Complete for all Hazardous Protocol Elements 
 NO NEW/CHANGES TO Occupational Health & Safety Form – FORM IS COMPLETE 
 
9.1. HAZARD ASSESSMENT FOR WORK WITH MICROORGANISMS OR BIOLOGICAL AGENTS – Schedule 1  
 NO NEW/CHANGES TO Microorganisms or Biological Agents - Go to L.9.2 
 
9.2. HAZARD ASSESSMENT FOR USE OF RECOMBINANT DNA OR VIRAL VECTORS DIRECTLY INTO ANIMALS  
–  
       Schedule 2  
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 NO NEW/CHANGES TO Recombinant DNA or Viral Vectors Directly Into Animals - Go to L.9.3 
 
9.3. HAZARD ASSESSMENT FOR WORK WITH HAZARDOUS CHEMICALS and/or DRUGS – Schedule 3  
 NO NEW/CHANGES TO Hazardous Chemicals and/or Drugs - Go to L.9.4 
 
9.4. HAZARD ASSESSMENT FOR WORK WITH NUCLEAR SUBSTANCES AND RADIATION / IMAGING DEVICES 
–  
       Schedule 4 
 NO NEW/CHANGES TO work with Nuclear Substance and/or Radiation / Imaging Devices – FORM IS 
COMPLETE 
Will nuclear substances and/or radiation devices be administered to live animals?  Yes   No 
If ‘Yes’, complete this section. If ‘No’ FORM IS COMPLETE. 
For containment level and other biosafety information, go to: www.uwo.ca/humanresources/biosafety 
• All procedures must follow the Radiation Safety Manual, available on the website: 
       www.uwo.ca/humanresources/facultystaff/h_and_s/h_and_sindex.htm 
• Carcasses must be disposed of per the radioactive waste protocol for the institution/facility. 
• All procedures must comply with the Nuclear Safety and Control Act, Canadian Nuclear Safety Commission Regulations 
and license issued to the institution/facility.  See www.nuclearsafety.gc.ca/engl 
For more information, contact the Radiation Safety Officer for your institution/facility where the work is performed. 
9.4.1. Nuclear Substance and/or Radiation / Imaging Devices Information - Please list and provide information for each 
hazardous nuclear substance and/or radiation / imaging device below. 
INFORMATION REQUIRED SUBSTANCE / DEVICE 1 
SUBSTANCE / 
DEVICE 2 
SUBSTANCE / 
DEVICE 3 
SUBSTANCE / 
DEVICE 4 
SUBSTANCE / 
DEVICE 5 
4.1.1.  Name Nuclear Substance 
and/or Radiation Device          14C-inulin 
14C-methyl-D-
glucose 14C-MeAIB             
4.1.2. Type  Nuclear Substance Nuclear Substance Nuclear Substance Click Here Click Here 
If Type = ‘Nuclear Substance’ Complete the Following: 
4.1.2.1. Radioisotope name &/or 
chemical form Carbon-14 Carbon-14 Carbon-14             
4.1.2.2. Dose to the animal. 1.3 kBq 1.3 kBq 1.3 kBq             
4.1.2.3. Will the radioisotope-  Yes   No  Yes   No  Yes   No  Yes   No  Yes   No 
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contaminated animal be returning 
alive for housing in the Animal 
Quarters?  
9.4.2. Risk Control Measures – List the control measures required to eliminate or further minimize the risk. 
ACTIVITY/HAZARD RISK CONTROL MEASURES/ACTION 
4.2.1 List all preventative 
measures to be taken to 
minimize the risk of exposure to 
RESEARCH STAFF handling the 
material 
 No Anticipated Risk to Humans 
 Safety Glasses 
 Gloves 
 Lab coat or equivalent 
 Fumehood Use 
 Other, please specify:       
4.2.2. List all preventative 
measures to be taken to 
minimize the risk of exposure to 
ANIMAL FACILITY STAFF 
handling the material. 
 No Anticipated Risk to Humans 
 Safety Glasses 
 Gloves 
 Lab coat or equivalent 
 Fumehood Use 
 Other, please specify:       
9.4.3 Training Requirements 
• All Personnel must be trained in Radiation Safety prior to doing work on the protocol. 
• All personnel must be trained to safely use the equipment specified, e.g. MRI, CT Scanner, X-ray machine and 3b or 4 
Lasers 
• CT Scanner and/or X-ray equipment users require X-Ray Safety training 
• Class 3b and/or class 4 laser users require Laser Safety training 
Training – List Completed Training for All Personnel Involved With Nuclear Substance and/or Radiation Devices 
NAME TRAINING TYPE 1 
TRAINING 
DATE TRAINING TYPE 2 
TRAINING 
DATE TRAINING TYPE 3 
TRAINING 
DATE 
Steven Dixon Radiation Safety Other:       Jan 9/09 
Click Here 
Other:             
Click Here 
Other:             
Caroline Albion Radiation Safety Other:       Oct 2/08 
Click Here 
Other:             
Click Here 
Other:             
9.4.4 Safety Officer Review: To be completed by safety officer associated with Section 9.4 only – Return by email to 
aus@uwo.ca 
Pick One 
 I authorize the contents of Section 9.4 – Schedule 4 with no further instructions or comments, or, 
 I do not authorize the contents of Section 9.4 – Schedule 4 due to      , or,  
 I authorize the contents of Section 9.4 – Schedule 4 with the following instructions/comments:      . 
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